{ "version": "2.2", "instance": { "apvo-20260630.htm": { "nsprefix": "apvo", "nsuri": "http://aptevotherapeutics.com/20260630", "dts": { "inline": { "local": [ "apvo-20260630.htm" ] }, "schema": { "local": [ "apvo-20260630.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/2023/calculation-1.1.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd", "https://xbrl.fasb.org/srt/2026/elts/srt-2026.xsd", "https://xbrl.fasb.org/srt/2026/elts/srt-roles-2026.xsd", "https://xbrl.fasb.org/srt/2026/elts/srt-types-2026.xsd", "https://xbrl.fasb.org/us-gaap/2026/elts/us-gaap-2026.xsd", "https://xbrl.fasb.org/us-gaap/2026/elts/us-roles-2026.xsd", "https://xbrl.fasb.org/us-gaap/2026/elts/us-types-2026.xsd", "https://xbrl.sec.gov/country/2026/country-2026.xsd", "https://xbrl.sec.gov/dei/2026/dei-2026.xsd", "https://xbrl.sec.gov/ecd/2026/ecd-2026.xsd", "https://xbrl.sec.gov/ecd/2026/ecd-sub-2026.xsd", "https://xbrl.sec.gov/exch/2026/exch-2026.xsd", "https://xbrl.sec.gov/stpr/2026/stpr-2026.xsd" ] } }, "keyStandard": 163, "keyCustom": 50, "axisStandard": 17, "axisCustom": 0, "memberStandard": 17, "memberCustom": 30, "hidden": { "total": 13, "http://fasb.org/us-gaap/2026": 9, "http://xbrl.sec.gov/dei/2026": 4 }, "contextCount": 155, "entityCount": 1, "segmentCount": 49, "elementCount": 586, "unitCount": 7, "baseTaxonomies": { "http://fasb.org/us-gaap/2026": 415, "http://xbrl.sec.gov/dei/2026": 30, "http://xbrl.sec.gov/ecd/2026": 4 }, "report": { "R1": { "role": "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DocumentDocumentAndEntityInformation", "longName": "75000 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "C_743c679d-bd29-40ba-8b42-af0f13f04b21", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "div", "body", "html" ], "reportCount": 1, "baseRef": "apvo-20260630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_743c679d-bd29-40ba-8b42-af0f13f04b21", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "div", "body", "html" ], "reportCount": 1, "baseRef": "apvo-20260630.htm", "first": true, "unique": true } }, "R2": { "role": "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited", "longName": "75010 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "C_a4cf77f2-0236-4a37-89e0-fafa3f00a45d", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "apvo-20260630.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_a4cf77f2-0236-4a37-89e0-fafa3f00a45d", "name": "us-gaap:AssetsCurrent", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "apvo-20260630.htm", "unique": true } }, "R3": { "role": "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical", "longName": "75020 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "C_a4cf77f2-0236-4a37-89e0-fafa3f00a45d", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "U_UnitedStatesOfAmericaDollarsShare", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "apvo-20260630.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_a4cf77f2-0236-4a37-89e0-fafa3f00a45d", "name": "us-gaap:PreferredStockSharesAuthorized", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "apvo-20260630.htm", "unique": true } }, "R4": { "role": "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited", "longName": "75030 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "C_2efc7f3d-25e6-47c9-8115-1a5d4b57cf90", "name": "us-gaap:ResearchAndDevelopmentExpense", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "apvo-20260630.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_2efc7f3d-25e6-47c9-8115-1a5d4b57cf90", "name": "us-gaap:OperatingIncomeLoss", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "apvo-20260630.htm", "unique": true } }, "R5": { "role": "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited", "longName": "75040 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "C_743c679d-bd29-40ba-8b42-af0f13f04b21", "name": "us-gaap:ProfitLoss", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "apvo-20260630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_743c679d-bd29-40ba-8b42-af0f13f04b21", "name": "us-gaap:ProfitLoss", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "apvo-20260630.htm", "first": true, "unique": true } }, "R6": { "role": "http://aptevotherapeutics.com/20260630/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit", "longName": "75050 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT)", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIT)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "C_e8acd138-b0d3-4019-8f4d-40a36bc57f70", "name": "us-gaap:StockholdersEquity", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "apvo-20260630.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_204e250f-a725-4537-9a3f-ce52dabda571", "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "apvo-20260630.htm", "unique": true } }, "R7": { "role": "http://aptevotherapeutics.com/20260630/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersDeficitEquityUnauditedParenthetical", "longName": "75060 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' DEFICIT EQUITY (Unaudited) (Parenthetical)", "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' DEFICIT EQUITY (Unaudited) (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "C_743c679d-bd29-40ba-8b42-af0f13f04b21", "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "p", "div", "body", "html" ], "reportCount": 1, "baseRef": "apvo-20260630.htm", "first": true }, "uniqueAnchor": null }, "R8": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "C_2efc7f3d-25e6-47c9-8115-1a5d4b57cf90", "name": "us-gaap:NetIncomeLoss", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "apvo-20260630.htm", "first": true }, "uniqueAnchor": null }, "R9": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "C_2efc7f3d-25e6-47c9-8115-1a5d4b57cf90", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "div", "body", "html" ], "reportCount": 1, "baseRef": "apvo-20260630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_2efc7f3d-25e6-47c9-8115-1a5d4b57cf90", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "div", "body", "html" ], "reportCount": 1, "baseRef": "apvo-20260630.htm", "first": true, "unique": true } }, "R10": { "role": "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureNatureOfBusinessAndSignificantAccountingPolicies", "longName": "995455 - Disclosure - Nature of Business and Significant Accounting Policies", "shortName": "Nature of Business and Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "C_743c679d-bd29-40ba-8b42-af0f13f04b21", "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "apvo-20260630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_743c679d-bd29-40ba-8b42-af0f13f04b21", "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "apvo-20260630.htm", "first": true, "unique": true } }, "R11": { "role": "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureCollaborationAgreements", "longName": "995485 - Disclosure - Collaboration Agreements", "shortName": "Collaboration Agreements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "C_743c679d-bd29-40ba-8b42-af0f13f04b21", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "apvo-20260630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_743c679d-bd29-40ba-8b42-af0f13f04b21", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "apvo-20260630.htm", "first": true, "unique": true } }, "R12": { "role": "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureFairValueMeasurements", "longName": "995495 - Disclosure - Fair Value Measurements", "shortName": "Fair Value Measurements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "C_743c679d-bd29-40ba-8b42-af0f13f04b21", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "apvo-20260630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_743c679d-bd29-40ba-8b42-af0f13f04b21", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "apvo-20260630.htm", "first": true, "unique": true } }, "R13": { "role": "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureCashAndCashEquivalents1", "longName": "995505 - Disclosure - Cash and Cash Equivalents", "shortName": "Cash and Cash Equivalents", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "C_743c679d-bd29-40ba-8b42-af0f13f04b21", "name": "us-gaap:CashAndCashEquivalentsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "apvo-20260630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_743c679d-bd29-40ba-8b42-af0f13f04b21", "name": "us-gaap:CashAndCashEquivalentsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "apvo-20260630.htm", "first": true, "unique": true } }, "R14": { "role": "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureLeases", "longName": "995535 - Disclosure - Leases", "shortName": "Leases", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "C_743c679d-bd29-40ba-8b42-af0f13f04b21", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "apvo-20260630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_743c679d-bd29-40ba-8b42-af0f13f04b21", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "apvo-20260630.htm", "first": true, "unique": true } }, "R15": { "role": "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosurePrepaidExpensesOtherCurrentAssetsAccruedExpensesAndOtherCurrentLiabilities", "longName": "995545 - Disclosure - Prepaid Expenses, Other Current Assets, Accrued Expenses, and Other Current Liabilities", "shortName": "Prepaid Expenses, Other Current Assets, Accrued Expenses, and Other Current Liabilities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "C_743c679d-bd29-40ba-8b42-af0f13f04b21", "name": "apvo:PrepaidExpensesOtherCurrentAssetsAccruedExpensesAndOtherCurrentLiabilitiesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "apvo-20260630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_743c679d-bd29-40ba-8b42-af0f13f04b21", "name": "apvo:PrepaidExpensesOtherCurrentAssetsAccruedExpensesAndOtherCurrentLiabilitiesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "apvo-20260630.htm", "first": true, "unique": true } }, "R16": { "role": "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureGrantAgreement", "longName": "995565 - Disclosure - Grant Agreement", "shortName": "Grant Agreement", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "C_743c679d-bd29-40ba-8b42-af0f13f04b21", "name": "us-gaap:GovernmentAssistanceTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "apvo-20260630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_743c679d-bd29-40ba-8b42-af0f13f04b21", "name": "us-gaap:GovernmentAssistanceTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "apvo-20260630.htm", "first": true, "unique": true } }, "R17": { "role": "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureNetLossPerShare", "longName": "995575 - Disclosure - Net Loss per Share", "shortName": "Net Loss per Share", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "C_743c679d-bd29-40ba-8b42-af0f13f04b21", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "apvo-20260630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_743c679d-bd29-40ba-8b42-af0f13f04b21", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "apvo-20260630.htm", "first": true, "unique": true } }, "R18": { "role": "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureEquity", "longName": "995585 - Disclosure - Equity", "shortName": "Equity", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "C_743c679d-bd29-40ba-8b42-af0f13f04b21", "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "apvo-20260630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_743c679d-bd29-40ba-8b42-af0f13f04b21", "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "apvo-20260630.htm", "first": true, "unique": true } }, "R19": { "role": "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureSegmentInformation", "longName": "995595 - Disclosure - Segment Information", "shortName": "Segment Information", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "C_743c679d-bd29-40ba-8b42-af0f13f04b21", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "apvo-20260630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_743c679d-bd29-40ba-8b42-af0f13f04b21", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "apvo-20260630.htm", "first": true, "unique": true } }, "R20": { "role": "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureSubsequentEvents", "longName": "995605 - Disclosure - Subsequent Events", "shortName": "Subsequent Events", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "C_743c679d-bd29-40ba-8b42-af0f13f04b21", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "apvo-20260630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_743c679d-bd29-40ba-8b42-af0f13f04b21", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "apvo-20260630.htm", "first": true, "unique": true } }, "R21": { "role": "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureNatureOfBusinessAndSignificantAccountingPoliciesPolicies", "longName": "995615 - Disclosure - Nature of Business and Significant Accounting Policies (Policies)", "shortName": "Nature of Business and Significant Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "21", "firstAnchor": { "contextRef": "C_743c679d-bd29-40ba-8b42-af0f13f04b21", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "apvo-20260630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_743c679d-bd29-40ba-8b42-af0f13f04b21", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "apvo-20260630.htm", "first": true, "unique": true } }, "R22": { "role": "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureCashAndCashEquivalentsTables", "longName": "995635 - Disclosure - Cash and Cash Equivalents (Tables)", "shortName": "Cash and Cash Equivalents (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "22", "firstAnchor": { "contextRef": "C_743c679d-bd29-40ba-8b42-af0f13f04b21", "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:CashAndCashEquivalentsDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "apvo-20260630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_743c679d-bd29-40ba-8b42-af0f13f04b21", "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:CashAndCashEquivalentsDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "apvo-20260630.htm", "first": true, "unique": true } }, "R23": { "role": "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureLeasesTables", "longName": "995655 - Disclosure - Leases (Tables)", "shortName": "Leases (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "23", "firstAnchor": { "contextRef": "C_743c679d-bd29-40ba-8b42-af0f13f04b21", "name": "us-gaap:LeaseCostTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "apvo-20260630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_743c679d-bd29-40ba-8b42-af0f13f04b21", "name": "us-gaap:LeaseCostTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "apvo-20260630.htm", "first": true, "unique": true } }, "R24": { "role": "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosurePrepaidExpensesOtherCurrentAssetsAccruedExpensesAndOtherCurrentLiabilitiesTables", "longName": "995665 - Disclosure - Prepaid Expenses, Other Current Assets, Accrued Expenses, and Other Current Liabilities (Tables)", "shortName": "Prepaid Expenses, Other Current Assets, Accrued Expenses, and Other Current Liabilities (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "24", "firstAnchor": { "contextRef": "C_743c679d-bd29-40ba-8b42-af0f13f04b21", "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "apvo:PrepaidExpensesOtherCurrentAssetsAccruedExpensesAndOtherCurrentLiabilitiesTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "apvo-20260630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_743c679d-bd29-40ba-8b42-af0f13f04b21", "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "apvo:PrepaidExpensesOtherCurrentAssetsAccruedExpensesAndOtherCurrentLiabilitiesTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "apvo-20260630.htm", "first": true, "unique": true } }, "R25": { "role": "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureNetLossPerShareTables", "longName": "995675 - Disclosure - Net Loss per Share (Tables)", "shortName": "Net Loss per Share (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "25", "firstAnchor": { "contextRef": "C_743c679d-bd29-40ba-8b42-af0f13f04b21", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "apvo-20260630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_743c679d-bd29-40ba-8b42-af0f13f04b21", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "apvo-20260630.htm", "first": true, "unique": true } }, "R26": { "role": "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureEquityTables", "longName": "995685 - Disclosure - Equity (Tables)", "shortName": "Equity (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "26", "firstAnchor": { "contextRef": "C_743c679d-bd29-40ba-8b42-af0f13f04b21", "name": "us-gaap:FairValueMeasurementInputsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "apvo-20260630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_743c679d-bd29-40ba-8b42-af0f13f04b21", "name": "us-gaap:FairValueMeasurementInputsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "apvo-20260630.htm", "first": true, "unique": true } }, "R27": { "role": "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureSegmentInformationTables", "longName": "995695 - Disclosure - Segment Information (Tables)", "shortName": "Segment Information (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "27", "firstAnchor": { "contextRef": "C_743c679d-bd29-40ba-8b42-af0f13f04b21", "name": "apvo:SummaryOfSignificantExpenseCategoriesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "apvo-20260630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_743c679d-bd29-40ba-8b42-af0f13f04b21", "name": "apvo:SummaryOfSignificantExpenseCategoriesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "apvo-20260630.htm", "first": true, "unique": true } }, "R28": { "role": "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureNatureOfBusinessAndSignificantAccountingPoliciesAdditionalInformationDetails", "longName": "995705 - Disclosure - Nature of Business and Significant Accounting Policies - Additional Information (Details)", "shortName": "Nature of Business and Significant Accounting Policies - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "28", "firstAnchor": { "contextRef": "C_2efc7f3d-25e6-47c9-8115-1a5d4b57cf90", "name": "us-gaap:NetIncomeLoss", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "apvo-20260630.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_c093870c-3ec0-4cdb-961e-21fdcc8f89e5", "name": "us-gaap:ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "p", "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "apvo-20260630.htm", "unique": true } }, "R29": { "role": "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetails", "longName": "995745 - Disclosure - Collaboration Agreements - Additional Information (Details)", "shortName": "Collaboration Agreements - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "29", "firstAnchor": { "contextRef": "C_743c679d-bd29-40ba-8b42-af0f13f04b21", "name": "apvo:ReductionInResearchAndDevelopmentExpense", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-4", "ancestors": [ "span", "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "apvo-20260630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_743c679d-bd29-40ba-8b42-af0f13f04b21", "name": "apvo:ReductionInResearchAndDevelopmentExpense", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-4", "ancestors": [ "span", "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "apvo-20260630.htm", "first": true, "unique": true } }, "R30": { "role": "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails", "longName": "995755 - Disclosure - Fair Value Measurements - Additional Information (Details)", "shortName": "Fair Value Measurements - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "30", "firstAnchor": { "contextRef": "C_a4cf77f2-0236-4a37-89e0-fafa3f00a45d", "name": "us-gaap:MoneyMarketFundsAtCarryingValue", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "p", "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "apvo-20260630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_a4cf77f2-0236-4a37-89e0-fafa3f00a45d", "name": "us-gaap:MoneyMarketFundsAtCarryingValue", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "p", "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "apvo-20260630.htm", "first": true, "unique": true } }, "R31": { "role": "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureCashAndCashEquivalentsAdditionalInformationDetails", "longName": "995765 - Disclosure - Cash and Cash Equivalents - Additional Information (Details)", "shortName": "Cash and Cash Equivalents - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "31", "firstAnchor": { "contextRef": "C_743c679d-bd29-40ba-8b42-af0f13f04b21", "name": "apvo:CashEquivalentsMaturityPeriod", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "us-gaap:CashAndCashEquivalentsDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "apvo-20260630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_743c679d-bd29-40ba-8b42-af0f13f04b21", "name": "apvo:CashEquivalentsMaturityPeriod", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "us-gaap:CashAndCashEquivalentsDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "apvo-20260630.htm", "first": true, "unique": true } }, "R32": { "role": "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureCashAndCashEquivalentsScheduleOfCashAndCashEquivalentsDetails", "longName": "995775 - Disclosure - Cash and Cash Equivalents - Schedule of Cash and Cash Equivalents (Details)", "shortName": "Cash and Cash Equivalents - Schedule of Cash and Cash Equivalents (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "32", "firstAnchor": { "contextRef": "C_a4cf77f2-0236-4a37-89e0-fafa3f00a45d", "name": "us-gaap:Cash", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock", "div", "us-gaap:CashAndCashEquivalentsDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "apvo-20260630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_a4cf77f2-0236-4a37-89e0-fafa3f00a45d", "name": "us-gaap:Cash", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock", "div", "us-gaap:CashAndCashEquivalentsDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "apvo-20260630.htm", "first": true, "unique": true } }, "R33": { "role": "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails", "longName": "995815 - Disclosure - Leases - Additional Information (Details)", "shortName": "Leases - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "33", "firstAnchor": { "contextRef": "C_a4cf77f2-0236-4a37-89e0-fafa3f00a45d", "name": "us-gaap:OperatingLeaseRightOfUseAsset", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "apvo-20260630.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_72a20bd3-b16c-44cb-baad-f9e5d1959683", "name": "apvo:InitialOperatingLeaseTermDate", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "us-gaap:LesseeOperatingLeaseOptionToExtend", "span", "p", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "apvo-20260630.htm", "unique": true } }, "R34": { "role": "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureLeasesComponentsOfLeaseExpenseDetails", "longName": "995825 - Disclosure - Leases - Components of Lease Expense (Details)", "shortName": "Leases - Components of Lease Expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "34", "firstAnchor": { "contextRef": "C_2efc7f3d-25e6-47c9-8115-1a5d4b57cf90", "name": "us-gaap:OperatingLeaseCost", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "div", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "apvo-20260630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_2efc7f3d-25e6-47c9-8115-1a5d4b57cf90", "name": "us-gaap:OperatingLeaseCost", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "div", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "apvo-20260630.htm", "first": true, "unique": true } }, "R35": { "role": "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureLeasesSummaryOfRightOfUseAssetsAcquiredUnderOperatingLeasesDetails", "longName": "995835 - Disclosure - Leases - Summary of Right of Use Assets Acquired Under Operating Leases (Details)", "shortName": "Leases - Summary of Right of Use Assets Acquired Under Operating Leases (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "C_a4cf77f2-0236-4a37-89e0-fafa3f00a45d", "name": "us-gaap:OperatingLeaseRightOfUseAsset", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "apvo-20260630.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_743c679d-bd29-40ba-8b42-af0f13f04b21", "name": "us-gaap:OperatingLeasePayments", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "apvo-20260630.htm", "unique": true } }, "R36": { "role": "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosurePrepaidExpensesOtherCurrentAssetsAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails", "longName": "995845 - Disclosure - Prepaid Expenses, Other Current Assets, Accrued Expenses, and Other Current Liabilities - Summary of Prepaid Expenses and Other Current Assets (Details)", "shortName": "Prepaid Expenses, Other Current Assets, Accrued Expenses, and Other Current Liabilities - Summary of Prepaid Expenses and Other Current Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "C_a4cf77f2-0236-4a37-89e0-fafa3f00a45d", "name": "us-gaap:PrepaidExpenseCurrent", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "div", "apvo:PrepaidExpensesOtherCurrentAssetsAccruedExpensesAndOtherCurrentLiabilitiesTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "apvo-20260630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_a4cf77f2-0236-4a37-89e0-fafa3f00a45d", "name": "us-gaap:PrepaidExpenseCurrent", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "div", "apvo:PrepaidExpensesOtherCurrentAssetsAccruedExpensesAndOtherCurrentLiabilitiesTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "apvo-20260630.htm", "first": true, "unique": true } }, "R37": { "role": "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosurePrepaidExpensesOtherCurrentAssetsAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDeta", "longName": "995855 - Disclosure - Prepaid Expenses, Other Current Assets, Accrued Expenses, and Other Current Liabilities - Summary of Accrued Expenses and Other Current Liabilities (Details)", "shortName": "Prepaid Expenses, Other Current Assets, Accrued Expenses, and Other Current Liabilities - Summary of Accrued Expenses and Other Current Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "C_a4cf77f2-0236-4a37-89e0-fafa3f00a45d", "name": "apvo:AccruedClinicalResearchAndDevelopmentCosts", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "div", "apvo:PrepaidExpensesOtherCurrentAssetsAccruedExpensesAndOtherCurrentLiabilitiesTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "apvo-20260630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_a4cf77f2-0236-4a37-89e0-fafa3f00a45d", "name": "apvo:AccruedClinicalResearchAndDevelopmentCosts", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "div", "apvo:PrepaidExpensesOtherCurrentAssetsAccruedExpensesAndOtherCurrentLiabilitiesTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "apvo-20260630.htm", "first": true, "unique": true } }, "R38": { "role": "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureReverseStockSplitAdditionalInformationDetails", "longName": "995865 - Disclosure - Reverse Stock Split - Additional Information (Details)", "shortName": "Reverse Stock Split - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": null, "uniqueAnchor": null }, "R39": { "role": "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureGrantAgreementAdditionalInformationDetails", "longName": "995875 - Disclosure - Grant Agreement - Additional Information (Details)", "shortName": "Grant Agreement - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "C_743c679d-bd29-40ba-8b42-af0f13f04b21", "name": "apvo:CostsUnderTheGrantAwardAgreement", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "apvo-20260630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_743c679d-bd29-40ba-8b42-af0f13f04b21", "name": "apvo:CostsUnderTheGrantAwardAgreement", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "apvo-20260630.htm", "first": true, "unique": true } }, "R40": { "role": "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureNetLossPerShareComputationOfBasicAndDilutedNetLossPerShareDetails3", "longName": "995885 - Disclosure - Net Loss per Share - Computation of Basic and Diluted Net Loss per Share (Details)", "shortName": "Net Loss per Share - Computation of Basic and Diluted Net Loss per Share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "C_2efc7f3d-25e6-47c9-8115-1a5d4b57cf90", "name": "us-gaap:NetIncomeLoss", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "apvo-20260630.htm", "first": true }, "uniqueAnchor": null }, "R41": { "role": "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureNetLossPerShareSummaryOfPotentiallyDilutiveSharesExcludedFromCalculationOfNetLossPerShareDetails", "longName": "995895 - Disclosure - Net Loss per Share - Summary of Potentially Dilutive Shares Excluded from Calculation of Net Loss Per Share (Details)", "shortName": "Net Loss per Share - Summary of Potentially Dilutive Shares Excluded from Calculation of Net Loss Per Share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "C_5500d756-2e73-4b03-8d3c-39f37cd6ec46", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "apvo-20260630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_5500d756-2e73-4b03-8d3c-39f37cd6ec46", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "apvo-20260630.htm", "first": true, "unique": true } }, "R42": { "role": "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails", "longName": "995905 - Disclosure - Equity - Additional Information (Details)", "shortName": "Equity - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "C_0f29daf4-4558-4e54-a1d6-93aa960a7bca", "name": "us-gaap:SharesIssuedPricePerShare", "unitRef": "U_UnitedStatesOfAmericaDollarsShare", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "span", "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "apvo-20260630.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_743c679d-bd29-40ba-8b42-af0f13f04b21", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-4", "ancestors": [ "span", "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "apvo-20260630.htm", "unique": true } }, "R43": { "role": "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureEquity2023And2024CommonWarrantsAdditionalInformationDetails", "longName": "995915 - Disclosure - Equity - 2023 and 2024 Common Warrants - Additional Information (Details)", "shortName": "Equity - 2023 and 2024 Common Warrants - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "C_a4cf77f2-0236-4a37-89e0-fafa3f00a45d", "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "td", "tr", "table", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "apvo-20260630.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_853417c2-abcd-4cdf-a99f-d1930809a70a", "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "unitRef": "U_UnitedStatesOfAmericaDollarsShare", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "span", "p", "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "apvo-20260630.htm", "unique": true } }, "R44": { "role": "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureEquity2024CommonWarrantsAdditionalInformationDetails", "longName": "995925 - Disclosure - Equity - 2024 Common Warrants - Additional Information (Details)", "shortName": "Equity - 2024 Common Warrants - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "C_a4cf77f2-0236-4a37-89e0-fafa3f00a45d", "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "td", "tr", "table", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "apvo-20260630.htm", "first": true }, "uniqueAnchor": null }, "R45": { "role": "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureEquity2025EquityOfferingsAndCommonWarrantsAdditionalInformationDetails", "longName": "995935 - Disclosure - Equity - 2025 Equity Offerings and Common Warrants - Additional Information (Details)", "shortName": "Equity - 2025 Equity Offerings and Common Warrants - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "C_743c679d-bd29-40ba-8b42-af0f13f04b21", "name": "us-gaap:ProceedsFromIssuanceOfCommonStock", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "apvo-20260630.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_469e8686-898a-427b-a266-5b930f118a8a", "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "unitRef": "U_UnitedStatesOfAmericaDollarsShare", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "span", "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "apvo-20260630.htm", "unique": true } }, "R46": { "role": "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureEquitySummaryOfAssumptionsUsedToEstimateTheFairValueOfTheWarrantsUsingTheBlackscholesOptionPricingModelDetails", "longName": "995945 - Disclosure - Equity - Summary of Assumptions Used to Estimate the Fair Value of the Warrants Using The Black-scholes Option Pricing Model (Details)", "shortName": "Equity - Summary of Assumptions Used to Estimate the Fair Value of the Warrants Using The Black-scholes Option Pricing Model (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "C_a93c48cf-abe0-4e21-a295-e010225b6b70", "name": "us-gaap:WarrantsAndRightsOutstandingMeasurementInput", "unitRef": "U_pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "span", "p", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "apvo-20260630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_a93c48cf-abe0-4e21-a295-e010225b6b70", "name": "us-gaap:WarrantsAndRightsOutstandingMeasurementInput", "unitRef": "U_pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "span", "p", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "apvo-20260630.htm", "first": true, "unique": true } }, "R47": { "role": "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureEquity2026NiowaveCommonWarrantsAdditionalInformationDetails", "longName": "995955 - Disclosure - Equity - 2026 Niowave Common Warrants - Additional Information (Details)", "shortName": "Equity - 2026 Niowave Common Warrants - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "C_a4cf77f2-0236-4a37-89e0-fafa3f00a45d", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef": "U_UnitedStatesOfAmericaDollarsShare", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "apvo-20260630.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_5a398134-8646-4d75-9140-b959b6229f81", "name": "us-gaap:SharesIssued", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "apvo-20260630.htm", "unique": true } }, "R48": { "role": "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureEquityStandbyEquityPurchaseAgreementAdditionalInformationDetails", "longName": "995965 - Disclosure - Equity - Standby Equity Purchase Agreement - Additional Information (Details)", "shortName": "Equity - Standby Equity Purchase Agreement - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "C_a4cf77f2-0236-4a37-89e0-fafa3f00a45d", "name": "us-gaap:CommonStockValue", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "apvo-20260630.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_a9452825-7913-4ee6-9248-d3c642085d09", "name": "us-gaap:CommonStockValue", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "apvo-20260630.htm", "unique": true } }, "R49": { "role": "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureEquityAtTheMarketOfferingAgreementAdditionalInformationDetails", "longName": "995975 - Disclosure - Equity - At The Market Offering Agreement - Additional Information (Details)", "shortName": "Equity - At The Market Offering Agreement - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "C_a4cf77f2-0236-4a37-89e0-fafa3f00a45d", "name": "us-gaap:SharePrice", "unitRef": "U_UnitedStatesOfAmericaDollarsShare", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "apvo-20260630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_a4cf77f2-0236-4a37-89e0-fafa3f00a45d", "name": "us-gaap:SharePrice", "unitRef": "U_UnitedStatesOfAmericaDollarsShare", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "apvo-20260630.htm", "first": true, "unique": true } }, "R50": { "role": "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureEquitySummaryOfCommonWarrantActivityDetails", "longName": "995985 - Disclosure - Equity - Summary of Common Warrant Activity (Details)", "shortName": "Equity - Summary of Common Warrant Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "C_1a6ff8e0-a180-474a-8496-cc0d47a08165", "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "td", "tr", "table", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "apvo-20260630.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_743c679d-bd29-40ba-8b42-af0f13f04b21", "name": "apvo:ClassOfWarrantOrRightIssued", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "td", "tr", "table", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "apvo-20260630.htm", "unique": true } }, "R51": { "role": "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureSegmentInformationAdditionalInformationDetails", "longName": "995995 - Disclosure - Segment Information - Additional Information (Details)", "shortName": "Segment Information - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "C_743c679d-bd29-40ba-8b42-af0f13f04b21", "name": "us-gaap:NumberOfOperatingSegments", "unitRef": "U_Segment", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "apvo-20260630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_743c679d-bd29-40ba-8b42-af0f13f04b21", "name": "us-gaap:NumberOfOperatingSegments", "unitRef": "U_Segment", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "apvo-20260630.htm", "first": true, "unique": true } }, "R52": { "role": "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureSegmentInformationSummaryOfSignificantExpenseCategoriesDetails", "longName": "996005 - Disclosure - Segment Information - Summary of Significant Expense Categories (Details)", "shortName": "Segment Information - Summary of Significant Expense Categories (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "C_2efc7f3d-25e6-47c9-8115-1a5d4b57cf90", "name": "us-gaap:ResearchAndDevelopmentExpense", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "apvo-20260630.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_2efc7f3d-25e6-47c9-8115-1a5d4b57cf90", "name": "apvo:OtherSegmentItems", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "apvo:SummaryOfSignificantExpenseCategoriesTableTextBlock", "div", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "apvo-20260630.htm", "unique": true } }, "R53": { "role": "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureSegmentInformationSummaryOfSignificantAssetCategoriesDetails", "longName": "996015 - Disclosure - Segment Information - Summary of Significant Asset Categories (Details)", "shortName": "Segment Information - Summary of Significant Asset Categories (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "C_a4cf77f2-0236-4a37-89e0-fafa3f00a45d", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "U_USD", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "span", "p", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "apvo-20260630.htm", "first": true }, "uniqueAnchor": null }, "R54": { "role": "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails", "longName": "996025 - Disclosure - Subsequent Events - Additional Information (Details)", "shortName": "Subsequent Events - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "C_0f29daf4-4558-4e54-a1d6-93aa960a7bca", "name": "us-gaap:SharesIssuedPricePerShare", "unitRef": "U_UnitedStatesOfAmericaDollarsShare", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "span", "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "apvo-20260630.htm", "first": true }, "uniqueAnchor": { "contextRef": "C_748bbcf9-9e2e-4cf8-aded-f8e88b048893", "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction", "unitRef": "U_shares", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "p", "us-gaap:SubsequentEventsTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "apvo-20260630.htm", "unique": true } } }, "tag": { "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "apvo_AccountingPronouncementsPendingAdoptionPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://aptevotherapeutics.com/20260630", "localname": "AccountingPronouncementsPendingAdoptionPolicyTextBlock", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureNatureOfBusinessAndSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Accounting Pronouncements Pending Adoption", "label": "Accounting Pronouncements Pending Adoption [Policy Text Block]", "documentation": "Accounting pronouncements pending adoption." } } }, "auth_ref": [] }, "apvo_AccountingStandardUpdate201705Member": { "xbrltype": "domainItemType", "nsuri": "http://aptevotherapeutics.com/20260630", "localname": "AccountingStandardUpdate201705Member", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureXomaTransactionAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureNatureOfBusinessAndSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Accounting standard update 2017 05.", "label": "Accounting Standard Update 2017 05 [Member]", "terseLabel": "ASC 610-20" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": { "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" ], "lang": { "en-us": { "role": { "label": "Accounts Payable, Current", "totalLabel": "Accounts Payable, Current, Total", "terseLabel": "Accounts payable", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r769", "r890", "r894" ] }, "apvo_AccruedClinicalResearchAndDevelopmentCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://aptevotherapeutics.com/20260630", "localname": "AccruedClinicalResearchAndDevelopmentCosts", "crdr": "credit", "calculation": { "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosurePrepaidExpensesOtherCurrentAssetsAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDeta": { "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosurePrepaidExpensesOtherCurrentAssetsAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDeta" ], "lang": { "en-us": { "role": { "label": "Accrued clinical, research and development costs", "documentation": "Accrued clinical, research and development costs.", "terseLabel": "Accrued clinical, research and development costs" } } }, "auth_ref": [] }, "us-gaap_AccruedLiabilitiesAndOtherLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "AccruedLiabilitiesAndOtherLiabilities", "crdr": "credit", "calculation": { "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 }, "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosurePrepaidExpensesOtherCurrentAssetsAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDeta": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosurePrepaidExpensesOtherCurrentAssetsAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDeta", "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" ], "lang": { "en-us": { "role": { "label": "Accrued Liabilities and Other Liabilities", "terseLabel": "Accrued expenses and other current liabilities", "totalLabel": "Total accrued expenses and other current liabilities", "documentation": "Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other." } } }, "auth_ref": [] }, "us-gaap_AccruedProfessionalFeesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "AccruedProfessionalFeesCurrent", "crdr": "credit", "calculation": { "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosurePrepaidExpensesOtherCurrentAssetsAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDeta": { "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosurePrepaidExpensesOtherCurrentAssetsAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDeta" ], "lang": { "en-us": { "role": { "label": "Accrued Professional Fees, Current", "terseLabel": "Accrued professional service costs", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r895" ] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "Additional402vDisclosureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Additional 402(v) Disclosure [Text Block]", "terseLabel": "Additional 402(v) Disclosure" } } }, "auth_ref": [ "r820" ] }, "apvo_AdditionalAmountToBeReceivedUponExerciseOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://aptevotherapeutics.com/20260630", "localname": "AdditionalAmountToBeReceivedUponExerciseOfWarrants", "crdr": "debit", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureEquity2023And2024CommonWarrantsAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureEquity2024CommonWarrantsAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureEquity2025EquityOfferingsAndCommonWarrantsAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Additional amount to be received upon exercise of warrants", "label": "Additional Amount To Be Received Upon Exercise Of Warrants", "documentation": "Additional amount to be received upon exercise of warrants." } } }, "auth_ref": [] }, "apvo_AdditionalMilestonePayment": { "xbrltype": "monetaryItemType", "nsuri": "http://aptevotherapeutics.com/20260630", "localname": "AdditionalMilestonePayment", "crdr": "credit", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureLiabilityRelatedToSaleOfRoyaltiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Additional milestone payment", "label": "Additional Milestone Payment", "documentation": "Additional milestone payment." } } }, "auth_ref": [] }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "AdditionalPaidInCapitalCommonStock", "crdr": "credit", "calculation": { "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Additional paid-in capital", "label": "Additional Paid in Capital, Common Stock", "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital." } } }, "auth_ref": [ "r900", "r969" ] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "terseLabel": "Additional Paid-In Capital", "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r571", "r611", "r926", "r927", "r928", "r929", "r1011", "r1044" ] }, "apvo_AdditionalPostClosingPayment": { "xbrltype": "monetaryItemType", "nsuri": "http://aptevotherapeutics.com/20260630", "localname": "AdditionalPostClosingPayment", "crdr": "credit", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureXomaTransactionAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Additional post-closing payment", "label": "Additional post-closing payment", "documentation": "Additional post-closing payment." } } }, "auth_ref": [] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "AdjToCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation Amount", "terseLabel": "Adjustment to Compensation, Amount" } } }, "auth_ref": [ "r833" ] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "AdjToCompAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation [Axis]", "terseLabel": "Adjustment to Compensation:" } } }, "auth_ref": [ "r833" ] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]", "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote" } } }, "auth_ref": [ "r833" ] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "AdjToPeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment To PEO Compensation, Footnote [Text Block]", "terseLabel": "Adjustment To PEO Compensation, Footnote" } } }, "auth_ref": [ "r833" ] }, "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "AdjustmentsForNewAccountingPronouncementsAxis", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureXomaTransactionAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureNatureOfBusinessAndSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Accounting Standards Update [Axis]", "documentation": "Information by amendment to accounting standards." } } }, "auth_ref": [ "r34", "r35", "r36", "r37", "r38", "r39", "r110", "r111", "r112", "r133", "r134", "r135", "r136", "r137", "r138", "r148", "r210", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r289", "r290", "r291", "r292", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r387", "r388", "r389", "r390", "r395", "r396", "r397", "r398", "r399", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r481", "r514", "r515", "r516", "r517", "r518", "r519", "r588", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598", "r599" ] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "totalLabel": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition, Total", "terseLabel": "Stock-based compensation", "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": [ "r356" ] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "AdjustmentsToAdditionalPaidInCapitalStockSplit", "crdr": "debit", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Adjustments to Additional Paid in Capital, Stock Split", "terseLabel": "Payment in lieu of fractional shares in connection with the 1-for-44 reverse stock split effected on March 5, 2024", "verboseLabel": "Payment in lieu of fractional shares", "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from a stock split in which per-share par value or stated value is not changed proportionately." } } }, "auth_ref": [ "r965", "r970", "r972" ] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued", "crdr": "credit", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureEquity2025EquityOfferingsAndCommonWarrantsAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersDeficitEquityUnauditedParenthetical", "http://aptevotherapeutics.com/20260630/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "terseLabel": "Warrant modification - incremental fair value", "label": "Adjustments to Additional Paid in Capital, Warrant Issued", "verboseLabel": "Warrant modification - incremental value", "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants." } } }, "auth_ref": [ "r7", "r965", "r970", "r972" ] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:", "label": "Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract]" } } }, "auth_ref": [] }, "apvo_AggregateBeneficialOwnershipLimitationPercentage": { "xbrltype": "percentItemType", "nsuri": "http://aptevotherapeutics.com/20260630", "localname": "AggregateBeneficialOwnershipLimitationPercentage", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureEquity2026NiowaveCommonWarrantsAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Aggregate Beneficial Ownership Limitation Percentage", "documentation": "Aggregate beneficial ownership limitation percentage.", "terseLabel": "Aggregate beneficial ownership limitation percentage" } } }, "auth_ref": [] }, "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]", "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table" } } }, "auth_ref": [ "r866" ] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "AggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Amount", "terseLabel": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r792", "r802", "r812", "r844" ] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]", "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined" } } }, "auth_ref": [ "r795", "r805", "r815", "r847" ] }, "ecd_AggtPnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "AggtPnsnAdjsSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Pension Adjustments Service Cost [Member]", "terseLabel": "Aggregate Pension Adjustments Service Cost" } } }, "auth_ref": [ "r867" ] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "AllAdjToCompMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "All Adjustments to Compensation [Member]", "terseLabel": "All Adjustments to Compensation" } } }, "auth_ref": [ "r833" ] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "AllExecutiveCategoriesMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "All Executive Categories [Member]", "terseLabel": "All Executive Categories" } } }, "auth_ref": [ "r840" ] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "AllIndividualsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "All Individuals [Member]", "terseLabel": "All Individuals" } } }, "auth_ref": [ "r796", "r806", "r816", "r840", "r848", "r852", "r860" ] }, "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "AllTradingArrangementsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "All Trading Arrangements [Member]", "terseLabel": "All Trading Arrangements" } } }, "auth_ref": [ "r858" ] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation expense", "label": "Share-Based Payment Arrangement, Expense", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": [ "r385", "r391", "r392" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "AmendmentFlag", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "verboseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "apvo_AndyHillCancerResearchEndowmentCAREFundMember": { "xbrltype": "domainItemType", "nsuri": "http://aptevotherapeutics.com/20260630", "localname": "AndyHillCancerResearchEndowmentCAREFundMember", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureGrantAgreementAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Andy Hill Cancer Research Endowment (CARE) Fund [Member]", "documentation": "Andyhillcancerresearchendowment(CARE)fundmember" } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureNetLossPerShareSummaryOfPotentiallyDilutiveSharesExcludedFromCalculationOfNetLossPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Anti-dilutive shares excluded from calculation of diluted net loss per share", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": [ "r161" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureNetLossPerShareSummaryOfPotentiallyDilutiveSharesExcludedFromCalculationOfNetLossPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities", "label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": [ "r161" ] }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureNetLossPerShareSummaryOfPotentiallyDilutiveSharesExcludedFromCalculationOfNetLossPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities, Name", "label": "Antidilutive Securities, Name [Domain]", "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": [ "r161" ] }, "apvo_April2024CommonWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://aptevotherapeutics.com/20260630", "localname": "April2024CommonWarrantsMember", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureEquity2024CommonWarrantsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "April 2024 Common Warrants [Member]", "documentation": "April 2024 common warrants.", "terseLabel": "April 2024 Warrants" } } }, "auth_ref": [] }, "apvo_April42025RegisteredDirectOfferingMember": { "xbrltype": "domainItemType", "nsuri": "http://aptevotherapeutics.com/20260630", "localname": "April42025RegisteredDirectOfferingMember", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureEquity2025EquityOfferingsAndCommonWarrantsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "April 4 2025 Registered Direct Offering [Member]", "documentation": "April 4 2025 registered direct offering.", "terseLabel": "April 4, 2025 Registered Direct Offering" } } }, "auth_ref": [] }, "apvo_AprilTwoThousandTwentyFourWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://aptevotherapeutics.com/20260630", "localname": "AprilTwoThousandTwentyFourWarrantsMember", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureEquity2023And2024CommonWarrantsAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureEquity2024CommonWarrantsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "April Two Thousand Twenty Four Warrants [Member]", "documentation": "April two thousand twenty four warrants.", "terseLabel": "April 2024 Warrant" } } }, "auth_ref": [] }, "apvo_AptevoBiotherapeuticsMember": { "xbrltype": "domainItemType", "nsuri": "http://aptevotherapeutics.com/20260630", "localname": "AptevoBiotherapeuticsMember", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureDiscontinuedOperationsAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureDiscontinuedOperationsSummaryOfReconciliationOfCarryingAmountsOfAssetsAndLiabilitiesAndIncomeLossFromDiscontinuedOperationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Aptevo BioTherapeutics", "label": "Aptevo BioTherapeutics [Member]", "documentation": "Aptevo BioTherapeutics." } } }, "auth_ref": [] }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ArrangementsAndNonarrangementTransactionsMember", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureEquity2023And2024CommonWarrantsAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureEquity2024CommonWarrantsAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureEquityStandbyEquityPurchaseAgreementAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureXomaTransactionAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureNatureOfBusinessAndSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]", "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r419" ] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "Assets", "crdr": "debit", "calculation": { "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total assets", "label": "Assets", "documentation": "Amount of asset recognized for present right to economic benefit." } } }, "auth_ref": [ "r59", "r66", "r77", "r119", "r122", "r123", "r166", "r179", "r198", "r202", "r209", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r325", "r421", "r425", "r483", "r549", "r550", "r551", "r565", "r566", "r573", "r647", "r724", "r725", "r741", "r769", "r771", "r772", "r783", "r960", "r961", "r1025" ] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "AssetsAbstract", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureSegmentInformationSummaryOfSignificantAssetCategoriesDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "ASSETS", "label": "Assets [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "label": "Assets, Current", "documentation": "Amount of asset recognized for present right to economic benefit, classified as current." } } }, "auth_ref": [ "r59", "r66", "r101", "r119", "r122", "r123", "r209", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r325", "r421", "r425", "r483", "r769", "r888", "r960", "r961", "r1025" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "AssetsCurrentAbstract", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Current assets:", "label": "Assets, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "AssetsFairValueDisclosure", "crdr": "debit", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Assets, Fair Value Disclosure", "totalLabel": "Assets, Fair Value Disclosure, Total", "terseLabel": "Fair value assets", "documentation": "Fair value portion of asset recognized for present right to economic benefit." } } }, "auth_ref": [ "r460", "r461", "r760" ] }, "apvo_AssumptionsOfFairValueOfWarrantsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://aptevotherapeutics.com/20260630", "localname": "AssumptionsOfFairValueOfWarrantsTableTextBlock", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureEquityTables" ], "lang": { "en-us": { "role": { "terseLabel": "Assumptions Used in Estimating Fair Value of Common Warrants under Black-Scholes Valuation Model", "label": "Assumptions Of Fair Value Of Warrants [Table Text Block]", "documentation": "Assumptions of fair value of warrants." } } }, "auth_ref": [] }, "apvo_AtTheMarketOfferingMember": { "xbrltype": "domainItemType", "nsuri": "http://aptevotherapeutics.com/20260630", "localname": "AtTheMarketOfferingMember", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureEquity2025EquityOfferingsAndCommonWarrantsAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureEquityAtTheMarketOfferingAgreementAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "At The Market Offering [Member]", "documentation": "At The Market Offering.", "terseLabel": "At-The-Market Offering", "verboseLabel": "At The Market Offering" } } }, "auth_ref": [] }, "apvo_AugustTwoThousandTwentyThreeWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://aptevotherapeutics.com/20260630", "localname": "AugustTwoThousandTwentyThreeWarrantsMember", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureEquity2023And2024CommonWarrantsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "August Two Thousand Twenty Three Warrants [Member]", "documentation": "August wo thousand twenty three warrants.", "terseLabel": "August 2023 Warrant" } } }, "auth_ref": [] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "AwardExrcPrice", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Exercise Price", "terseLabel": "Exercise Price" } } }, "auth_ref": [ "r855" ] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "AwardGrantDateFairValue", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Grant Date Fair Value", "terseLabel": "Fair Value as of Grant Date" } } }, "auth_ref": [ "r856" ] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]", "terseLabel": "Award Timing Disclosures" } } }, "auth_ref": [ "r851" ] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing, How MNPI Considered [Text Block]", "terseLabel": "Award Timing, How MNPI Considered" } } }, "auth_ref": [ "r851" ] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "AwardTmgMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing Method [Text Block]", "terseLabel": "Award Timing Method" } } }, "auth_ref": [ "r851" ] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Considered [Flag]", "terseLabel": "Award Timing MNPI Considered" } } }, "auth_ref": [ "r851" ] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Disclosure [Text Block]", "terseLabel": "Award Timing MNPI Disclosure" } } }, "auth_ref": [ "r851" ] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "AwardTmgPredtrmndFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing Predetermined [Flag]", "terseLabel": "Award Timing Predetermined" } } }, "auth_ref": [ "r851" ] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "AwardTypeAxis", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Type [Axis]", "terseLabel": "Award Type", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r380", "r381", "r382", "r383", "r384" ] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "AwardUndrlygSecuritiesAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Underlying Securities Amount", "terseLabel": "Underlying Securities" } } }, "auth_ref": [ "r854" ] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r853" ] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "AwardsCloseToMnpiDiscTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table]", "terseLabel": "Awards Close in Time to MNPI Disclosures" } } }, "auth_ref": [ "r852" ] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]", "terseLabel": "Awards Close in Time to MNPI Disclosures, Table" } } }, "auth_ref": [ "r852" ] }, "apvo_BasicAndDilutedNetIncomeLossPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://aptevotherapeutics.com/20260630", "localname": "BasicAndDilutedNetIncomeLossPerShareAbstract", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureNetLossPerShareComputationOfBasicAndDilutedNetLossPerShareDetails3" ], "lang": { "en-us": { "role": { "label": "Basic and Diluted Net Income (Loss) per Share [Abstract]", "documentation": "Basic and diluted net income (loss) per share.", "terseLabel": "Basic and diluted net loss per share:" } } }, "auth_ref": [] }, "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureNatureOfBusinessAndSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Basis of Presentation", "label": "Basis of Presentation and Significant Accounting Policies [Text Block]", "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity." } } }, "auth_ref": [ "r917" ] }, "apvo_BeneficialOwnershipExceedingPercentageOfOutstandingCommonStock": { "xbrltype": "percentItemType", "nsuri": "http://aptevotherapeutics.com/20260630", "localname": "BeneficialOwnershipExceedingPercentageOfOutstandingCommonStock", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureEquityStandbyEquityPurchaseAgreementAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Beneficial ownership exceeding percentage of outstanding common stock", "documentation": "Beneficial ownership exceeding percentage of outstanding common stock.", "terseLabel": "Beneficial ownership exceeding percentage of outstanding common stock" } } }, "auth_ref": [] }, "apvo_BeneficialOwnershipLimitation": { "xbrltype": "percentItemType", "nsuri": "http://aptevotherapeutics.com/20260630", "localname": "BeneficialOwnershipLimitation", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Beneficial ownership limitation", "documentation": "Beneficial ownership limitation." } } }, "auth_ref": [] }, "apvo_BeneficialOwnershipLimitationPercentage": { "xbrltype": "percentItemType", "nsuri": "http://aptevotherapeutics.com/20260630", "localname": "BeneficialOwnershipLimitationPercentage", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureEquity2026NiowaveCommonWarrantsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Beneficial Ownership Limitation Percentage", "documentation": "Beneficial ownership limitation percentage.", "terseLabel": "Beneficial ownership limitation percentage" } } }, "auth_ref": [] }, "apvo_BroadridgeCorporateIssuerSolutionsMember": { "xbrltype": "domainItemType", "nsuri": "http://aptevotherapeutics.com/20260630", "localname": "BroadridgeCorporateIssuerSolutionsMember", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Broadridge Corporate Issuer Solutions", "label": "Broadridge Corporate Issuer Solutions [Member]", "documentation": "Broadridge Corporate Issuer Solutions." } } }, "auth_ref": [] }, "us-gaap_BusinessExitCosts1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "BusinessExitCosts1", "crdr": "debit", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exit fees", "label": "Business Exit Costs", "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Includes, but is not limited to, one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, and relocating employees, and termination benefits associated with an ongoing benefit arrangement. Excludes expenses associated with special or contractual termination benefits, a discontinued operation or an asset retirement obligation." } } }, "auth_ref": [ "r4" ] }, "us-gaap_Cash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "Cash", "crdr": "debit", "calculation": { "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureCashAndCashEquivalentsScheduleOfCashAndCashEquivalentsDetails": { "parentTag": "us-gaap_CashAndCashEquivalentsAtCarryingValue", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureCashAndCashEquivalentsScheduleOfCashAndCashEquivalentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash", "label": "Cash", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r29", "r116", "r118", "r574", "r623", "r642", "r769", "r771", "r772", "r783", "r892", "r1033", "r1034", "r1035" ] }, "us-gaap_CashAndCashEquivalentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "CashAndCashEquivalentsAbstract", "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 0.0 }, "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureCashAndCashEquivalentsScheduleOfCashAndCashEquivalentsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureCashAndCashEquivalentsScheduleOfCashAndCashEquivalentsDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureSegmentInformationSummaryOfSignificantAssetCategoriesDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "label": "Cash and Cash Equivalent", "totalLabel": "Total cash and cash equivalents", "documentation": "Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate." } } }, "auth_ref": [ "r76", "r116", "r118", "r703", "r1027" ] }, "us-gaap_CashAndCashEquivalentsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "CashAndCashEquivalentsDisclosureTextBlock", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureCashAndCashEquivalents1" ], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents Disclosure [Text Block]", "terseLabel": "Cash and Cash Equivalents", "documentation": "The entire disclosure for cash and cash equivalent footnotes, which may include the types of deposits and money market instruments, applicable carrying amounts, restricted amounts and compensating balance arrangements. Cash and equivalents include: (1) currency on hand (2) demand deposits with banks or financial institutions (3) other kinds of accounts that have the general characteristics of demand deposits (4) short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments maturing within three months from the date of acquisition qualify." } } }, "auth_ref": [ "r76", "r117", "r574", "r870" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "crdr": "debit", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations, Total", "label": "Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Including Discontinued Operation", "periodStartLabel": "Cash and cash equivalents at beginning of period", "periodEndLabel": "Cash and cash equivalents at end of period", "documentation": "Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate." } } }, "auth_ref": [ "r14", "r116", "r118" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "lang": { "en-us": { "role": { "label": "Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation", "totalLabel": "Increase (decrease) in cash and cash equivalents", "documentation": "Amount of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including effect from exchange rate change and including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate." } } }, "auth_ref": [ "r0", "r14" ] }, "us-gaap_CashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "CashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureCashAndCashEquivalentsScheduleOfCashAndCashEquivalentsDetails": { "parentTag": "us-gaap_CashAndCashEquivalentsAtCarryingValue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureCashAndCashEquivalentsScheduleOfCashAndCashEquivalentsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Cash Equivalents, at Carrying Value, Total", "terseLabel": "Cash equivalents", "label": "Cash Equivalents, at Carrying Value", "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r116", "r118", "r892", "r1041" ] }, "apvo_CashEquivalentsMaturityPeriod": { "xbrltype": "durationItemType", "nsuri": "http://aptevotherapeutics.com/20260630", "localname": "CashEquivalentsMaturityPeriod", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureCashAndCashEquivalentsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash equivalents, maturity period", "label": "Cash Equivalents Maturity Period", "documentation": "Cash equivalents maturity period." } } }, "auth_ref": [] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "ChangedPeerGroupFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Changed Peer Group, Footnote [Text Block]", "terseLabel": "Changed Peer Group, Footnote" } } }, "auth_ref": [ "r831" ] }, "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]", "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year" } } }, "auth_ref": [ "r828" ] }, "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]", "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested" } } }, "auth_ref": [ "r826" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "CityAreaCode", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ClassOfStockDomain", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Stock", "label": "Class of Stock [Domain]", "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "auth_ref": [ "r33", "r72", "r73", "r90", "r91", "r92", "r93", "r94", "r95", "r119", "r123", "r154", "r155", "r158", "r160", "r168", "r169", "r209", "r252", "r254", "r255", "r256", "r259", "r260", "r293", "r294", "r296", "r297", "r299", "r302", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r320", "r321", "r324", "r325", "r326", "r483", "r549", "r550", "r556", "r557", "r558", "r571", "r602", "r603", "r604", "r605", "r611", "r613", "r614", "r615", "r616", "r617", "r618", "r619", "r620", "r621", "r622", "r624", "r634", "r655", "r677", "r687", "r688", "r689", "r690", "r691", "r871", "r920", "r922", "r930", "r971", "r976" ] }, "us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable": { "xbrltype": "dateItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right, Date from which Warrants or Rights Exercisable", "terseLabel": "Warrants exercisable date", "documentation": "Date the warrants or rights are exercisable, in YYYY-MM-DD format." } } }, "auth_ref": [ "r315" ] }, "us-gaap_ClassOfWarrantOrRightAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ClassOfWarrantOrRightAxis", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureEquity2023And2024CommonWarrantsAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureEquity2024CommonWarrantsAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureEquity2025EquityOfferingsAndCommonWarrantsAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureEquity2026NiowaveCommonWarrantsAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureEquitySummaryOfAssumptionsUsedToEstimateTheFairValueOfTheWarrantsUsingTheBlackscholesOptionPricingModelDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureEquityTables" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Axis]", "documentation": "Information by type of warrant or right issued." } } }, "auth_ref": [ "r966" ] }, "us-gaap_ClassOfWarrantOrRightDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ClassOfWarrantOrRightDomain", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureEquity2023And2024CommonWarrantsAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureEquity2024CommonWarrantsAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureEquity2025EquityOfferingsAndCommonWarrantsAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureEquity2026NiowaveCommonWarrantsAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureEquitySummaryOfAssumptionsUsedToEstimateTheFairValueOfTheWarrantsUsingTheBlackscholesOptionPricingModelDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureEquityTables" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Domain]", "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months." } } }, "auth_ref": [ "r966" ] }, "apvo_ClassOfWarrantOrRightExercisable": { "xbrltype": "sharesItemType", "nsuri": "http://aptevotherapeutics.com/20260630", "localname": "ClassOfWarrantOrRightExercisable", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureEquitySummaryOfCommonWarrantActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of Shares, Exercisable", "label": "Class Of Warrant Or Right Exercisable", "documentation": "Class of warrant or right exercisable" } } }, "auth_ref": [] }, "apvo_ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://aptevotherapeutics.com/20260630", "localname": "ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureEquitySummaryOfCommonWarrantActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-Average Exercise Price, Exercisable", "label": "Class Of Warrant Or Right Exercisable Weighted Average Exercise Price", "documentation": "Class of warrant or right exercisable weighted average exercise price." } } }, "auth_ref": [] }, "apvo_ClassOfWarrantOrRightExercisableWeightedAverageRemainingContractualTerm": { "xbrltype": "durationItemType", "nsuri": "http://aptevotherapeutics.com/20260630", "localname": "ClassOfWarrantOrRightExercisableWeightedAverageRemainingContractualTerm", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureEquitySummaryOfCommonWarrantActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-Average Remaining Term, Exercisable", "label": "Class Of Warrant Or Right Exercisable Weighted Average Remaining Contractual Term", "documentation": "Class of warrant or right exercisable weighted average remaining contractual term." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureEquity2023And2024CommonWarrantsAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureEquity2024CommonWarrantsAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureEquity2025EquityOfferingsAndCommonWarrantsAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureEquity2026NiowaveCommonWarrantsAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureLeasesSummaryOfRightOfUseAssetsAcquiredUnderOperatingLeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warrants exercise price, per share", "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights", "verboseLabel": "Share of common stock underlying common warrants", "documentation": "Exercise price per share or per unit of warrants or rights outstanding." } } }, "auth_ref": [ "r119", "r124", "r315" ] }, "apvo_ClassOfWarrantOrRightExercised": { "xbrltype": "sharesItemType", "nsuri": "http://aptevotherapeutics.com/20260630", "localname": "ClassOfWarrantOrRightExercised", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureEquity2025EquityOfferingsAndCommonWarrantsAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureEquitySummaryOfCommonWarrantActivityDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Number of Shares, Exercised", "label": "Class Of Warrant Or Right Exercised", "documentation": "Class of warrant or right exercised.", "terseLabel": "Common warrants exercised" } } }, "auth_ref": [] }, "apvo_ClassOfWarrantOrRightExercisedWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://aptevotherapeutics.com/20260630", "localname": "ClassOfWarrantOrRightExercisedWeightedAverageExercisePrice", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureEquitySummaryOfCommonWarrantActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-Average Exercise Price, Exercised", "label": "Class Of Warrant Or Right Exercised Weighted Average Exercise Price", "documentation": "Class of warrant or right exercised weighted average exercise price." } } }, "auth_ref": [] }, "apvo_ClassOfWarrantOrRightExercisedWeightedAverageRemainingContractualTerm": { "xbrltype": "durationItemType", "nsuri": "http://aptevotherapeutics.com/20260630", "localname": "ClassOfWarrantOrRightExercisedWeightedAverageRemainingContractualTerm", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureEquitySummaryOfCommonWarrantActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-Average Remaining Term, Exercised", "label": "Class Of Warrant Or Right Exercised Weighted Average Remaining Contractual Term", "documentation": "Class of warrant or right exercised weighted average remaining contractual term." } } }, "auth_ref": [] }, "apvo_ClassOfWarrantOrRightExpired": { "xbrltype": "sharesItemType", "nsuri": "http://aptevotherapeutics.com/20260630", "localname": "ClassOfWarrantOrRightExpired", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureEquitySummaryOfCommonWarrantActivityDetails" ], "lang": { "en-us": { "role": { "documentation": "Class of warrant or right, expired.", "negatedLabel": "Number of Shares, Expired", "label": "Class of warrant or right, expired" } } }, "auth_ref": [] }, "apvo_ClassOfWarrantOrRightExpiredWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://aptevotherapeutics.com/20260630", "localname": "ClassOfWarrantOrRightExpiredWeightedAverageExercisePrice", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureEquitySummaryOfCommonWarrantActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-Average Exercise Price, Expired", "label": "Class of warrant or right expired weighted average exercise price", "documentation": "Class of warrant or right expired weighted average exercise price." } } }, "auth_ref": [] }, "apvo_ClassOfWarrantOrRightExpiredWeightedAverageRemainingContractualTerm": { "xbrltype": "durationItemType", "nsuri": "http://aptevotherapeutics.com/20260630", "localname": "ClassOfWarrantOrRightExpiredWeightedAverageRemainingContractualTerm", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureEquitySummaryOfCommonWarrantActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-Average Remaining Term, Expired", "label": "Class of warrant or right expired weighted average remaining contractual term", "documentation": "Class of warrant or right expired weighted average remaining contractual term." } } }, "auth_ref": [] }, "apvo_ClassOfWarrantOrRightIssued": { "xbrltype": "sharesItemType", "nsuri": "http://aptevotherapeutics.com/20260630", "localname": "ClassOfWarrantOrRightIssued", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureEquitySummaryOfCommonWarrantActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of Shares, Issued", "label": "Class Of Warrant Or Right Issued", "documentation": "Class of warrant or right issued." } } }, "auth_ref": [] }, "apvo_ClassOfWarrantOrRightIssuedWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://aptevotherapeutics.com/20260630", "localname": "ClassOfWarrantOrRightIssuedWeightedAverageExercisePrice", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureEquitySummaryOfCommonWarrantActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-Average Exercise Price, Issued", "label": "Class Of Warrant Or Right Issued Weighted Average Exercise Price", "documentation": "Class of warrant or right issued weighted average exercise price." } } }, "auth_ref": [] }, "apvo_ClassOfWarrantOrRightIssuedWeightedAverageRemainingContractualTerm": { "xbrltype": "durationItemType", "nsuri": "http://aptevotherapeutics.com/20260630", "localname": "ClassOfWarrantOrRightIssuedWeightedAverageRemainingContractualTerm", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureEquitySummaryOfCommonWarrantActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-Average Remaining Term, Issued", "label": "Class Of Warrant Or Right Issued Weighted Average Remaining Contractual Term", "documentation": "Class of warrant or right issued weighted average remaining contractual term." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureEquity2023And2024CommonWarrantsAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureEquity2025EquityOfferingsAndCommonWarrantsAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureEquity2026NiowaveCommonWarrantsAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of common stock to be issued up conversion of warrants", "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights", "verboseLabel": "Warrants to purchase common stock", "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares." } } }, "auth_ref": [ "r966" ] }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ClassOfWarrantOrRightOutstanding", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureEquity2023And2024CommonWarrantsAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureEquity2024CommonWarrantsAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureEquity2025EquityOfferingsAndCommonWarrantsAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureEquitySummaryOfCommonWarrantActivityDetails" ], "lang": { "en-us": { "role": { "periodEndLabel": "Number of Shares, Outstanding, Ending Balance", "periodStartLabel": "Number of Shares, Outstanding, Beginning Balance", "terseLabel": "Warrants outstanding", "label": "Class of Warrant or Right, Outstanding", "verboseLabel": "Outstanding warrants issued", "documentation": "Number of warrants or rights outstanding." } } }, "auth_ref": [] }, "apvo_ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://aptevotherapeutics.com/20260630", "localname": "ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureEquitySummaryOfCommonWarrantActivityDetails" ], "lang": { "en-us": { "role": { "periodEndLabel": "Weighted-Average Exercise Price, Outstanding, Ending Balance", "periodStartLabel": "Weighted-Average Exercise Price, Outstanding, Beginning Balance", "label": "Class Of Warrant Or Right Outstanding Weighted Average Exercise Price", "documentation": "Class of warrant or right outstanding weighted average exercise\u00a0price." } } }, "auth_ref": [] }, "apvo_ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualTerm": { "xbrltype": "durationItemType", "nsuri": "http://aptevotherapeutics.com/20260630", "localname": "ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualTerm", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureEquitySummaryOfCommonWarrantActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-Average Remaining Term, Outstanding", "label": "Class Of Warrant Or Right Outstanding Weighted Average Remaining Contractual Term", "documentation": "Class of warrant or right outstanding weighted average remaining contractual term." } } }, "auth_ref": [] }, "apvo_ClosingPaymentsReceived": { "xbrltype": "monetaryItemType", "nsuri": "http://aptevotherapeutics.com/20260630", "localname": "ClosingPaymentsReceived", "crdr": "credit", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureLiabilityRelatedToSaleOfRoyaltiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Closing payments", "label": "Closing payments received", "documentation": "Closing payments received." } } }, "auth_ref": [] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "CoSelectedMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Company Selected Measure Amount", "terseLabel": "Company Selected Measure Amount" } } }, "auth_ref": [ "r832" ] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "CoSelectedMeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Company Selected Measure Name", "terseLabel": "Company Selected Measure Name" } } }, "auth_ref": [ "r832" ] }, "us-gaap_CollaborativeArrangementDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "CollaborativeArrangementDisclosureTextBlock", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureCollaborationAgreements" ], "lang": { "en-us": { "role": { "terseLabel": "Collaboration Agreements", "label": "Collaborative Arrangement Disclosure [Text Block]", "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants." } } }, "auth_ref": [ "r32", "r417", "r418" ] }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r419" ] }, "us-gaap_CommonClassAMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "CommonClassAMember", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureEquity2023And2024CommonWarrantsAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Common Class A [Member]", "terseLabel": "Series A", "documentation": "Classification of common stock representing ownership interest in a corporation." } } }, "auth_ref": [ "r899", "r966", "r968", "r1033", "r1034", "r1037", "r1044" ] }, "us-gaap_CommonClassBMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "CommonClassBMember", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureEquity2023And2024CommonWarrantsAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Common Class B [Member]", "terseLabel": "Series B", "documentation": "Classification of common stock that has different rights than Common Class A, representing ownership interest in a corporation." } } }, "auth_ref": [ "r899", "r966", "r968", "r1033", "r1034", "r1037", "r1044" ] }, "apvo_CommonStockIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://aptevotherapeutics.com/20260630", "localname": "CommonStockIssuanceCosts", "crdr": "debit", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureEquityAtTheMarketOfferingAgreementAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersDeficitEquityUnauditedParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance costs", "label": "Common Stock Issuance Costs", "documentation": "Common stock issuance costs." } } }, "auth_ref": [] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "CommonStockMember", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersDeficitEquityUnauditedParenthetical", "http://aptevotherapeutics.com/20260630/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "terseLabel": "Common Stock", "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r95", "r321", "r549", "r550", "r558", "r773", "r774", "r775", "r777", "r778", "r779", "r780", "r926", "r927", "r929", "r1011", "r1042", "r1044" ] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureEquity2026NiowaveCommonWarrantsAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, par value", "label": "Common Stock, Par or Stated Value Per Share", "verboseLabel": "Par value", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r899", "r968", "r1033", "r1034", "r1037" ] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "CommonStockSharesAuthorized", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares authorized", "label": "Common Stock, Shares Authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r95", "r321", "r549", "r550", "r558", "r634" ] }, "apvo_CommonStockSharesIssuanceApprovalThresholdPercentage": { "xbrltype": "percentItemType", "nsuri": "http://aptevotherapeutics.com/20260630", "localname": "CommonStockSharesIssuanceApprovalThresholdPercentage", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureEquityStandbyEquityPurchaseAgreementAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Common Stock Shares Issuance Approval Threshold Percentage", "documentation": "Common stock shares issuance approval threshold percentage.", "terseLabel": "Percentage of outstanding shares approved for potential issuance" } } }, "auth_ref": [] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "CommonStockSharesIssued", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares issued", "label": "Common Stock, Shares, Issued", "verboseLabel": "Common stock issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r95", "r321", "r549", "r550", "r558" ] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "CommonStockSharesOutstanding", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical" ], "lang": { "en-us": { "role": { "verboseLabel": "Common stock outstanding", "periodEndLabel": "Common Stock, Shares, Outstanding, Ending Balance", "periodStartLabel": "Common Stock, Shares, Outstanding, Beginning Balance", "terseLabel": "Common stock, shares outstanding", "label": "Common Stock, Shares, Outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r95", "r321", "r549", "r550", "r558", "r634", "r653", "r965", "r1044", "r1045" ] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureEquityStandbyEquityPurchaseAgreementAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" ], "lang": { "en-us": { "role": { "label": "Common Stock, Value, Issued", "verboseLabel": "Common stock value", "terseLabel": "Common stock: $0.001 par value; 500,000,000 shares authorized; 1,418,952 and 997,830 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r95", "r294", "r301", "r321", "r549", "r550", "r558", "r576", "r769" ] }, "apvo_CommonWarrantIssued": { "xbrltype": "sharesItemType", "nsuri": "http://aptevotherapeutics.com/20260630", "localname": "CommonWarrantIssued", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureEquity2026NiowaveCommonWarrantsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Common Warrant Issued", "documentation": "Common warrant issued.", "terseLabel": "Common warrant issued" } } }, "auth_ref": [] }, "apvo_CommonWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://aptevotherapeutics.com/20260630", "localname": "CommonWarrantsMember", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureEquity2023And2024CommonWarrantsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "2023 Common Warrants [Member]", "documentation": "2023 Common Warrants.", "terseLabel": "2023 Common Warrants" } } }, "auth_ref": [] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Company Selected Measure" } } }, "auth_ref": [ "r837" ] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Net Income [Text Block]", "terseLabel": "Compensation Actually Paid vs. Net Income" } } }, "auth_ref": [ "r836" ] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Other Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Other Measure" } } }, "auth_ref": [ "r838" ] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]", "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return" } } }, "auth_ref": [ "r835" ] }, "apvo_CostsUnderTheGrantAwardAgreement": { "xbrltype": "monetaryItemType", "nsuri": "http://aptevotherapeutics.com/20260630", "localname": "CostsUnderTheGrantAwardAgreement", "crdr": "debit", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureGrantAgreementAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Costs Under the Grant Award Agreement", "documentation": "Costsunderthegrantawardagreement." } } }, "auth_ref": [] }, "srt_CounterpartyNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2026", "localname": "CounterpartyNameAxis", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureLiabilityRelatedToSaleOfRoyaltiesAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureNatureOfBusinessAndSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Counterparty Name", "label": "Counterparty Name [Axis]" } } }, "auth_ref": [ "r119", "r127", "r128", "r265", "r310", "r525", "r530", "r544", "r572", "r707", "r708", "r709", "r903", "r904", "r905", "r906", "r907", "r908", "r909", "r910", "r911", "r1006", "r1007", "r1008", "r1009", "r1028", "r1029" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "apvo_CreditAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://aptevotherapeutics.com/20260630", "localname": "CreditAgreementMember", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Credit Agreement", "label": "Credit Agreement [Member]", "documentation": "Credit agreement member." } } }, "auth_ref": [] }, "us-gaap_CreditFacilityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "CreditFacilityAxis", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureCashAndCashEquivalentsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Credit Facility", "label": "Credit Facility [Axis]", "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": [ "r74", "r79", "r251", "r549", "r550", "r552", "r958" ] }, "us-gaap_CreditFacilityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "CreditFacilityDomain", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureCashAndCashEquivalentsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Credit Facility", "label": "Credit Facility [Domain]", "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": [ "r74", "r79", "r251", "r549", "r550", "r552", "r958" ] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Current Fiscal Year End Date", "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "DebtDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "DebtDisclosureTextBlock", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureDebt" ], "lang": { "en-us": { "role": { "terseLabel": "Debt", "label": "Debt Disclosure [Text Block]", "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants." } } }, "auth_ref": [ "r20", "r74", "r75", "r79", "r80", "r82", "r84", "r85", "r87", "r88", "r119", "r121", "r241", "r242", "r243", "r244", "r245", "r250", "r251", "r261", "r267", "r268", "r269", "r270", "r271", "r272", "r277", "r284", "r285", "r287", "r427", "r497", "r549", "r550", "r555" ] }, "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "DebtInstrumentAxis", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument", "label": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } }, "auth_ref": [ "r74", "r75", "r79", "r82", "r83", "r84", "r85", "r86", "r88", "r262", "r263", "r264", "r265", "r266", "r268", "r273", "r274", "r275", "r276", "r278", "r279", "r280", "r281", "r282", "r283", "r315", "r549", "r550", "r555", "r736", "r737", "r738", "r739", "r740", "r767", "r918", "r919", "r921", "r924", "r954", "r955", "r956", "r1018", "r1019", "r1038" ] }, "us-gaap_DebtInstrumentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "DebtInstrumentLineItems", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureLiabilityRelatedToSaleOfRoyaltiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument [Line Items]", "label": "Debt Instrument [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r75", "r82", "r83", "r84", "r85", "r86", "r88", "r262", "r263", "r264", "r265", "r266", "r268", "r273", "r274", "r275", "r276", "r278", "r279", "r280", "r281", "r282", "r283", "r286", "r315", "r427", "r549", "r550", "r555", "r568", "r736", "r737", "r738", "r739", "r740", "r767", "r918", "r919", "r921", "r924", "r1018", "r1019" ] }, "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "DebtInstrumentNameDomain", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument, Name", "label": "Debt Instrument, Name [Domain]", "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth_ref": [ "r74", "r75", "r79", "r82", "r83", "r84", "r85", "r86", "r88", "r262", "r263", "r264", "r265", "r266", "r268", "r273", "r274", "r275", "r276", "r278", "r279", "r280", "r281", "r282", "r283", "r315", "r549", "r550", "r555", "r736", "r737", "r738", "r739", "r740", "r767", "r918", "r919", "r921", "r924", "r954", "r955", "r956", "r1018", "r1019", "r1038" ] }, "us-gaap_DebtInstrumentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "DebtInstrumentTable", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureLiabilityRelatedToSaleOfRoyaltiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument [Table]", "label": "Schedule of Long-Term Debt Instruments [Table]", "documentation": "Disclosure of information about long-term debt instrument or arrangement." } } }, "auth_ref": [ "r10", "r26", "r27", "r28", "r75", "r82", "r83", "r84", "r85", "r86", "r88", "r262", "r263", "r264", "r265", "r266", "r268", "r273", "r274", "r275", "r276", "r278", "r279", "r280", "r281", "r282", "r283", "r286", "r315", "r427", "r549", "r550", "r555", "r568", "r736", "r737", "r738", "r739", "r740", "r767", "r918", "r919", "r921", "r924", "r1018", "r1019" ] }, "apvo_December2024WarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://aptevotherapeutics.com/20260630", "localname": "December2024WarrantsMember", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureEquity2024CommonWarrantsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "December 2024 Warrants", "label": "December 2024 Warrants [Member]", "documentation": "December 2024 Warrants." } } }, "auth_ref": [] }, "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosurePrepaidExpensesOtherCurrentAssetsAccruedExpensesAndOtherCurrentLiabilitiesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Prepaid Expenses and Other Current Assets", "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]", "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs." } } }, "auth_ref": [] }, "us-gaap_DeferredFinanceCostsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "DeferredFinanceCostsGross", "crdr": "debit", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureLiabilityRelatedToSaleOfRoyaltiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Transaction costs", "label": "Debt Issuance Costs, Gross", "documentation": "Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs." } } }, "auth_ref": [ "r1018", "r1019" ] }, "apvo_DeferredPaymentsIncreasePercentage": { "xbrltype": "percentItemType", "nsuri": "http://aptevotherapeutics.com/20260630", "localname": "DeferredPaymentsIncreasePercentage", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureDiscontinuedOperationsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred payments increase percentage", "label": "Deferred Payments Increase Percentage", "documentation": "Deferred payments increase percentage." } } }, "auth_ref": [] }, "us-gaap_DepreciationDepletionAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "DepreciationDepletionAndAmortization", "crdr": "debit", "calculation": { "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Depreciation, Depletion and Amortization, Total", "terseLabel": "Depreciation and amortization", "label": "Depreciation, Depletion and Amortization", "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets." } } }, "auth_ref": [ "r4", "r109", "r166", "r184", "r202", "r710", "r724", "r725", "r941", "r942", "r945", "r947" ] }, "apvo_DiscontinuedOperatingGainOnContingentConsideration": { "xbrltype": "monetaryItemType", "nsuri": "http://aptevotherapeutics.com/20260630", "localname": "DiscontinuedOperatingGainOnContingentConsideration", "crdr": "credit", "calculation": { "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureDiscontinuedOperationsSummaryOfReconciliationOfCarryingAmountsOfAssetsAndLiabilitiesAndIncomeLossFromDiscontinuedOperationDetails": { "parentTag": "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureDiscontinuedOperationsSummaryOfReconciliationOfCarryingAmountsOfAssetsAndLiabilitiesAndIncomeLossFromDiscontinuedOperationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gain on contingent consideration", "label": "Discontinued Operating Gain On Contingent Consideration", "documentation": "Discontinued Operating Gain on Contingent Consideration." } } }, "auth_ref": [] }, "us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "DiscontinuedOperationsAndDisposalGroupsAbstract", "lang": { "en-us": { "role": { "label": "Discontinued Operations and Disposal Groups [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DisposalGroupClassificationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "DisposalGroupClassificationAxis", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureDiscontinuedOperationsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Disposal Group Classification [Axis]", "documentation": "Information by disposal group classification." } } }, "auth_ref": [ "r43", "r44", "r60", "r61", "r62", "r63", "r64", "r68", "r70", "r232", "r235", "r236", "r237", "r238", "r239", "r701", "r944", "r950", "r951", "r952", "r953" ] }, "us-gaap_DisposalGroupClassificationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "DisposalGroupClassificationDomain", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureDiscontinuedOperationsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Disposal Group Classification [Domain]", "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations." } } }, "auth_ref": [ "r43", "r44", "r60", "r61", "r62", "r63", "r64", "r68", "r70", "r232", "r235", "r236", "r237", "r238", "r239", "r701", "r944", "r950", "r951", "r952", "r953" ] }, "apvo_DisposalGroupIncludingDiscontinuedOperationsAccountsReceivableAndDeferredRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://aptevotherapeutics.com/20260630", "localname": "DisposalGroupIncludingDiscontinuedOperationsAccountsReceivableAndDeferredRevenue", "crdr": "credit", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureDiscontinuedOperationsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts receivable and deferred payments from Medexus", "label": "Disposal Group Including Discontinued Operations Accounts Receivable And Deferred Revenue", "documentation": "Disposal group including discontinued operations accounts receivable and deferred revenue." } } }, "auth_ref": [] }, "apvo_DisposalGroupIncludingDiscontinuedOperationsDeferredRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://aptevotherapeutics.com/20260630", "localname": "DisposalGroupIncludingDiscontinuedOperationsDeferredRevenue", "crdr": "credit", "calculation": { "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureDiscontinuedOperationsSummaryOfReconciliationOfCarryingAmountsOfAssetsAndLiabilitiesAndIncomeLossFromDiscontinuedOperationDetails": { "parentTag": "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureDiscontinuedOperationsAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureDiscontinuedOperationsSummaryOfReconciliationOfCarryingAmountsOfAssetsAndLiabilitiesAndIncomeLossFromDiscontinuedOperationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred payment from Medexus", "verboseLabel": "Deferred payment", "label": "Disposal Group Including Discontinued Operations Deferred Revenue", "documentation": "Disposal group including discontinued operations deferred revenue." } } }, "auth_ref": [] }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureDiscontinuedOperations" ], "lang": { "en-us": { "role": { "terseLabel": "Discontinued Operations", "label": "Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]", "documentation": "The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component." } } }, "auth_ref": [ "r42", "r49", "r50", "r51", "r231" ] }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureXomaTransactionAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureDiscontinuedOperationsAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureDiscontinuedOperationsSummaryOfReconciliationOfCarryingAmountsOfAssetsAndLiabilitiesAndIncomeLossFromDiscontinuedOperationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disposal Group Name", "label": "Disposal Group Name [Domain]", "documentation": "Name of disposal group." } } }, "auth_ref": [ "r52", "r53", "r54", "r55", "r56", "r57", "r58", "r238", "r240", "r747", "r748", "r878", "r879", "r950", "r951", "r952", "r953" ] }, "apvo_DividendAttributableToDownRoundFeatureOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://aptevotherapeutics.com/20260630", "localname": "DividendAttributableToDownRoundFeatureOfWarrants", "crdr": "credit", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Dividend Attributable To Down Round Feature Of Warrants", "documentation": "Dividend Attributable To Down Round Feature Of Warrants", "terseLabel": "Dividend attributable to down round feature of warrants" } } }, "auth_ref": [] }, "apvo_DividendDeclaredOfPreferredSharePurchaseRight": { "xbrltype": "sharesItemType", "nsuri": "http://aptevotherapeutics.com/20260630", "localname": "DividendDeclaredOfPreferredSharePurchaseRight", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred share purchase right", "label": "Dividend Declared Of Preferred Share Purchase Right", "documentation": "Dividend declared of preferred share purchase right." } } }, "auth_ref": [] }, "us-gaap_Dividends": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "Dividends", "crdr": "debit", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureEquity2025EquityOfferingsAndCommonWarrantsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Dividends", "totalLabel": "Dividends, Total", "terseLabel": "Deemed dividend", "documentation": "Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock." } } }, "auth_ref": [ "r970", "r972" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "verboseLabel": "Document Fiscal Period Focus", "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Year Focus", "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "DocumentPeriodEndDate", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "verboseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "DocumentQuarterlyReport", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Document Quarterly Report", "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r787" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "DocumentTransitionReport", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Document Transition Report", "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r819" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "DocumentType", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "verboseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]", "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year" } } }, "auth_ref": [ "r830" ] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "EarningsPerShareAbstract", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited" ], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]", "terseLabel": "Basic and diluted net loss per share:" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "EarningsPerShareBasic", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureNetLossPerShareComputationOfBasicAndDilutedNetLossPerShareDetails3", "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Basic net loss per share", "terseLabel": "Basic net loss per share", "label": "Earnings Per Share, Basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r39", "r107", "r134", "r137", "r138", "r139", "r140", "r141", "r142", "r143", "r144", "r150", "r154", "r158", "r159", "r160", "r165", "r228", "r292", "r338", "r389", "r407", "r416", "r456", "r457", "r564", "r585", "r715" ] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "EarningsPerShareDiluted", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureNetLossPerShareComputationOfBasicAndDilutedNetLossPerShareDetails3", "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Diluted net loss per share", "terseLabel": "Diluted net loss per share", "label": "Earnings Per Share, Diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r39", "r107", "r134", "r137", "r138", "r139", "r140", "r141", "r142", "r143", "r144", "r154", "r158", "r159", "r160", "r165", "r228", "r292", "r338", "r389", "r407", "r416", "r456", "r457", "r564", "r585", "r715" ] }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "EarningsPerShareTextBlock", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureNetLossPerShare" ], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Text Block]", "terseLabel": "Net Loss per Share", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": [ "r149", "r161", "r162", "r163", "r164", "r330" ] }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "EmployeeRelatedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosurePrepaidExpensesOtherCurrentAssetsAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDeta": { "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosurePrepaidExpensesOtherCurrentAssetsAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDeta" ], "lang": { "en-us": { "role": { "label": "Employee-related Liabilities, Current", "totalLabel": "Employee-related Liabilities, Current, Total", "terseLabel": "Accrued compensation and benefits", "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r895" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions", "crdr": "debit", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unrecognized compensation expense", "label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount", "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": [ "r1005" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "crdr": "debit", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unrecognized compensation expense", "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount", "documentation": "Amount of cost to be recognized for option under share-based payment arrangement." } } }, "auth_ref": [ "r1005" ] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "EmployeeStockOptionMember", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Employee Stock Option [Member]", "terseLabel": "Employee Stock Option", "verboseLabel": "Outstanding Options to Purchase Common Stock", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [ "r978", "r979", "r980", "r981", "r982", "r983", "r984", "r985", "r986", "r987", "r988", "r989", "r990", "r991", "r992", "r993", "r994", "r995", "r996", "r997", "r998", "r1000", "r1001", "r1002", "r1003", "r1004" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "EntityAddressAddressLine1", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "EntityAddressAddressLine2", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line Two", "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "EntityAddressCityOrTown", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "EntityCentralIndexKey", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r785" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Common Stock, Shares Outstanding", "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Current Reporting Status", "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r785" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "EntityFileNumber", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Securities Act File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "EntityFilerCategory", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Filer Category", "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r785" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Interactive Data Current", "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r869" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "EntityRegistrantName", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "verboseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r785" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "EntityShellCompany", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Shell Company", "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r785" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "EntitySmallBusiness", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Small Business", "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r785" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r785" ] }, "ecd_EqtyAwrdsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "EqtyAwrdsAdjFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments, Footnote [Text Block]", "terseLabel": "Equity Awards Adjustments, Footnote" } } }, "auth_ref": [ "r824" ] }, "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]", "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table" } } }, "auth_ref": [ "r865" ] }, "ecd_EqtyAwrdsAdjsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "EqtyAwrdsAdjsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments [Member]", "terseLabel": "Equity Awards Adjustments" } } }, "auth_ref": [ "r865" ] }, "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]", "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table" } } }, "auth_ref": [ "r865" ] }, "us-gaap_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "EquityAbstract", "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "EquityComponentDomain", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureEquity2023And2024CommonWarrantsAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureEquity2024CommonWarrantsAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureEquity2025EquityOfferingsAndCommonWarrantsAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersDeficitEquityUnauditedParenthetical", "http://aptevotherapeutics.com/20260630/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Component", "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r38", "r39", "r72", "r94", "r95", "r104", "r105", "r106", "r130", "r131", "r132", "r135", "r143", "r145", "r147", "r167", "r210", "r213", "r227", "r228", "r230", "r291", "r314", "r319", "r320", "r321", "r324", "r326", "r329", "r336", "r337", "r341", "r342", "r389", "r395", "r396", "r403", "r404", "r405", "r408", "r415", "r416", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r439", "r443", "r444", "r445", "r446", "r455", "r484", "r485", "r486", "r487", "r488", "r489", "r499", "r519", "r545", "r549", "r550", "r557", "r558", "r571", "r584", "r590", "r591", "r592", "r611", "r677", "r976" ] }, "apvo_EquityDistributionAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://aptevotherapeutics.com/20260630", "localname": "EquityDistributionAgreementMember", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Distribution Agreement", "label": "Equity Distribution Agreement [Member]", "documentation": "Equity distribution agreement." } } }, "auth_ref": [] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Valuation Assumption Difference, Footnote [Text Block]", "terseLabel": "Equity Valuation Assumption Difference, Footnote" } } }, "auth_ref": [ "r834" ] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "ErrCompAnalysisTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Erroneous Compensation Analysis [Text Block]", "terseLabel": "Erroneous Compensation Analysis" } } }, "auth_ref": [ "r792", "r802", "r812", "r844" ] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "ErrCompRecoveryTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Erroneously Awarded Compensation Recovery [Table]", "terseLabel": "Erroneously Awarded Compensation Recovery" } } }, "auth_ref": [ "r789", "r799", "r809", "r841" ] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "ExecutiveCategoryAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Executive Category [Axis]", "terseLabel": "Executive Category:" } } }, "auth_ref": [ "r840" ] }, "apvo_ExercisePriceOf1798200Member": { "xbrltype": "domainItemType", "nsuri": "http://aptevotherapeutics.com/20260630", "localname": "ExercisePriceOf1798200Member", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureEquity2024CommonWarrantsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Exercise Price of 17,982.00 [Member]", "documentation": "Exercise price of 17,982.00.", "terseLabel": "Exercise Price of 17,982.00" } } }, "auth_ref": [] }, "apvo_ExercisePriceOf309600Member": { "xbrltype": "domainItemType", "nsuri": "http://aptevotherapeutics.com/20260630", "localname": "ExercisePriceOf309600Member", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureEquity2024CommonWarrantsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise Price of 3,096.00", "label": "Exercise Price of 3,096.00 [Member]", "documentation": "Exercise price of 3,096.00." } } }, "auth_ref": [] }, "apvo_ExercisePriceOf860Member": { "xbrltype": "domainItemType", "nsuri": "http://aptevotherapeutics.com/20260630", "localname": "ExercisePriceOf860Member", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureEquity2024CommonWarrantsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise Price of $8.60", "label": "Exercise Price Of 8.60 [Member]", "documentation": "Exercise price of 8.60." } } }, "auth_ref": [] }, "apvo_ExistingWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://aptevotherapeutics.com/20260630", "localname": "ExistingWarrantsMember", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureEquity2023And2024CommonWarrantsAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureEquity2024CommonWarrantsAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureEquity2025EquityOfferingsAndCommonWarrantsAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Existing Warrants", "label": "Existing Warrants [Member]", "documentation": "Existing warrants." } } }, "auth_ref": [] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r458", "r460", "r461", "r474", "r760" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]", "label": "Fair Value, Recurring and Nonrecurring [Table]", "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis." } } }, "auth_ref": [ "r458", "r460", "r461", "r474", "r760" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureEquitySummaryOfAssumptionsUsedToEstimateTheFairValueOfTheWarrantsUsingTheBlackscholesOptionPricingModelDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r462", "r463", "r464", "r753", "r754", "r761", "r1030" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureEquitySummaryOfAssumptionsUsedToEstimateTheFairValueOfTheWarrantsUsingTheBlackscholesOptionPricingModelDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]", "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis." } } }, "auth_ref": [ "r462", "r463", "r464", "r753", "r754", "r761", "r1030" ] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV", "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": [ "r275", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r458", "r459", "r461", "r462", "r463", "r464", "r473", "r474", "r476", "r482", "r531", "r532", "r533", "r538", "r737", "r738", "r742", "r743", "r744", "r745", "r746", "r760", "r761", "r765", "r766" ] }, "us-gaap_FairValueByLiabilityClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "FairValueByLiabilityClassAxis", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureLiabilityRelatedToSaleOfRoyaltiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Liability Class", "label": "Liability Class [Axis]", "documentation": "Information by class of liability." } } }, "auth_ref": [ "r465", "r466", "r467", "r468", "r469", "r470", "r475" ] }, "us-gaap_FairValueDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "FairValueDisclosuresAbstract", "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FairValueDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "FairValueDisclosuresTextBlock", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureFairValueMeasurements" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Measurements", "label": "Fair Value Disclosures [Text Block]", "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information." } } }, "auth_ref": [ "r462", "r469", "r471", "r472", "r473", "r476", "r477", "r478", "r479", "r480", "r548", "r760", "r762" ] }, "us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "FairValueInputsLevel2Member", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Level Two", "label": "Fair Value, Inputs, Level 2 [Member]", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": [ "r275", "r344", "r349", "r350", "r352", "r461", "r462", "r474", "r482", "r532", "r737", "r738", "r742", "r743", "r744", "r745", "r746", "r760", "r765", "r766" ] }, "us-gaap_FairValueInputsLevel3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "FairValueInputsLevel3Member", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Level Three", "label": "Fair Value, Inputs, Level 3 [Member]", "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r275", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r461", "r462", "r463", "r464", "r474", "r482", "r533", "r737", "r738", "r742", "r743", "r744", "r745", "r746", "r760", "r761", "r765", "r766" ] }, "us-gaap_FairValueInputsQuantitativeInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "FairValueInputsQuantitativeInformationAbstract", "lang": { "en-us": { "role": { "label": "Fair Value Measurement Inputs and Valuation Techniques [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureLiabilityRelatedToSaleOfRoyaltiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value by Liability Class", "label": "Fair Value by Liability Class [Domain]", "documentation": "Represents classes of liabilities measured and disclosed at fair value." } } }, "auth_ref": [ "r465", "r466", "r467", "r468", "r469", "r470", "r475" ] }, "us-gaap_FairValueMeasurementInputsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "FairValueMeasurementInputsDisclosureTextBlock", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureEquityTables" ], "lang": { "en-us": { "role": { "label": "Fair Value Measurement and Measurement Inputs, Recurring and Nonrecurring [Text Block]", "terseLabel": "Summary of Fair Value of Common Warrants Prior to and Immediately After Exercise Price Adjustment, were Estimated Using Black-Scholes Option-Pricing Model Assumptions", "verboseLabel": "Summary of Assumptions Used to Estimate the Fair Value of the Warrants Using The Black-scholes Option Pricing Model", "documentation": "The entire disclosure of the fair value measurement of assets and liabilities, which includes financial instruments measured at fair value that are classified in shareholders' equity, which may be measured on a recurring or nonrecurring basis." } } }, "auth_ref": [ "r1012" ] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV", "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": [ "r275", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r458", "r459", "r461", "r462", "r463", "r464", "r473", "r474", "r476", "r482", "r531", "r532", "r533", "r538", "r737", "r738", "r742", "r743", "r744", "r745", "r746", "r760", "r761", "r765", "r766" ] }, "apvo_FirstAndSecondSEPAMember": { "xbrltype": "domainItemType", "nsuri": "http://aptevotherapeutics.com/20260630", "localname": "FirstAndSecondSEPAMember", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureNatureOfBusinessAndSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "First and Second SEPA", "label": "First and Second SEPA [Member]", "documentation": "First and Second SEPA." } } }, "auth_ref": [] }, "apvo_FirstStandbyEquityPurchaseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://aptevotherapeutics.com/20260630", "localname": "FirstStandbyEquityPurchaseAgreementMember", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureEquityStandbyEquityPurchaseAgreementAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "First Standby Equity Purchase Agreement [Member]", "documentation": "First standby equity purchase agreement member.", "terseLabel": "First Standby Equity Purchase Agreement" } } }, "auth_ref": [] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": [ "r796", "r806", "r816", "r848" ] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Expense of Enforcement, Amount", "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": [ "r796", "r806", "r816", "r848" ] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Violation of Home Country Law, Amount", "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": [ "r796", "r806", "r816", "r848" ] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Explanation of Impracticability [Text Block]", "terseLabel": "Forgone Recovery, Explanation of Impracticability" } } }, "auth_ref": [ "r796", "r806", "r816", "r848" ] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "ForgoneRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r796", "r806", "r816", "r848" ] }, "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]", "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year" } } }, "auth_ref": [ "r829" ] }, "apvo_GainOnExtinguishmentOfLiabilityRelatedToSaleOfRoyalties": { "xbrltype": "monetaryItemType", "nsuri": "http://aptevotherapeutics.com/20260630", "localname": "GainOnExtinguishmentOfLiabilityRelatedToSaleOfRoyalties", "crdr": "credit", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureLiabilityRelatedToSaleOfRoyaltiesAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureLiabilityRelatedToSaleOfRoyaltiesScheduleOfChangesInLiabilityRelatedToSaleOfRoyaltiesDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Gain on extinguishment of liability related to sale of royalties", "terseLabel": "Gain from extinguishment of liability related to sale of royalties", "label": "Gain On Extinguishment Of Liability Related To Sale Of Royalties", "documentation": "Gain on extinguishment of liability related to sale of royalties." } } }, "auth_ref": [] }, "apvo_GainRelatedToSaleOfNonfinancialAssetPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://aptevotherapeutics.com/20260630", "localname": "GainRelatedToSaleOfNonfinancialAssetPolicyTextBlock", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureNatureOfBusinessAndSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Gain Related to Sale of Nonfinancial Asset", "label": "Gain Related to Sale of Nonfinancial Asset [Policy Text Block]", "documentation": "Gain related to sale of nonfinancial asset." } } }, "auth_ref": [] }, "us-gaap_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureSegmentInformationSummaryOfSignificantExpenseCategoriesDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "General and Administrative Expense, Total", "negatedLabel": "General and administrative", "label": "General and Administrative Expense", "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": [ "r12", "r657" ] }, "us-gaap_GovernmentAssistanceAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "GovernmentAssistanceAbstract", "lang": { "en-us": { "role": { "label": "Government Assistance [Abstract]" } } }, "auth_ref": [] }, "us-gaap_GovernmentAssistanceAwardAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "GovernmentAssistanceAwardAmount", "crdr": "debit", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureGrantAgreementAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Government Assistance, Award Amount", "documentation": "Amount of government assistance awarded that comprises amount received, receivable, and to be received unless condition for government assistance is not met. Includes, but is not limited to, government grant, assistance, incentive, award, subsidy, and loan." } } }, "auth_ref": [ "r1017" ] }, "us-gaap_GovernmentAssistanceLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "GovernmentAssistanceLineItems", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureGrantAgreementAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Government Assistance [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r492" ] }, "us-gaap_GovernmentAssistanceTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "GovernmentAssistanceTable", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureGrantAgreementAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Government Assistance [Table]", "documentation": "Disclosure of information about government assistance." } } }, "auth_ref": [ "r492" ] }, "us-gaap_GovernmentAssistanceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "GovernmentAssistanceTextBlock", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureGrantAgreement" ], "lang": { "en-us": { "role": { "terseLabel": "Grant Agreement", "label": "Government Assistance [Text Block]", "documentation": "The entire disclosure for government assistance." } } }, "auth_ref": [ "r491", "r493", "r494", "r495", "r496" ] }, "us-gaap_GovernmentAssistanceTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "GovernmentAssistanceTypeAxis", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureGrantAgreementAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Government Assistance, Type [Axis]", "documentation": "Information by type of government assistance." } } }, "auth_ref": [ "r492" ] }, "us-gaap_GovernmentAssistanceTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "GovernmentAssistanceTypeDomain", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureGrantAgreementAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Government Assistance, Type [Domain]", "documentation": "Type of government assistance." } } }, "auth_ref": [ "r492" ] }, "apvo_GovernmentGrantReimbursements": { "xbrltype": "monetaryItemType", "nsuri": "http://aptevotherapeutics.com/20260630", "localname": "GovernmentGrantReimbursements", "crdr": "credit", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureGrantAgreementAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Government Grant Reimbursements", "documentation": "Governmentgrantreimbursements." } } }, "auth_ref": [] }, "apvo_HCRMember": { "xbrltype": "domainItemType", "nsuri": "http://aptevotherapeutics.com/20260630", "localname": "HCRMember", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureLiabilityRelatedToSaleOfRoyaltiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "HCR [member].", "label": "H C R [Member]", "terseLabel": "HCR" } } }, "auth_ref": [] }, "apvo_HyperimmuneBusinessMember": { "xbrltype": "domainItemType", "nsuri": "http://aptevotherapeutics.com/20260630", "localname": "HyperimmuneBusinessMember", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureDiscontinuedOperationsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Hyperimmune Business", "label": "Hyperimmune Business [Member]", "documentation": "Hyperimmune business." } } }, "auth_ref": [] }, "us-gaap_IPOMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "IPOMember", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureEquity2023And2024CommonWarrantsAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureEquity2024CommonWarrantsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Public Offering", "label": "IPO [Member]", "documentation": "First sale of stock by a private company to the public." } } }, "auth_ref": [] }, "apvo_IXINITYMember": { "xbrltype": "domainItemType", "nsuri": "http://aptevotherapeutics.com/20260630", "localname": "IXINITYMember", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureXomaTransactionAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureDiscontinuedOperationsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "IXINITY.", "terseLabel": "IXINITY", "label": "I X I N I T Y [Member]" } } }, "auth_ref": [] }, "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit", "calculation": { "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited": { "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited" ], "lang": { "en-us": { "role": { "label": "Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest", "totalLabel": "Net loss", "documentation": "Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest." } } }, "auth_ref": [ "r24", "r39", "r48", "r119", "r122", "r123", "r134", "r143", "r228", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r292", "r325", "r338", "r389", "r407", "r416", "r457", "r483", "r580", "r699", "r718", "r883", "r886", "r933", "r935", "r936", "r937", "r938", "r940", "r960" ] }, "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "IncomeLossFromDiscontinuedOperationsNetOfTax", "crdr": "credit", "calculation": { "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureDiscontinuedOperationsSummaryOfReconciliationOfCarryingAmountsOfAssetsAndLiabilitiesAndIncomeLossFromDiscontinuedOperationDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureXomaTransactionAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureDiscontinuedOperationsAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureDiscontinuedOperationsSummaryOfReconciliationOfCarryingAmountsOfAssetsAndLiabilitiesAndIncomeLossFromDiscontinuedOperationDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Income from discontinued operations", "terseLabel": "Income from discontinued operations", "label": "Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest", "verboseLabel": "Income from discontinued operations", "documentation": "Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal." } } }, "auth_ref": [ "r45", "r46", "r48", "r65", "r400", "r581", "r702" ] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureXomaTransactionAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureDiscontinuedOperationsAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureDiscontinuedOperationsSummaryOfReconciliationOfCarryingAmountsOfAssetsAndLiabilitiesAndIncomeLossFromDiscontinuedOperationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disposal Group Name", "label": "Disposal Group Name [Axis]", "documentation": "Information by name of disposal group." } } }, "auth_ref": [ "r52", "r53", "r54", "r55", "r56", "r57", "r58", "r238", "r240", "r747", "r748", "r878", "r879", "r950", "r951", "r952", "r953" ] }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureDiscontinuedOperationsAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureDiscontinuedOperationsSummaryOfReconciliationOfCarryingAmountsOfAssetsAndLiabilitiesAndIncomeLossFromDiscontinuedOperationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Line Items]", "label": "Disposal Group, Including Discontinued Operations [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r43", "r44", "r47", "r48", "r52", "r53", "r54", "r55", "r56", "r57", "r58", "r60", "r61", "r62", "r63", "r64", "r67", "r68", "r69", "r70", "r232", "r235", "r236", "r237", "r238", "r239", "r240", "r701", "r878", "r879", "r944", "r950", "r951", "r952", "r953" ] }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureDiscontinuedOperationsAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureDiscontinuedOperationsSummaryOfReconciliationOfCarryingAmountsOfAssetsAndLiabilitiesAndIncomeLossFromDiscontinuedOperationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Statement Balance Sheet And Additional Disclosures By Disposal Groups Including Discontinued Operations [Table]", "label": "Disposal Groups, Including Discontinued Operations [Table]", "documentation": "Disclosure of information about a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component." } } }, "auth_ref": [ "r44", "r47", "r48", "r52", "r53", "r54", "r55", "r56", "r57", "r58", "r60", "r61", "r62", "r63", "r64", "r67", "r68", "r69", "r70", "r232", "r235", "r236", "r237", "r238", "r239", "r240", "r701", "r878", "r879", "r944", "r950", "r951", "r952", "r953" ] }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "IncreaseDecreaseInAccountsPayable", "crdr": "debit", "calculation": { "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable", "label": "Increase (Decrease) in Accounts Payable", "totalLabel": "Increase (Decrease) in Accounts Payable, Total", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business." } } }, "auth_ref": [ "r3" ] }, "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities", "crdr": "debit", "calculation": { "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities", "terseLabel": "Accrued expenses and other current liabilities", "negatedLabel": "Accrued expenses and other current liabilities", "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other." } } }, "auth_ref": [ "r915" ] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Changes in operating assets and liabilities:", "label": "Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "IncreaseDecreaseInOperatingLeaseLiability", "crdr": "debit", "calculation": { "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Lease Liability", "terseLabel": "Operating lease liability", "documentation": "Amount of increase (decrease) in obligation for operating lease." } } }, "auth_ref": [ "r874", "r915" ] }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "crdr": "credit", "calculation": { "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Prepaid expenses and other current assets", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other." } } }, "auth_ref": [ "r3" ] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "IndividualAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Individual [Axis]", "terseLabel": "Individual:" } } }, "auth_ref": [ "r796", "r806", "r816", "r840", "r848", "r852", "r860" ] }, "apvo_InducementWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://aptevotherapeutics.com/20260630", "localname": "InducementWarrantsMember", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Inducement Warrants.", "label": "Inducement Warrants" } } }, "auth_ref": [] }, "apvo_InitialOperatingLeaseTermDate": { "xbrltype": "gYearMonthItemType", "nsuri": "http://aptevotherapeutics.com/20260630", "localname": "InitialOperatingLeaseTermDate", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Initial operating lease term date", "label": "Initial Operating Lease Term Date", "documentation": "Initial operating lease term date." } } }, "auth_ref": [] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]", "terseLabel": "Insider Trading Arrangements:" } } }, "auth_ref": [ "r858" ] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]", "terseLabel": "Insider Trading Policies and Procedures:" } } }, "auth_ref": [ "r788", "r864" ] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Adopted [Flag]", "terseLabel": "Insider Trading Policies and Procedures Adopted" } } }, "auth_ref": [ "r788", "r864" ] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]", "terseLabel": "Insider Trading Policies and Procedures Not Adopted" } } }, "auth_ref": [ "r788", "r864" ] }, "apvo_InvestorRightsAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://aptevotherapeutics.com/20260630", "localname": "InvestorRightsAgreementMember", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Investor Rights Agreement [Member]", "documentation": "Investor rights agreement." } } }, "auth_ref": [] }, "apvo_KamadaMember": { "xbrltype": "domainItemType", "nsuri": "http://aptevotherapeutics.com/20260630", "localname": "KamadaMember", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureDiscontinuedOperationsSummaryOfReconciliationOfCarryingAmountsOfAssetsAndLiabilitiesAndIncomeLossFromDiscontinuedOperationDetails" ], "lang": { "en-us": { "role": { "label": "Kamada [Member]", "documentation": "Kamada." } } }, "auth_ref": [] }, "us-gaap_LeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "LeaseCost", "crdr": "debit", "calculation": { "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureLeasesComponentsOfLeaseExpenseDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureLeasesComponentsOfLeaseExpenseDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total lease cost", "label": "Lease, Cost", "documentation": "Amount of lease cost recognized by lessee for lease contract." } } }, "auth_ref": [ "r506", "r768" ] }, "us-gaap_LeaseCostTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "LeaseCostTableTextBlock", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureLeasesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Components of Lease Expense", "label": "Lease, Cost [Table Text Block]", "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income." } } }, "auth_ref": [ "r1022" ] }, "us-gaap_LeasesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "LeasesAbstract", "lang": { "en-us": { "role": { "label": "Leases [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LesseeLeaseDescriptionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "LesseeLeaseDescriptionLineItems", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureLeasesSummaryOfRightOfUseAssetsAcquiredUnderOperatingLeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lessee Lease Description [Line Items]", "label": "Lessee, Lease, Description [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r504", "r513", "r1020" ] }, "us-gaap_LesseeLeaseDescriptionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "LesseeLeaseDescriptionTable", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureLeasesSummaryOfRightOfUseAssetsAcquiredUnderOperatingLeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lessee Lease Description [Table]", "label": "Lessee, Lease, Description [Table]", "documentation": "Disclosure of information about lessee's leases." } } }, "auth_ref": [ "r504", "r513", "r1020" ] }, "us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend": { "xbrltype": "booleanItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "LesseeOperatingLeaseExistenceOfOptionToExtend", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease option to extend", "label": "Lessee, Operating Lease, Existence of Option to Extend [true false]", "documentation": "Indicates (true false) whether lessee has option to extend operating lease." } } }, "auth_ref": [ "r505" ] }, "us-gaap_LesseeOperatingLeaseOptionToExtend": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "LesseeOperatingLeaseOptionToExtend", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease renewal option description", "label": "Lessee, Operating Lease, Option to Extend", "documentation": "Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability." } } }, "auth_ref": [ "r505" ] }, "us-gaap_LesseeOperatingLeaseRenewalTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "LesseeOperatingLeaseRenewalTerm", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease renewal option term", "label": "Lessee, Operating Lease, Renewal Term", "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r1021" ] }, "us-gaap_LesseeOperatingLeasesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "LesseeOperatingLeasesTextBlock", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureLeases" ], "lang": { "en-us": { "role": { "terseLabel": "Leases", "label": "Lessee, Operating Leases [Text Block]", "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability." } } }, "auth_ref": [ "r498" ] }, "us-gaap_LetterOfCreditMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "LetterOfCreditMember", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureCashAndCashEquivalentsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Letter of Credit", "label": "Letter of Credit [Member]", "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit)." } } }, "auth_ref": [ "r1039" ] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities", "label": "Liabilities", "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others." } } }, "auth_ref": [ "r59", "r66", "r119", "r122", "r123", "r209", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r325", "r422", "r425", "r426", "r483", "r633", "r717", "r741", "r783", "r902", "r960", "r1025", "r1026" ] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" ], "lang": { "en-us": { "role": { "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders' equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r98", "r549", "r550", "r560", "r578", "r769", "r771", "r772", "r918", "r923", "r940", "r1016" ] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" ], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "LIABILITIES AND STOCKHOLDERS' EQUITY" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r59", "r66", "r71", "r81", "r119", "r122", "r123", "r209", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r325", "r422", "r425", "r426", "r483", "r769", "r960", "r1025", "r1026" ] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Current liabilities:", "label": "Liabilities, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilityMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "LiabilityMember", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureLiabilityRelatedToSaleOfRoyaltiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Liability", "label": "Liability [Member]", "documentation": "Liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others." } } }, "auth_ref": [] }, "apvo_LiabilityRelatedToSaleOfRoyalties": { "xbrltype": "monetaryItemType", "nsuri": "http://aptevotherapeutics.com/20260630", "localname": "LiabilityRelatedToSaleOfRoyalties", "crdr": "credit", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureLiabilityRelatedToSaleOfRoyaltiesScheduleOfChangesInLiabilityRelatedToSaleOfRoyaltiesDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Liability related to sale of royalties, beginning balance", "periodEndLabel": "Liability related to sale of royalties, ending balance", "label": "Liability Related To Sale Of Royalties", "documentation": "Liability related to sale of royalties." } } }, "auth_ref": [] }, "apvo_LiabilityRelatedToSaleOfRoyaltiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://aptevotherapeutics.com/20260630", "localname": "LiabilityRelatedToSaleOfRoyaltiesCurrent", "crdr": "credit", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureLiabilityRelatedToSaleOfRoyaltiesScheduleOfChangesInLiabilityRelatedToSaleOfRoyaltiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Current portion of liability related to sale of royalties", "label": "Liability Related To Sale Of Royalties Current", "documentation": "Liability related to sale of royalties current." } } }, "auth_ref": [] }, "apvo_LiabilityRelatedToSaleOfRoyaltiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://aptevotherapeutics.com/20260630", "localname": "LiabilityRelatedToSaleOfRoyaltiesDisclosureTextBlock", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureLiabilityRelatedToSaleOfRoyalties" ], "lang": { "en-us": { "role": { "terseLabel": "Liability Related to Sale of Royalties", "label": "Liability Related To Sale Of Royalties Disclosure [Text Block]", "documentation": "Liability related to sale of royalties disclosure." } } }, "auth_ref": [] }, "apvo_LiabilityRelatedToSaleOfRoyaltiesNonCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://aptevotherapeutics.com/20260630", "localname": "LiabilityRelatedToSaleOfRoyaltiesNonCurrent", "crdr": "credit", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureLiabilityRelatedToSaleOfRoyaltiesScheduleOfChangesInLiabilityRelatedToSaleOfRoyaltiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Liability related to sale of royalties, non-current", "label": "Liability Related To Sale Of Royalties Non Current", "documentation": "Liability related to sale of royalties non current." } } }, "auth_ref": [] }, "apvo_LincolnParkMember": { "xbrltype": "domainItemType", "nsuri": "http://aptevotherapeutics.com/20260630", "localname": "LincolnParkMember", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lincoln Park", "label": "Lincoln Park [Member]", "documentation": "Lincoln Park Member" } } }, "auth_ref": [] }, "us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "LineOfCreditFacilityCurrentBorrowingCapacity", "crdr": "credit", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Line of credit facility, used borrowing capacity", "label": "Line of Credit Facility, Current Borrowing Capacity", "documentation": "Amount of current borrowing capacity under the credit facility considering any current restrictions on the amount that could be borrowed (for example, borrowings may be limited by the amount of current assets), but without considering any amounts currently outstanding under the facility." } } }, "auth_ref": [ "r890", "r893" ] }, "us-gaap_LineOfCreditFacilityLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "LineOfCreditFacilityLineItems", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Line Of Credit Facility [Line Items]", "label": "Line of Credit Facility [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r74", "r79", "r251", "r549", "r550", "r552", "r918", "r921", "r958" ] }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "crdr": "credit", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum borrowing capacity", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility." } } }, "auth_ref": [ "r890", "r893" ] }, "us-gaap_LineOfCreditFacilityTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "LineOfCreditFacilityTable", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Line Of Credit Facility [Table]", "label": "Line of Credit Facility [Table]", "documentation": "Disclosure of information about short-term and long-term contractual arrangements with lender under which borrowing can occur up to maximum amount. Includes, but is not limited to, letter of credit, standby letter of credit, and revolving credit arrangement." } } }, "auth_ref": [ "r74", "r79", "r251", "r549", "r550", "r552", "r918", "r921", "r958" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "LocalPhoneNumber", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_LongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "LongTermDebt", "crdr": "credit", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt outstanding", "label": "Long-Term Debt", "totalLabel": "Long-Term Debt, Total", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation." } } }, "auth_ref": [ "r120", "r129", "r274", "r288", "r549", "r550", "r555", "r568", "r737", "r738", "r767", "r891", "r897", "r1040" ] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2026", "localname": "MaximumMember", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureEquity2023And2024CommonWarrantsAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureEquity2025EquityOfferingsAndCommonWarrantsAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureEquity2026NiowaveCommonWarrantsAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureEquitySummaryOfAssumptionsUsedToEstimateTheFairValueOfTheWarrantsUsingTheBlackscholesOptionPricingModelDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureReverseStockSplitAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureLiabilityRelatedToSaleOfRoyaltiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum", "label": "Maximum [Member]" } } }, "auth_ref": [ "r67", "r69", "r173", "r246", "r247", "r248", "r249", "r353", "r381", "r382", "r383", "r393", "r464", "r534", "r535", "r536", "r537", "r539", "r540", "r541", "r542", "r546", "r586", "r587", "r600", "r625", "r626", "r682", "r683", "r684", "r685", "r686", "r692", "r693", "r694", "r695", "r696", "r697", "r731", "r749", "r753", "r754", "r755", "r761", "r762", "r763", "r764", "r770", "r962", "r964" ] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "MeasureAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Measure [Axis]", "terseLabel": "Measure:" } } }, "auth_ref": [ "r832" ] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "MeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Measure Name", "terseLabel": "Name" } } }, "auth_ref": [ "r832" ] }, "us-gaap_MeasurementInputExercisePriceMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "MeasurementInputExercisePriceMember", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureEquitySummaryOfAssumptionsUsedToEstimateTheFairValueOfTheWarrantsUsingTheBlackscholesOptionPricingModelDetails" ], "lang": { "en-us": { "role": { "label": "Measurement Input, Exercise Price [Member]", "terseLabel": "Exercise Price", "documentation": "Measurement input using agreed upon price for exchange of underlying asset." } } }, "auth_ref": [ "r999", "r1013", "r1014", "r1015" ] }, "us-gaap_MeasurementInputExpectedTermMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "MeasurementInputExpectedTermMember", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureEquitySummaryOfAssumptionsUsedToEstimateTheFairValueOfTheWarrantsUsingTheBlackscholesOptionPricingModelDetails" ], "lang": { "en-us": { "role": { "label": "Measurement Input, Expected Term [Member]", "terseLabel": "Expected Average Life of Warrants", "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date." } } }, "auth_ref": [ "r380", "r1013", "r1014", "r1015" ] }, "us-gaap_MeasurementInputOptionVolatilityMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "MeasurementInputOptionVolatilityMember", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureEquitySummaryOfAssumptionsUsedToEstimateTheFairValueOfTheWarrantsUsingTheBlackscholesOptionPricingModelDetails" ], "lang": { "en-us": { "role": { "label": "Measurement Input, Option Volatility [Member]", "terseLabel": "Expected Volatility", "documentation": "Measurement input using rate at which price of option increases (decreases) for given set of returns." } } }, "auth_ref": [ "r1013", "r1014", "r1015" ] }, "us-gaap_MeasurementInputRiskFreeInterestRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "MeasurementInputRiskFreeInterestRateMember", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureEquitySummaryOfAssumptionsUsedToEstimateTheFairValueOfTheWarrantsUsingTheBlackscholesOptionPricingModelDetails" ], "lang": { "en-us": { "role": { "label": "Measurement Input, Risk Free Interest Rate [Member]", "terseLabel": "Risk-free Interest Rate", "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss." } } }, "auth_ref": [ "r383", "r1013", "r1014", "r1015" ] }, "us-gaap_MeasurementInputTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "MeasurementInputTypeAxis", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureEquitySummaryOfAssumptionsUsedToEstimateTheFairValueOfTheWarrantsUsingTheBlackscholesOptionPricingModelDetails" ], "lang": { "en-us": { "role": { "label": "Measurement Input Type [Axis]", "documentation": "Information by type of measurement input used to determine value of asset and liability." } } }, "auth_ref": [ "r379", "r380", "r381", "r382", "r383", "r384", "r462", "r463", "r464", "r753", "r754", "r755", "r761", "r1030" ] }, "us-gaap_MeasurementInputTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "MeasurementInputTypeDomain", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureEquitySummaryOfAssumptionsUsedToEstimateTheFairValueOfTheWarrantsUsingTheBlackscholesOptionPricingModelDetails" ], "lang": { "en-us": { "role": { "label": "Measurement Input Type [Domain]", "documentation": "Measurement input used to determine value of asset and liability." } } }, "auth_ref": [ "r462", "r463", "r464", "r753", "r754", "r755", "r761", "r1030" ] }, "apvo_MilestonePayment": { "xbrltype": "monetaryItemType", "nsuri": "http://aptevotherapeutics.com/20260630", "localname": "MilestonePayment", "crdr": "credit", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureLiabilityRelatedToSaleOfRoyaltiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Milestone payment", "label": "Milestone Payment", "documentation": "Milestone payments." } } }, "auth_ref": [] }, "apvo_MilestonePaymentReceivedNetOfTransactionCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://aptevotherapeutics.com/20260630", "localname": "MilestonePaymentReceivedNetOfTransactionCosts", "crdr": "debit", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureLiabilityRelatedToSaleOfRoyaltiesScheduleOfChangesInLiabilityRelatedToSaleOfRoyaltiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from milestone payments, net of transaction costs", "label": "Milestone Payment Received Net Of Transaction Costs", "documentation": "Milestone payment received net of transaction costs." } } }, "auth_ref": [] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2026", "localname": "MinimumMember", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureEquity2023And2024CommonWarrantsAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureEquity2025EquityOfferingsAndCommonWarrantsAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureEquitySummaryOfAssumptionsUsedToEstimateTheFairValueOfTheWarrantsUsingTheBlackscholesOptionPricingModelDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureReverseStockSplitAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureLiabilityRelatedToSaleOfRoyaltiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Minimum", "label": "Minimum [Member]" } } }, "auth_ref": [ "r67", "r69", "r173", "r246", "r247", "r248", "r249", "r353", "r381", "r382", "r383", "r393", "r464", "r534", "r535", "r536", "r537", "r539", "r540", "r541", "r542", "r546", "r586", "r587", "r600", "r625", "r626", "r682", "r683", "r684", "r685", "r686", "r692", "r693", "r694", "r695", "r696", "r697", "r731", "r749", "r753", "r754", "r755", "r761", "r762", "r763", "r770", "r962", "r964" ] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "MnpiDiscTimedForCompValFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "MNPI Disclosure Timed for Compensation Value [Flag]", "terseLabel": "MNPI Disclosure Timed for Compensation Value" } } }, "auth_ref": [ "r851" ] }, "apvo_ModifiedWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://aptevotherapeutics.com/20260630", "localname": "ModifiedWarrantsMember", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureEquity2024CommonWarrantsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Modified warrants member.", "label": "Modified Warrants [Member]", "terseLabel": "Modified Warrants" } } }, "auth_ref": [] }, "us-gaap_MoneyMarketFundsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "MoneyMarketFundsAtCarryingValue", "crdr": "debit", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Money market funds", "label": "Cash Equivalent, Money Market Fund, Carrying Value", "documentation": "Investment in short-term money-market instruments (such as commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and so forth) which are highly liquid (that is, readily convertible to known amounts of cash) and so near their maturity that they present an insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify as cash equivalents by definition. Original maturity means an original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months." } } }, "auth_ref": [ "r892" ] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Material Terms of Trading Arrangement [Text Block]", "terseLabel": "Material Terms of Trading Arrangement" } } }, "auth_ref": [ "r859" ] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Named Executive Officers, Footnote [Text Block]", "terseLabel": "Named Executive Officers, Footnote" } } }, "auth_ref": [ "r833" ] }, "apvo_NatureOfBusinessLineItems": { "xbrltype": "stringItemType", "nsuri": "http://aptevotherapeutics.com/20260630", "localname": "NatureOfBusinessLineItems", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureNatureOfBusinessAndSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Nature Of Business [Line Items]", "label": "Nature Of Business [Line Items]", "documentation": "Nature Of Business [Line Items]" } } }, "auth_ref": [] }, "apvo_NatureOfBusinessTable": { "xbrltype": "stringItemType", "nsuri": "http://aptevotherapeutics.com/20260630", "localname": "NatureOfBusinessTable", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureNatureOfBusinessAndSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Nature Of Business [Table]", "label": "Nature Of Business [Table]", "documentation": "Nature Of Business [Table]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "lang": { "en-us": { "role": { "label": "Cash Provided by (Used in) Financing Activity, Including Discontinued Operation", "totalLabel": "Net cash provided by financing activities", "documentation": "Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit." } } }, "auth_ref": [ "r114" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Financing Activities", "label": "Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "lang": { "en-us": { "role": { "label": "Cash Provided by (Used in) Investing Activity, Including Discontinued Operation", "totalLabel": "Net cash from investing activities", "documentation": "Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets." } } }, "auth_ref": [ "r114" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Investing Activities", "label": "Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureSegmentInformationAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureNatureOfBusinessAndSignificantAccountingPoliciesAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in operating activities", "terseLabel": "Net cash used in operating activities", "label": "Cash Provided by (Used in) Operating Activity, Including Discontinued Operation", "negatedLabel": "Net cash used in operating activities", "documentation": "Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity." } } }, "auth_ref": [ "r14", "r15", "r18" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Operating Activities", "label": "Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "NetIncomeLoss", "crdr": "credit", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureNetLossPerShareComputationOfBasicAndDilutedNetLossPerShareDetails3", "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureSegmentInformationSummaryOfSignificantExpenseCategoriesDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureNatureOfBusinessAndSignificantAccountingPoliciesAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Net Income (Loss)", "terseLabel": "Net Income (Loss)", "totalLabel": "Net loss", "verboseLabel": "Net loss", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r11", "r18", "r25", "r39", "r59", "r66", "r102", "r103", "r106", "r119", "r122", "r123", "r126", "r134", "r139", "r140", "r141", "r142", "r143", "r146", "r147", "r156", "r209", "r228", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r292", "r295", "r298", "r303", "r325", "r338", "r389", "r407", "r416", "r457", "r483", "r583", "r654", "r675", "r676", "r711", "r713", "r714", "r781", "r960" ] }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "crdr": "credit", "calculation": { "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureNetLossPerShareComputationOfBasicAndDilutedNetLossPerShareDetails3", "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited" ], "lang": { "en-us": { "role": { "label": "Net Income (Loss) Available to Common Stockholders, Basic", "terseLabel": "Net loss attributable to common stockholders", "totalLabel": "Net loss attributable to common stockholders", "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders." } } }, "auth_ref": [ "r39", "r108", "r139", "r140", "r141", "r142", "r150", "r151", "r157", "r160", "r295", "r298", "r303", "r416" ] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureNatureOfBusinessAndSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recently Adopted Accounting Pronouncements", "verboseLabel": "Recently Adopted Accounting Pronouncements", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [ "r148" ] }, "apvo_NewWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://aptevotherapeutics.com/20260630", "localname": "NewWarrantsMember", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "New Warrants", "label": "New Warrants [Member]", "documentation": "New warrants." } } }, "auth_ref": [] }, "apvo_NiowaveAdditionalSharePurchaseRightMember": { "xbrltype": "domainItemType", "nsuri": "http://aptevotherapeutics.com/20260630", "localname": "NiowaveAdditionalSharePurchaseRightMember", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureNetLossPerShareSummaryOfPotentiallyDilutiveSharesExcludedFromCalculationOfNetLossPerShareDetails" ], "lang": { "en-us": { "role": { "label": "Niowave Additional Share Purchase Right [Member]", "terseLabel": "Niowave Additional Share Purchase Right", "documentation": "Niowave additional share purchase right." } } }, "auth_ref": [] }, "apvo_NiowaveMember": { "xbrltype": "domainItemType", "nsuri": "http://aptevotherapeutics.com/20260630", "localname": "NiowaveMember", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureNatureOfBusinessAndSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Niowave [Member]", "documentation": "Niowave." } } }, "auth_ref": [] }, "apvo_NonCashInterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://aptevotherapeutics.com/20260630", "localname": "NonCashInterestExpense", "crdr": "debit", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureLiabilityRelatedToSaleOfRoyaltiesScheduleOfChangesInLiabilityRelatedToSaleOfRoyaltiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-cash interest expense", "label": "Non Cash Interest Expense", "documentation": "Non cash interest expense." } } }, "auth_ref": [] }, "apvo_NonEmployeeDirectorsMember": { "xbrltype": "domainItemType", "nsuri": "http://aptevotherapeutics.com/20260630", "localname": "NonEmployeeDirectorsMember", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-employee Directors", "label": "Non Employee Directors [Member]", "documentation": "Non-employee directors." } } }, "auth_ref": [] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-GAAP Measure Description [Text Block]", "terseLabel": "Non-GAAP Measure Description" } } }, "auth_ref": [ "r832" ] }, "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "NonNeosMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-NEOs [Member]", "terseLabel": "Non-NEOs" } } }, "auth_ref": [ "r796", "r806", "r816", "r840", "r848" ] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Compensation Actually Paid Amount", "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": [ "r823" ] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Total Compensation Amount", "terseLabel": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": [ "r822" ] }, "ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "NonPeoNeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO [Member]", "terseLabel": "Non-PEO NEO" } } }, "auth_ref": [ "r840" ] }, "apvo_NonRule10B51ArrModifiedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://aptevotherapeutics.com/20260630", "localname": "NonRule10B51ArrModifiedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Non Rule 10b51 Arr Modified [Flag]", "documentation": "Non Rule 10b51 Arr Modified [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Modified" } } }, "auth_ref": [] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": [ "r859" ] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": [ "r859" ] }, "apvo_NovemberTwoThousandTwentyThreeWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://aptevotherapeutics.com/20260630", "localname": "NovemberTwoThousandTwentyThreeWarrantsMember", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureEquity2023And2024CommonWarrantsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "November Two Thousand Twenty Three Warrants [Member]", "documentation": "November two thousand twenty three warrants.", "terseLabel": "November 2023 Warrants" } } }, "auth_ref": [] }, "apvo_NumberOfOperatingLeaseRenewalOptions": { "xbrltype": "integerItemType", "nsuri": "http://aptevotherapeutics.com/20260630", "localname": "NumberOfOperatingLeaseRenewalOptions", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of operating lease renewal option", "label": "Number Of Operating Lease Renewal Options", "documentation": "Number of operating lease renewal options." } } }, "auth_ref": [] }, "us-gaap_NumberOfOperatingSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "NumberOfOperatingSegments", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureSegmentInformationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of operating segments", "label": "Number of Operating Segments", "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues." } } }, "auth_ref": [ "r725", "r934" ] }, "apvo_NumberOfTechnologyPlatforms": { "xbrltype": "integerItemType", "nsuri": "http://aptevotherapeutics.com/20260630", "localname": "NumberOfTechnologyPlatforms", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureNatureOfBusinessAndSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of technology platforms", "label": "Number Of Technology Platforms", "documentation": "Number of technology platforms." } } }, "auth_ref": [] }, "apvo_OfficeSpaceLeaseMember": { "xbrltype": "domainItemType", "nsuri": "http://aptevotherapeutics.com/20260630", "localname": "OfficeSpaceLeaseMember", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Office Space Lease", "label": "Office Space Lease [Member]", "documentation": "Office space lease." } } }, "auth_ref": [] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "OperatingExpensesAbstract", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Operating expenses:", "label": "Operating Expenses [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Loss from operations", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r711", "r714", "r718", "r883", "r886", "r933", "r935", "r936", "r937", "r938", "r940" ] }, "us-gaap_OperatingLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "OperatingLeaseCost", "crdr": "debit", "calculation": { "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureLeasesComponentsOfLeaseExpenseDetails": { "parentTag": "us-gaap_LeaseCost", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureLeasesComponentsOfLeaseExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease cost", "label": "Operating Lease, Cost", "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability." } } }, "auth_ref": [ "r507", "r768" ] }, "us-gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "OperatingLeaseLiability", "crdr": "credit", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Operating Lease, Liability, Total", "terseLabel": "Operating lease liability", "label": "Operating Lease, Liability", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } } }, "auth_ref": [ "r501" ] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Liability, Current", "terseLabel": "Operating lease liability, current portion", "verboseLabel": "Current portion of operating lease liabilities", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": [ "r501", "r706" ] }, "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]", "documentation": "Indicates line item in statement of financial position that includes current operating lease liability." } } }, "auth_ref": [ "r502" ] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "Long term portion of operating lease liabilities", "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Operating lease liability, current portion", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": [ "r501" ] }, "us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]", "documentation": "Indicates line item in statement of financial position that includes noncurrent operating lease liability." } } }, "auth_ref": [ "r502" ] }, "us-gaap_OperatingLeasePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "OperatingLeasePayments", "crdr": "credit", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureLeasesSummaryOfRightOfUseAssetsAcquiredUnderOperatingLeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "For operating leases", "label": "Operating Lease, Payments", "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use." } } }, "auth_ref": [ "r503", "r509" ] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureLeasesSummaryOfRightOfUseAssetsAcquiredUnderOperatingLeasesDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease right-of-use asset", "label": "Operating Lease, Right-of-Use Asset", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": [ "r500" ] }, "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense", "crdr": "debit", "calculation": { "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Right-of-Use Asset, Periodic Reduction", "terseLabel": "Non-cash lease expense", "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease." } } }, "auth_ref": [ "r916" ] }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted discount rate for operating leases", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "documentation": "Weighted average discount rate for operating lease calculated at point in time." } } }, "auth_ref": [ "r511", "r768" ] }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average remaining lease term for operating leases", "label": "Operating Lease, Weighted Average Remaining Lease Term", "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r510", "r768" ] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureNatureOfBusinessAndSignificantAccountingPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Nature of Business and Significant Accounting Policies", "label": "Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]", "documentation": "The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles." } } }, "auth_ref": [ "r23", "r917", "r925" ] }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "OtherAccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosurePrepaidExpensesOtherCurrentAssetsAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDeta": { "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosurePrepaidExpensesOtherCurrentAssetsAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfAccruedExpensesAndOtherCurrentLiabilitiesDeta" ], "lang": { "en-us": { "role": { "label": "Other Accrued Liabilities, Current", "terseLabel": "Other accruals", "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r895" ] }, "us-gaap_OtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "OtherAssetsCurrent", "crdr": "debit", "calculation": { "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosurePrepaidExpensesOtherCurrentAssetsAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails": { "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosurePrepaidExpensesOtherCurrentAssetsAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other current assets", "label": "Other Assets, Current", "documentation": "Amount of current assets classified as other." } } }, "auth_ref": [ "r100", "r769" ] }, "us-gaap_OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "OtherNonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Other Nonoperating Income (Expense), Total", "label": "Other Nonoperating Income (Expense)", "terseLabel": "Other income, net", "documentation": "Amount of income (expense) related to nonoperating activities, classified as other." } } }, "auth_ref": [ "r13", "r758" ] }, "us-gaap_OtherNonoperatingIncomeExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "OtherNonoperatingIncomeExpenseAbstract", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Other income:", "label": "Other Nonoperating Income (Expense) [Abstract]" } } }, "auth_ref": [] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "OtherPerfMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Other Performance Measure, Amount", "terseLabel": "Other Performance Measure, Amount" } } }, "auth_ref": [ "r832" ] }, "apvo_OtherSegmentItems": { "xbrltype": "monetaryItemType", "nsuri": "http://aptevotherapeutics.com/20260630", "localname": "OtherSegmentItems", "crdr": "debit", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureSegmentInformationSummaryOfSignificantExpenseCategoriesDetails" ], "lang": { "en-us": { "role": { "label": "Other Segment Items", "documentation": "Other segment items.", "terseLabel": "Other segment items" } } }, "auth_ref": [] }, "apvo_OtherSignificantAccountingPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://aptevotherapeutics.com/20260630", "localname": "OtherSignificantAccountingPolicyTextBlock", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureNatureOfBusinessAndSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Other Significant Accounting Policies", "label": "Other Significant Accounting Policy [Text Block]", "documentation": "Other significant accounting policy." } } }, "auth_ref": [] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "OutstandingAggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Outstanding Aggregate Erroneous Compensation Amount", "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r794", "r804", "r814", "r846" ] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "OutstandingRecoveryCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Outstanding Recovery Compensation Amount", "terseLabel": "Compensation Amount" } } }, "auth_ref": [ "r797", "r807", "r817", "r849" ] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "OutstandingRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Outstanding Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r797", "r807", "r817", "r849" ] }, "apvo_OwnershipPercentage": { "xbrltype": "percentItemType", "nsuri": "http://aptevotherapeutics.com/20260630", "localname": "OwnershipPercentage", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureEquity2026NiowaveCommonWarrantsAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Ownership Percentage", "documentation": "Ownership percentage.", "terseLabel": "Ownership percentage" } } }, "auth_ref": [] }, "apvo_PIPEWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://aptevotherapeutics.com/20260630", "localname": "PIPEWarrantsMember", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "PIPE Warrants.", "label": "PIPE Warrants" } } }, "auth_ref": [] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": [ "r821" ] }, "apvo_PaymentInterestPurchaseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://aptevotherapeutics.com/20260630", "localname": "PaymentInterestPurchaseAgreementMember", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureXomaTransactionAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureNatureOfBusinessAndSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Payment Interest Purchase Agreement", "label": "Payment Interest Purchase Agreement [Member]", "documentation": "Payment interest purchase agreement." } } }, "auth_ref": [] }, "apvo_PaymentOfCommitmentFee": { "xbrltype": "monetaryItemType", "nsuri": "http://aptevotherapeutics.com/20260630", "localname": "PaymentOfCommitmentFee", "crdr": "credit", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureEquityStandbyEquityPurchaseAgreementAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Payment of commitment fees", "label": "Payment of Commitment Fee", "documentation": "Payment of commitment fee." } } }, "auth_ref": [] }, "apvo_PaymentOfRoyaltyPurchaseAgreementPercentage": { "xbrltype": "percentItemType", "nsuri": "http://aptevotherapeutics.com/20260630", "localname": "PaymentOfRoyaltyPurchaseAgreementPercentage", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureLiabilityRelatedToSaleOfRoyaltiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Payment of royalty purchase agreement", "label": "Payment Of Royalty Purchase Agreement Percentage", "documentation": "Payment of Royalty Purchase Agreement, Percentage." } } }, "auth_ref": [] }, "apvo_PaymentOfRoyaltyRevenuePercentage": { "xbrltype": "percentItemType", "nsuri": "http://aptevotherapeutics.com/20260630", "localname": "PaymentOfRoyaltyRevenuePercentage", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureLiabilityRelatedToSaleOfRoyaltiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Payment of royalty revenue", "terseLabel": "Payment of royalty revenue, percentage", "label": "Payment Of Royalty Revenue Percentage", "documentation": "Payment of royalty revenue, percentage." } } }, "auth_ref": [] }, "us-gaap_PaymentsForRoyalties": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "PaymentsForRoyalties", "crdr": "credit", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureLiabilityRelatedToSaleOfRoyaltiesScheduleOfChangesInLiabilityRelatedToSaleOfRoyaltiesDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "RUXIENCE royalties paid by Pfizer to HCR", "terseLabel": "One time payment of royalties", "label": "Payments for Royalties", "documentation": "The amount of cash paid for royalties during the current period." } } }, "auth_ref": [ "r2" ] }, "apvo_PaymentsInLieuOfFractionalShares": { "xbrltype": "monetaryItemType", "nsuri": "http://aptevotherapeutics.com/20260630", "localname": "PaymentsInLieuOfFractionalShares", "crdr": "credit", "calculation": { "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "lang": { "en-us": { "role": { "documentation": "Payments in lieu of fractional shares.", "label": "Payments In Lieu Of Fractional Shares", "negatedLabel": "Payments in lieu of fractional shares" } } }, "auth_ref": [] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "PeerGroupIssuersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Peer Group Issuers, Footnote [Text Block]", "terseLabel": "Peer Group Issuers, Footnote" } } }, "auth_ref": [ "r831" ] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Peer Group Total Shareholder Return Amount", "terseLabel": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": [ "r831" ] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "PeoActuallyPaidCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Actually Paid Compensation Amount", "terseLabel": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": [ "r823" ] }, "ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "PeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO [Member]", "terseLabel": "PEO" } } }, "auth_ref": [ "r840" ] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "PeoName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Name", "terseLabel": "PEO Name" } } }, "auth_ref": [ "r833" ] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "PeoTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Total Compensation Amount", "terseLabel": "PEO Total Compensation Amount" } } }, "auth_ref": [ "r822" ] }, "apvo_PercentageOfBeneficialOwnership": { "xbrltype": "percentItemType", "nsuri": "http://aptevotherapeutics.com/20260630", "localname": "PercentageOfBeneficialOwnership", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of beneficial ownership", "label": "Percentage Of Beneficial Ownership", "documentation": "Percentage Of Beneficial Ownership." } } }, "auth_ref": [] }, "apvo_PercentageOfCommitmentFee": { "xbrltype": "percentItemType", "nsuri": "http://aptevotherapeutics.com/20260630", "localname": "PercentageOfCommitmentFee", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureEquityStandbyEquityPurchaseAgreementAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Percentage of Commitment Fee", "documentation": "Percentage of commitment fee.", "terseLabel": "Percentage of commitment fee" } } }, "auth_ref": [] }, "apvo_PercentageOfEntitlementToReceiveCanadianApprovalMilestonePayment": { "xbrltype": "percentItemType", "nsuri": "http://aptevotherapeutics.com/20260630", "localname": "PercentageOfEntitlementToReceiveCanadianApprovalMilestonePayment", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureXomaTransactionAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of entitlement to receive Canadian approval milestone payment", "label": "Percentage of entitlement to receive Canadian Approval Milestone Payment", "documentation": "Percentage of entitlement to receive Canadian approval milestone payment." } } }, "auth_ref": [] }, "apvo_PercentageOfEntitlementToReceiveDeferredPayments": { "xbrltype": "percentItemType", "nsuri": "http://aptevotherapeutics.com/20260630", "localname": "PercentageOfEntitlementToReceiveDeferredPayments", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureXomaTransactionAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of entitlement to receive deferred payments", "label": "Percentage of entitlement to receive deferred payments", "documentation": "Percentage of entitlement to receive deferred payments." } } }, "auth_ref": [] }, "apvo_PercentageOfEntitlementToReceiveEuropeanApprovalMilestonePayment": { "xbrltype": "percentItemType", "nsuri": "http://aptevotherapeutics.com/20260630", "localname": "PercentageOfEntitlementToReceiveEuropeanApprovalMilestonePayment", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureXomaTransactionAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of entitlement to receive European approval milestone payment", "label": "Percentage of entitlement to receive European approval milestone payment", "documentation": "Percentage of entitlement to receive European approval milestone payment." } } }, "auth_ref": [] }, "apvo_PercentageOfGrossSalesPriceSharesSold": { "xbrltype": "percentItemType", "nsuri": "http://aptevotherapeutics.com/20260630", "localname": "PercentageOfGrossSalesPriceSharesSold", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureEquityAtTheMarketOfferingAgreementAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Percentage of Gross Sales Price Shares Sold", "documentation": "Percentage of gross sales price shares sold.", "terseLabel": "Percentage of gross sales price shares sold" } } }, "auth_ref": [] }, "us-gaap_PlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "PlanNameAxis", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Plan Name", "label": "Plan Name [Axis]", "documentation": "Information by plan name for share-based payment arrangement." } } }, "auth_ref": [ "r978", "r979", "r980", "r981", "r982", "r983", "r984", "r985", "r986", "r987", "r988", "r989", "r990", "r991", "r992", "r993", "r994", "r995", "r996", "r997", "r998", "r1000", "r1001", "r1002", "r1003", "r1004" ] }, "us-gaap_PlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "PlanNameDomain", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Plan Name", "label": "Plan Name [Domain]", "documentation": "Plan name for share-based payment arrangement." } } }, "auth_ref": [ "r978", "r979", "r980", "r981", "r982", "r983", "r984", "r985", "r986", "r987", "r988", "r989", "r990", "r991", "r992", "r993", "r994", "r995", "r996", "r997", "r998", "r1000", "r1001", "r1002", "r1003", "r1004" ] }, "ecd_PnsnAdjsPrrSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "PnsnAdjsPrrSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pension Adjustments Prior Service Cost [Member]", "terseLabel": "Pension Adjustments Prior Service Cost" } } }, "auth_ref": [ "r824" ] }, "ecd_PnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "PnsnAdjsSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pension Adjustments Service Cost [Member]", "terseLabel": "Pension Adjustments Service Cost" } } }, "auth_ref": [ "r868" ] }, "ecd_PnsnBnftsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "PnsnBnftsAdjFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pension Benefits Adjustments, Footnote [Text Block]", "terseLabel": "Pension Benefits Adjustments, Footnote" } } }, "auth_ref": [ "r823" ] }, "apvo_PreFundedWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://aptevotherapeutics.com/20260630", "localname": "PreFundedWarrantsMember", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureEquity2024CommonWarrantsAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Pre-funded Warrants", "terseLabel": "Pre-funded Warrants 2023", "label": "Pre-funded Warrants [Member]", "documentation": "Pre-funded Warrants." } } }, "auth_ref": [] }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, par value", "label": "Preferred Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": [ "r306", "r889", "r898", "r967", "r1033", "r1034", "r1036" ] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "PreferredStockSharesAuthorized", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, shares authorized", "label": "Preferred Stock, Shares Authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r72", "r94", "r320", "r549", "r550", "r557", "r634" ] }, "us-gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "PreferredStockSharesIssued", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, shares issued", "label": "Preferred Stock, Shares Issued", "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt." } } }, "auth_ref": [ "r72", "r94", "r306", "r320", "r549", "r550", "r557" ] }, "us-gaap_PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "PreferredStockSharesOutstanding", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETSUnauditedParenthetical" ], "lang": { "en-us": { "role": { "periodEndLabel": "Preferred Stock, Shares Outstanding, Ending Balance", "periodStartLabel": "Preferred Stock, Shares Outstanding, Beginning Balance", "terseLabel": "Preferred stock, shares outstanding", "label": "Preferred Stock, Shares Outstanding", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": [ "r72", "r94", "r320", "r549", "r550", "r557", "r634", "r653", "r965", "r1044", "r1045" ] }, "us-gaap_PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "PreferredStockValue", "crdr": "credit", "calculation": { "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock: $0.001 par value; 15,000,000 shares authorized, zero shares issued or outstanding", "label": "Preferred Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r72", "r94", "r294", "r300", "r320", "r549", "r550", "r557", "r575", "r769" ] }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "calculation": { "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 }, "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosurePrepaidExpensesOtherCurrentAssetsAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosurePrepaidExpensesOtherCurrentAssetsAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" ], "lang": { "en-us": { "role": { "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Prepaid expenses and other current assets", "totalLabel": "Total prepaid expenses and other current assets", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r901" ] }, "us-gaap_PrepaidExpenseCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "PrepaidExpenseCurrent", "crdr": "debit", "calculation": { "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosurePrepaidExpensesOtherCurrentAssetsAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails": { "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosurePrepaidExpensesOtherCurrentAssetsAccruedExpensesAndOtherCurrentLiabilitiesSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Prepaid Expense, Current", "totalLabel": "Prepaid Expense, Current, Total", "terseLabel": "Prepaid clinical expenses", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r99", "r218", "r219", "r705" ] }, "apvo_PrepaidExpensesOtherCurrentAssetsAccruedExpensesAndOtherCurrentLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://aptevotherapeutics.com/20260630", "localname": "PrepaidExpensesOtherCurrentAssetsAccruedExpensesAndOtherCurrentLiabilitiesAbstract", "lang": { "en-us": { "role": { "label": "Prepaid Expenses, Other Current Assets, Accrued Expenses, and Other Current Liabilities [Abstract]", "documentation": "Prepaid expenses, other current assets, accrued expenses, and other current liabilities." } } }, "auth_ref": [] }, "apvo_PrepaidExpensesOtherCurrentAssetsAccruedExpensesAndOtherCurrentLiabilitiesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://aptevotherapeutics.com/20260630", "localname": "PrepaidExpensesOtherCurrentAssetsAccruedExpensesAndOtherCurrentLiabilitiesTextBlock", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosurePrepaidExpensesOtherCurrentAssetsAccruedExpensesAndOtherCurrentLiabilities" ], "lang": { "en-us": { "role": { "label": "Prepaid Expenses, Other Current Assets, Accrued Expenses, and Other Current Liabilities [Text Block]", "documentation": "The entire disclosure for prepaid expenses, other current assets, accrued expenses, and other current liabilities.", "terseLabel": "Prepaid Expenses, Other Current Assets, Accrued Expenses, and Other Current Liabilities" } } }, "auth_ref": [] }, "us-gaap_PriorPeriodReclassificationAdjustmentDescription": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "PriorPeriodReclassificationAdjustmentDescription", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureNatureOfBusinessAndSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Reclassification, Comparability Adjustment [Policy Text Block]", "terseLabel": "Reclassification", "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error." } } }, "auth_ref": [ "r875" ] }, "apvo_PrivatePlacementAndWarrantInducementMember": { "xbrltype": "domainItemType", "nsuri": "http://aptevotherapeutics.com/20260630", "localname": "PrivatePlacementAndWarrantInducementMember", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureNatureOfBusinessAndSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Private Placement and Warrant Inducement", "label": "Private Placement And Warrant Inducement [Member]", "documentation": "Private placement and warrant inducement." } } }, "auth_ref": [] }, "us-gaap_PrivatePlacementMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "PrivatePlacementMember", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureEquity2026NiowaveCommonWarrantsAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Private Placement", "label": "Private Placement [Member]", "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts." } } }, "auth_ref": [] }, "us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital", "crdr": "debit", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureNatureOfBusinessAndSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Proceeds from Equity Method Investment, Distribution, Return of Capital", "terseLabel": "Proceeds from a strategic equity investment", "documentation": "Amount of distribution received from equity method investee for return of investment, classified as investing activities. Excludes distribution for return on investment, classified as operating activities." } } }, "auth_ref": [ "r113", "r913" ] }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ProceedsFromIssuanceOfCommonStock", "crdr": "debit", "calculation": { "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureEquity2025EquityOfferingsAndCommonWarrantsAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureEquity2026NiowaveCommonWarrantsAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureEquityAtTheMarketOfferingAgreementAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited", "http://aptevotherapeutics.com/20260630/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersDeficitEquityUnauditedParenthetical" ], "lang": { "en-us": { "role": { "verboseLabel": "Gross proceeds", "terseLabel": "Costs from issuance of common stock", "netLabel": "Proceeds from issuance of common stock and pre-funded warrants exercise, net of issuance costs", "label": "Proceeds from issuance of common stock", "documentation": "The cash inflow from the additional capital contribution to the entity." } } }, "auth_ref": [ "r1" ] }, "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ProceedsFromIssuanceOrSaleOfEquity", "crdr": "debit", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureEquityAtTheMarketOfferingAgreementAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net proceeds from sale of stock", "label": "Proceeds from Issuance or Sale of Equity", "totalLabel": "Proceeds from Issuance or Sale of Equity, Total", "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity." } } }, "auth_ref": [ "r1", "r602" ] }, "apvo_ProceedsFromIssuancesOfPreFundedWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://aptevotherapeutics.com/20260630", "localname": "ProceedsFromIssuancesOfPreFundedWarrants", "crdr": "credit", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "documentation": "Proceeds from issuances of pre-funded warrants.", "label": "Proceeds From Issuances Of Pre funded Warrants", "terseLabel": "Issuances of pre-funded warrants" } } }, "auth_ref": [] }, "apvo_ProceedsFromIssuancesOfPreFundedWarrantsShares": { "xbrltype": "sharesItemType", "nsuri": "http://aptevotherapeutics.com/20260630", "localname": "ProceedsFromIssuancesOfPreFundedWarrantsShares", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "terseLabel": "Issuances of pre-funded warrants, shares", "documentation": "Proceeds from issuances of pre-funded warrants, shares.", "label": "Proceeds From Issuances Of Pre-funded Warrants, Shares" } } }, "auth_ref": [] }, "apvo_ProceedsFromMilestonesRelatedToSaleOfRoyalties": { "xbrltype": "monetaryItemType", "nsuri": "http://aptevotherapeutics.com/20260630", "localname": "ProceedsFromMilestonesRelatedToSaleOfRoyalties", "crdr": "debit", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureLiabilityRelatedToSaleOfRoyaltiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from milestones related to sale of royalties", "label": "Proceeds From Milestones Related To Sale Of Royalties", "documentation": "Proceeds from milestones related to sale of royalties." } } }, "auth_ref": [] }, "us-gaap_ProceedsFromRoyaltiesReceived": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ProceedsFromRoyaltiesReceived", "crdr": "debit", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureLiabilityRelatedToSaleOfRoyaltiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from royalties received", "label": "Proceeds from Royalties Received", "documentation": "Cash received for royalties during the current period." } } }, "auth_ref": [ "r16", "r17" ] }, "apvo_ProceedsFromSaleOfInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://aptevotherapeutics.com/20260630", "localname": "ProceedsFromSaleOfInvestments", "crdr": "debit", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureLiabilityRelatedToSaleOfRoyaltiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from sale of investments", "label": "Proceeds From Sale Of Investments", "documentation": "Proceeds from Sale of Investments." } } }, "auth_ref": [] }, "apvo_ProceedsOfWarrantsIssuedDuringPeriodGross": { "xbrltype": "monetaryItemType", "nsuri": "http://aptevotherapeutics.com/20260630", "localname": "ProceedsOfWarrantsIssuedDuringPeriodGross", "crdr": "debit", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureEquity2025EquityOfferingsAndCommonWarrantsAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersDeficitEquityUnauditedParenthetical" ], "lang": { "en-us": { "role": { "documentation": "Proceeds of warrants issued during period gross.", "label": "Proceeds Of Warrants Issued During Period Gross", "terseLabel": "Gross proceeds from the offering", "verboseLabel": "Gross proceeds" } } }, "auth_ref": [] }, "apvo_ProceedsOfWarrantsIssuedDuringPeriodNet": { "xbrltype": "monetaryItemType", "nsuri": "http://aptevotherapeutics.com/20260630", "localname": "ProceedsOfWarrantsIssuedDuringPeriodNet", "crdr": "debit", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureEquity2023And2024CommonWarrantsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds of warrants issued during period net", "label": "Proceeds Of Warrants Issued During Period Net", "documentation": "Proceeds of warrants issued during period net." } } }, "auth_ref": [] }, "us-gaap_ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ProfitLoss", "crdr": "credit", "calculation": { "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 0.0 } }, "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Net loss", "totalLabel": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest." } } }, "auth_ref": [ "r39", "r59", "r66", "r102", "r103", "r115", "r119", "r122", "r123", "r126", "r134", "r143", "r146", "r147", "r209", "r228", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r292", "r325", "r338", "r389", "r407", "r416", "r420", "r423", "r424", "r457", "r483", "r565", "r567", "r582", "r610", "r654", "r675", "r676", "r699", "r756", "r757", "r782", "r912", "r960" ] }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureLeasesSummaryOfRightOfUseAssetsAcquiredUnderOperatingLeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-Lived Tangible Asset", "label": "Long-Lived Asset, Class [Axis]", "documentation": "Information by class of long-lived asset. Includes, but is not limited to, property, plant, and equipment; right-of-use asset from finance lease; long-lived asset of lessor subject to operating lease; proved oil and gas property accounted for under successful efforts method; and long-term prepaid asset." } } }, "auth_ref": [ "r233", "r234", "r512", "r732", "r733", "r734", "r735", "r942", "r943", "r1031" ] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Property, Plant and Equipment, Net, Total", "terseLabel": "Property and equipment, net", "label": "Property, Plant, and Equipment, after Accumulated Depreciation, Depletion, and Amortization", "documentation": "Amount, after accumulated depreciation, depletion, and amortization, of property, plant, and equipment. Includes, but is not limited to, land and land improvement; building; machinery and equipment; furniture and fixture; and work of art, historical treasure, or similar asset classified as collection." } } }, "auth_ref": [ "r512", "r549", "r550", "r563", "r569", "r570", "r579", "r769", "r946" ] }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "PropertyPlantAndEquipmentTypeDomain", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureLeasesSummaryOfRightOfUseAssetsAcquiredUnderOperatingLeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-Lived Tangible Asset", "label": "Long-Lived Asset, Class [Domain]", "documentation": "Class of long-lived asset. Includes, but is not limited to, property, plant, and equipment; right-of-use asset from finance lease; long-lived asset of lessor subject to operating lease; proved oil and gas property accounted for under successful efforts method; and long-term prepaid asset." } } }, "auth_ref": [ "r233", "r234", "r512", "r732", "r733", "r734", "r735", "r942", "r943", "r1031" ] }, "apvo_PurchaseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://aptevotherapeutics.com/20260630", "localname": "PurchaseAgreementMember", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Purchase Agreement", "label": "Purchase Agreement [Member]", "documentation": "Purchase agreement." } } }, "auth_ref": [] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "PvpTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Table]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": [ "r821" ] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "PvpTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pay vs Performance [Table Text Block]", "terseLabel": "Pay vs Performance Disclosure, Table" } } }, "auth_ref": [ "r821" ] }, "apvo_RUXIENCEMember": { "xbrltype": "domainItemType", "nsuri": "http://aptevotherapeutics.com/20260630", "localname": "RUXIENCEMember", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureLiabilityRelatedToSaleOfRoyaltiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "RUXIENCE", "label": "R U X I E N C E [Member]", "documentation": "RUXIENCE" } } }, "auth_ref": [] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2026", "localname": "RangeAxis", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureEquity2023And2024CommonWarrantsAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureEquity2024CommonWarrantsAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureEquity2025EquityOfferingsAndCommonWarrantsAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureEquity2026NiowaveCommonWarrantsAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureEquitySummaryOfAssumptionsUsedToEstimateTheFairValueOfTheWarrantsUsingTheBlackscholesOptionPricingModelDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureReverseStockSplitAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureLiabilityRelatedToSaleOfRoyaltiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement", "label": "Statistical Measurement [Axis]" } } }, "auth_ref": [ "r67", "r69", "r173", "r246", "r247", "r248", "r249", "r343", "r353", "r381", "r382", "r383", "r386", "r393", "r464", "r534", "r535", "r536", "r537", "r539", "r540", "r541", "r542", "r543", "r546", "r586", "r587", "r600", "r625", "r626", "r682", "r683", "r684", "r685", "r686", "r692", "r693", "r694", "r695", "r696", "r697", "r731", "r749", "r753", "r754", "r755", "r761", "r762", "r763", "r764", "r770", "r775", "r957", "r962", "r964", "r1014" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2026", "localname": "RangeMember", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureEquity2023And2024CommonWarrantsAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureEquity2024CommonWarrantsAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureEquity2025EquityOfferingsAndCommonWarrantsAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureEquity2026NiowaveCommonWarrantsAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureEquitySummaryOfAssumptionsUsedToEstimateTheFairValueOfTheWarrantsUsingTheBlackscholesOptionPricingModelDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureReverseStockSplitAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureLiabilityRelatedToSaleOfRoyaltiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement", "label": "Statistical Measurement [Domain]" } } }, "auth_ref": [ "r67", "r69", "r173", "r246", "r247", "r248", "r249", "r343", "r353", "r381", "r382", "r383", "r386", "r393", "r464", "r534", "r535", "r536", "r537", "r539", "r540", "r541", "r542", "r543", "r546", "r586", "r587", "r600", "r625", "r626", "r682", "r683", "r684", "r685", "r686", "r692", "r693", "r694", "r695", "r696", "r697", "r731", "r749", "r753", "r754", "r755", "r761", "r762", "r763", "r764", "r770", "r775", "r957", "r962", "r964", "r1014" ] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]", "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure" } } }, "auth_ref": [ "r789", "r799", "r809", "r841" ] }, "apvo_ReductionInResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://aptevotherapeutics.com/20260630", "localname": "ReductionInResearchAndDevelopmentExpense", "crdr": "credit", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Research and development expense", "label": "Reduction In Research And Development Expense", "documentation": "Reduction in research and development expense." } } }, "auth_ref": [] }, "apvo_RegisteredDirectOfferingMember": { "xbrltype": "domainItemType", "nsuri": "http://aptevotherapeutics.com/20260630", "localname": "RegisteredDirectOfferingMember", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureEquity2023And2024CommonWarrantsAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureEquity2024CommonWarrantsAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureEquity2025EquityOfferingsAndCommonWarrantsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Registered Direct Offering", "label": "Registered Direct Offering [Member]", "documentation": "Registered Direct Offering." } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "RelatedPartyTransactionAxis", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party Transaction", "label": "Related Party Transaction [Axis]", "documentation": "Information by type of related party transaction." } } }, "auth_ref": [ "r119", "r125", "r126", "r523", "r524", "r1024" ] }, "us-gaap_RelatedPartyTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "RelatedPartyTransactionDomain", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party Transaction", "label": "Related Party Transaction [Domain]", "documentation": "Transaction between related party." } } }, "auth_ref": [ "r119", "r125", "r126", "r1024" ] }, "us-gaap_RelatedPartyTransactionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "RelatedPartyTransactionLineItems", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureXomaTransactionAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Related Party Transaction [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r119", "r125", "r126", "r208", "r523", "r524", "r525", "r549", "r550", "r553", "r554", "r555", "r561", "r658", "r659", "r662", "r1046" ] }, "us-gaap_RelatedPartyTransactionsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "RelatedPartyTransactionsAbstract", "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "RelatedPartyTransactionsDisclosureTextBlock", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureXomaTransaction1" ], "lang": { "en-us": { "role": { "terseLabel": "XOMA Transaction", "label": "Related Party Transactions Disclosure [Text Block]", "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates." } } }, "auth_ref": [ "r520", "r521", "r522", "r524", "r526", "r549", "r550", "r562", "r607", "r608", "r609", "r660", "r661", "r662", "r680", "r681" ] }, "us-gaap_RepaymentsOfDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "RepaymentsOfDebt", "crdr": "credit", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Repayment of debt", "label": "Repayments of Debt", "documentation": "Amount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation." } } }, "auth_ref": [ "r914" ] }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2026", "localname": "RepurchaseAgreementCounterpartyNameDomain", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureLiabilityRelatedToSaleOfRoyaltiesAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureNatureOfBusinessAndSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Counterparty Name", "label": "Counterparty Name [Domain]" } } }, "auth_ref": [ "r119", "r127", "r128", "r265", "r310", "r525", "r530", "r544", "r572", "r707", "r708", "r709", "r903", "r904", "r905", "r906", "r907", "r908", "r909", "r910", "r911", "r1006", "r1007", "r1008", "r1009", "r1028", "r1029" ] }, "apvo_ResearchAndDevelopmentCostPercentage": { "xbrltype": "percentItemType", "nsuri": "http://aptevotherapeutics.com/20260630", "localname": "ResearchAndDevelopmentCostPercentage", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of cost related to research and development", "label": "Research And Development Cost Percentage", "documentation": "Research and development cost percentage." } } }, "auth_ref": [] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 0.0 } }, "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureSegmentInformationSummaryOfSignificantExpenseCategoriesDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Research and Development Expense, Total", "negatedLabel": "Research and development", "label": "Research and Development Expense", "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity." } } }, "auth_ref": [ "r394", "r698", "r711", "r712", "r724", "r1032" ] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "RestatementDateAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Determination Date [Axis]", "terseLabel": "Restatement Determination Date:" } } }, "auth_ref": [ "r790", "r800", "r810", "r842" ] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "RestatementDeterminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Determination Date", "terseLabel": "Restatement Determination Date" } } }, "auth_ref": [ "r791", "r801", "r811", "r843" ] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Does Not Require Recovery [Text Block]", "terseLabel": "Restatement does not require Recovery" } } }, "auth_ref": [ "r798", "r808", "r818", "r850" ] }, "us-gaap_RestrictedCashAndCashEquivalentsItemsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "RestrictedCashAndCashEquivalentsItemsLineItems", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureCashAndCashEquivalentsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted Cash And Cash Equivalents Items [Line Items]", "label": "Restricted Cash and Cash Equivalent Item [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r892", "r1041" ] }, "us-gaap_RestrictedCashCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "RestrictedCashCurrent", "crdr": "debit", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureCashAndCashEquivalentsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Current restricted cash", "terseLabel": "Restricted cash", "label": "Restricted Cash, Current", "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits." } } }, "auth_ref": [ "r116", "r118", "r892" ] }, "us-gaap_RestrictedStockUnitsRSUMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "RestrictedStockUnitsRSUMember", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureNetLossPerShareSummaryOfPotentiallyDilutiveSharesExcludedFromCalculationOfNetLossPerShareDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unvested RSUs", "label": "Restricted Stock Units (RSUs) [Member]", "verboseLabel": "Restricted Stock Units", "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met." } } }, "auth_ref": [ "r978", "r979", "r980", "r981", "r982", "r983", "r984", "r985", "r986", "r987", "r988", "r989", "r990", "r991", "r992", "r993", "r994", "r995", "r996", "r997", "r998", "r1000", "r1001", "r1002", "r1003", "r1004" ] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureNatureOfBusinessAndSignificantAccountingPoliciesAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Retained Earnings (Accumulated Deficit), Total", "negatedLabel": "Accumulated deficit", "terseLabel": "Accumulated deficit", "label": "Retained Earnings (Accumulated Deficit)", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r96", "r97", "r322", "r549", "r550", "r559", "r577", "r594", "r599", "r606", "r635", "r769" ] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "RetainedEarningsMember", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Deficit", "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r38", "r39", "r130", "r131", "r132", "r135", "r143", "r145", "r147", "r210", "r213", "r227", "r228", "r230", "r291", "r319", "r329", "r336", "r337", "r341", "r342", "r389", "r395", "r396", "r403", "r404", "r405", "r408", "r415", "r416", "r430", "r431", "r432", "r433", "r435", "r436", "r439", "r455", "r499", "r545", "r571", "r590", "r592", "r611", "r970", "r972", "r1044" ] }, "apvo_ReverseStockSplit": { "xbrltype": "textBlockItemType", "nsuri": "http://aptevotherapeutics.com/20260630", "localname": "ReverseStockSplit", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureReverseStockSplit1" ], "lang": { "en-us": { "role": { "documentation": "Reverse stock split.", "label": "Reverse Stock Split" } } }, "auth_ref": [] }, "apvo_ReverseStockSplitAbstract": { "xbrltype": "stringItemType", "nsuri": "http://aptevotherapeutics.com/20260630", "localname": "ReverseStockSplitAbstract", "lang": { "en-us": { "role": { "documentation": "Reverse stock split.", "label": "Reverse Stock Split [Abstract]" } } }, "auth_ref": [] }, "apvo_ReverseStockSplitLineItem": { "xbrltype": "stringItemType", "nsuri": "http://aptevotherapeutics.com/20260630", "localname": "ReverseStockSplitLineItem", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureReverseStockSplitAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Reverse stock split.", "label": "Reverse Stock Split [Line Item]" } } }, "auth_ref": [] }, "apvo_ReverseStockSplitTable": { "xbrltype": "stringItemType", "nsuri": "http://aptevotherapeutics.com/20260630", "localname": "ReverseStockSplitTable", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureReverseStockSplitAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Reverse stock split.", "label": "Reverse Stock Split [Table]" } } }, "auth_ref": [] }, "apvo_RightToPurchaseAdditionalShares": { "xbrltype": "sharesItemType", "nsuri": "http://aptevotherapeutics.com/20260630", "localname": "RightToPurchaseAdditionalShares", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Right to purcahse additional shares", "label": "Right to Purchase Additional Shares", "documentation": "Right to purchase additional shares." } } }, "auth_ref": [] }, "apvo_Rule10B51ArrModifiedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://aptevotherapeutics.com/20260630", "localname": "Rule10B51ArrModifiedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Rule 10b51 Arr Modified [Flag]", "documentation": "Rule 10b51 arr modified flag.", "terseLabel": "Rule 10b5-1 Arrangement Modified" } } }, "auth_ref": [] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "Rule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": [ "r859" ] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "Rule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": [ "r859" ] }, "apvo_SaleOfRoyaltiesLiabilityDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://aptevotherapeutics.com/20260630", "localname": "SaleOfRoyaltiesLiabilityDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Sale Of Royalties Liability Disclosure [Abstract]", "documentation": "Sale of royalties liability disclosure abstract." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "SaleOfStockConsiderationReceivedOnTransaction", "crdr": "debit", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureNatureOfBusinessAndSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Sale of Stock, Consideration Received on Transaction", "verboseLabel": "Gross proceeds", "terseLabel": "Net/gross proceeds", "documentation": "Cash received on stock transaction after deduction of issuance costs." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "SaleOfStockNameOfTransactionDomain", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureEquity2023And2024CommonWarrantsAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureEquity2024CommonWarrantsAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureEquity2025EquityOfferingsAndCommonWarrantsAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureEquity2026NiowaveCommonWarrantsAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureEquityAtTheMarketOfferingAgreementAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureNatureOfBusinessAndSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Sale of Stock [Domain]", "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "SaleOfStockNumberOfSharesIssuedInTransaction", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of shares sold", "label": "Sale of Stock, Number of Shares Issued in Transaction", "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "SaleOfStockPricePerShare", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Sale of stock per share", "label": "Sale of Stock, Price Per Share", "terseLabel": "Average price", "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction." } } }, "auth_ref": [] }, "srt_ScenarioForecastMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2026", "localname": "ScenarioForecastMember", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureLiabilityRelatedToSaleOfRoyaltiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Forecast", "label": "Forecast [Member]" } } }, "auth_ref": [ "r354" ] }, "srt_ScenarioUnspecifiedDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2026", "localname": "ScenarioUnspecifiedDomain", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureLiabilityRelatedToSaleOfRoyaltiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Scenario", "label": "Scenario [Domain]" } } }, "auth_ref": [ "r40", "r41", "r148", "r354", "r872" ] }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosurePrepaidExpensesOtherCurrentAssetsAccruedExpensesAndOtherCurrentLiabilitiesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Accrued Liabilities [Table Text Block]", "terseLabel": "Summary of Accrued Expenses and Other Current Liabilities", "documentation": "Tabular disclosure of the components of accrued liabilities." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureNetLossPerShareTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Potentially Dilutive Shares Excluded from Calculation of Net Loss Per Share", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities." } } }, "auth_ref": [ "r932" ] }, "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureCashAndCashEquivalentsTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Cash and Cash Equivalents [Table Text Block]", "terseLabel": "Schedule of Cash and Cash Equivalents", "documentation": "Tabular disclosure of the components of cash and cash equivalents." } } }, "auth_ref": [] }, "apvo_ScheduleOfChangesInLiabilityRelatedToSaleOfRoyaltiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://aptevotherapeutics.com/20260630", "localname": "ScheduleOfChangesInLiabilityRelatedToSaleOfRoyaltiesTableTextBlock", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureLiabilityRelatedToSaleOfRoyaltiesTables" ], "lang": { "en-us": { "role": { "documentation": "Schedule of changes in the liability related to the sale of royalties.", "terseLabel": "Schedule of Changes in the Liability Related to the Sale of Royalties", "label": "Schedule Of Changes In Liability Related To Sale Of Royalties Table [Text Block]" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]", "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r419" ] }, "us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureDiscontinuedOperationsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Reconciliation of Carrying Amounts of Assets and Liabilities and Income (Loss) from Discontinued Operation", "label": "Disposal Groups, Including Discontinued Operations [Table Text Block]", "documentation": "Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component." } } }, "auth_ref": [ "r700", "r701", "r702", "r876", "r877", "r880", "r881", "r882", "r884", "r885", "r887", "r948", "r949" ] }, "apvo_ScheduleOfEarningsPerShareBasicAndDilutedLineItems": { "xbrltype": "stringItemType", "nsuri": "http://aptevotherapeutics.com/20260630", "localname": "ScheduleOfEarningsPerShareBasicAndDilutedLineItems", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureNetLossPerShareSummaryOfPotentiallyDilutiveSharesExcludedFromCalculationOfNetLossPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule Of Earnings Per Share Basic And Diluted [Line Items]", "label": "Schedule Of Earnings Per Share Basic And Diluted [Line Items]", "documentation": "Schedule of earnings per share basic and diluted." } } }, "auth_ref": [] }, "apvo_ScheduleOfEarningsPerShareBasicAndDilutedTable": { "xbrltype": "stringItemType", "nsuri": "http://aptevotherapeutics.com/20260630", "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTable", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureNetLossPerShareSummaryOfPotentiallyDilutiveSharesExcludedFromCalculationOfNetLossPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule Of Earnings Per Share Basic And Diluted [Table]", "label": "Schedule Of Earnings Per Share Basic And Diluted [Table]", "documentation": "Schedule of earnings per share basic and diluted." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureNetLossPerShareTables" ], "lang": { "en-us": { "role": { "terseLabel": "Computation of Basic and Diluted Net Loss per Share", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations." } } }, "auth_ref": [ "r931" ] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureEquityTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Stock-based Compensation Expense Includes Amortization of Stock Options and Restricted Stock Units Granted", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement." } } }, "auth_ref": [ "r9" ] }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureXomaTransactionAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Related Party Transaction [Table]", "documentation": "Disclosure of information about related party transaction." } } }, "auth_ref": [ "r119", "r125", "r126", "r523", "r524", "r525", "r549", "r550", "r553", "r554", "r555", "r561", "r658", "r659", "r662", "r1046" ] }, "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTable", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureCashAndCashEquivalentsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule Of Restricted Cash And Cash Equivalents [Table]", "label": "Restrictions on Cash and Cash Equivalents [Table]", "documentation": "Disclosure of information about cash and cash equivalents restricted as to withdrawal or usage." } } }, "auth_ref": [ "r892", "r1041" ] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureEquity2023And2024CommonWarrantsAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureEquity2024CommonWarrantsAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureEquity2025EquityOfferingsAndCommonWarrantsAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureEquity2026NiowaveCommonWarrantsAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureEquityAtTheMarketOfferingAgreementAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureEquityStandbyEquityPurchaseAgreementAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureEquitySummaryOfCommonWarrantActivityDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureEquityTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": [ "r355", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r386" ] }, "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureEquityTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of RSU Activity", "label": "Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]", "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year." } } }, "auth_ref": [ "r21" ] }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureEquityTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Stock Option Activity", "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value." } } }, "auth_ref": [ "r5", "r6", "r21" ] }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureEquityTables" ], "lang": { "en-us": { "role": { "terseLabel": "Assumptions used in Valuing the Stock Options Granted under Black-Scholes Valuation Model", "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions." } } }, "auth_ref": [ "r22" ] }, "apvo_SeattleOfficeLeaseIncludingAmendmentMember": { "xbrltype": "domainItemType", "nsuri": "http://aptevotherapeutics.com/20260630", "localname": "SeattleOfficeLeaseIncludingAmendmentMember", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureLeasesSummaryOfRightOfUseAssetsAcquiredUnderOperatingLeasesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Seattle Office Lease, Including Amendment", "label": "Seattle Office Lease Including Amendment [Member]", "documentation": "Seattle office lease including amendment." } } }, "auth_ref": [] }, "apvo_SecondStandbyEquityPurchaseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://aptevotherapeutics.com/20260630", "localname": "SecondStandbyEquityPurchaseAgreementMember", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureEquityStandbyEquityPurchaseAgreementAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Second Standby Equity Purchase Agreement [Member]", "documentation": "Second Standby Equity Purchase Agreement member.", "terseLabel": "Second Standby Equity Purchase Agreement" } } }, "auth_ref": [] }, "us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate", "label": "Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member]", "documentation": "Fixed rate on U.S. dollar, constant-notional interest rate swap that has its variable-rate leg referenced to Secured Overnight Financing Rate (SOFR) with no additional spread over SOFR on variable-rate leg." } } }, "auth_ref": [ "r759", "r891", "r896" ] }, "apvo_SecuritiesPurchaseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://aptevotherapeutics.com/20260630", "localname": "SecuritiesPurchaseAgreementMember", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Securities Purchase Agreement.", "label": "Securities Purchase Agreement" } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "Security12bTitle", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r784" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "SecurityExchangeName", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r786" ] }, "us-gaap_SegmentReportingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "SegmentReportingAbstract", "lang": { "en-us": { "role": { "label": "Segment Reporting [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "SegmentReportingCodmIndividualTitleAndPositionOrGroupOrCommitteeNameExtensibleEnumeration", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureSegmentInformationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Segment Reporting, CODM, Individual Title and Position or Group Name [Extensible Enumeration]", "documentation": "Indicates title and position of individual or name of group identified as chief operating decision maker (CODM) for segment reporting." } } }, "auth_ref": [ "r178", "r723", "r730" ] }, "us-gaap_SegmentReportingCodmProfitLossMeasureHowUsedDescription": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "SegmentReportingCodmProfitLossMeasureHowUsedDescription", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureSegmentInformationAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Segment Reporting, CODM, Profit (Loss) Measure, How Used, Description", "documentation": "Description of how chief operating decision maker (CODM) uses reported segment profit (loss) measure to assess performance and allocate resource." } } }, "auth_ref": [ "r195", "r720", "r727" ] }, "us-gaap_SegmentReportingDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "SegmentReportingDisclosureTextBlock", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureSegmentInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Segment Information", "label": "Segment Reporting [Text Block]", "documentation": "The entire disclosure for segment reporting." } } }, "auth_ref": [ "r166", "r174", "r175", "r176", "r177", "r179", "r191", "r193", "r194", "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r719", "r721", "r722", "r724", "r726", "r728", "r729" ] }, "us-gaap_SegmentReportingInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "SegmentReportingInformationLineItems", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureSegmentInformationAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureSegmentInformationSummaryOfSignificantAssetCategoriesDetails" ], "lang": { "en-us": { "role": { "label": "Segment Reporting [Line Items]", "verboseLabel": "Segment Reporting Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r175", "r179", "r180", "r181", "r182", "r183", "r184", "r185", "r186", "r187", "r188", "r189", "r190", "r192", "r193", "r194", "r196", "r197", "r198", "r199", "r200", "r202", "r203", "r204" ] }, "apvo_September2024RegisteredDirectOfferingMember": { "xbrltype": "domainItemType", "nsuri": "http://aptevotherapeutics.com/20260630", "localname": "September2024RegisteredDirectOfferingMember", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureEquity2024CommonWarrantsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "September 2024 Registered Direct Offering [Member]", "label": "September 2024 Registered Direct Offering [Member]", "terseLabel": "September 2024 Registered Direct Offering" } } }, "auth_ref": [] }, "apvo_SeriesAAndSeriesBCommonWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://aptevotherapeutics.com/20260630", "localname": "SeriesAAndSeriesBCommonWarrantsMember", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureEquity2023And2024CommonWarrantsAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Series A and Series B Common Warrants", "label": "Series A and Series B common warrants [Member]", "documentation": "Series A and Series B common warrants." } } }, "auth_ref": [] }, "apvo_SeriesACommonWarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://aptevotherapeutics.com/20260630", "localname": "SeriesACommonWarrantMember", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Series A common warrant.", "label": "Series A Common Warrant [Member]", "terseLabel": "Series A Common Warrants" } } }, "auth_ref": [] }, "apvo_SeriesAJuniorParticipatingPreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://aptevotherapeutics.com/20260630", "localname": "SeriesAJuniorParticipatingPreferredStockMember", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Series A Junior Participating Preferred Stock [Member]", "terseLabel": "Series A Junior Participating Preferred Stock [Member]", "documentation": "Series A Junior Participating Preferred Stock." } } }, "auth_ref": [] }, "apvo_SeriesAOneCommonWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://aptevotherapeutics.com/20260630", "localname": "SeriesAOneCommonWarrantsMember", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureEquity2023And2024CommonWarrantsAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Series a one common warrants.", "label": "Series A One Common Warrants [Member]", "terseLabel": "Series A-1 Common Warrants" } } }, "auth_ref": [] }, "apvo_SeriesATwoCommonWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://aptevotherapeutics.com/20260630", "localname": "SeriesATwoCommonWarrantsMember", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureEquity2023And2024CommonWarrantsAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Series a two common warrants.", "label": "Series A Two Common Warrants [Member]", "terseLabel": "Series A-2 Common Warrants" } } }, "auth_ref": [] }, "apvo_SeriesBCommonWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://aptevotherapeutics.com/20260630", "localname": "SeriesBCommonWarrantsMember", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Series B Common Warrants 2023", "label": "Series B Common Warrants [Member]", "documentation": "Series B Common Warrants.", "verboseLabel": "Series B Common Warrants" } } }, "auth_ref": [] }, "apvo_SeriesBOneCommonWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://aptevotherapeutics.com/20260630", "localname": "SeriesBOneCommonWarrantsMember", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureEquity2023And2024CommonWarrantsAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Series b one common warrants.", "label": "Series B One Common Warrants [Member]", "terseLabel": "Series B-1 Common Warrants" } } }, "auth_ref": [] }, "apvo_SeriesBTwoCommonWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://aptevotherapeutics.com/20260630", "localname": "SeriesBTwoCommonWarrantsMember", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureEquity2023And2024CommonWarrantsAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Series b two common warrants.", "label": "Series B Two Common Warrants [Member]", "terseLabel": "Series B-2 Common Warrants" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Share-Based Payment Arrangement, Noncash Expense, Total", "terseLabel": "Stock-based compensation", "label": "Share-Based Payment Arrangement, Noncash Expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": [ "r3" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period", "terseLabel": "Stock plan vesting period", "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition." } } }, "auth_ref": [ "r750" ] }, "apvo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsNonvestedAndExpectedToVestNumber": { "xbrltype": "sharesItemType", "nsuri": "http://aptevotherapeutics.com/20260630", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentOtherThanOptionsNonvestedAndExpectedToVestNumber", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of Units, Outstanding and expected to vest", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instrument Other Than Options Nonvested And Expected To Vest Number", "documentation": "Share based compensation arrangement by share based payment award equity instrument other than options nonvested and expected to vest number." } } }, "auth_ref": [] }, "apvo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://aptevotherapeutics.com/20260630", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpectedToVestWeightedAverageGrantDateFairValue", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Share based compensation arrangement by share based payment award equity instruments other than options, expected to vest, weighted average grant date fair value.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Expected To Vest Weighted Average Grant Date Fair Value", "periodEndLabel": "Weighted Average Fair Value per Unit, Expected to Vest", "terseLabel": "Weighted average fair value" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureEquity2023And2024CommonWarrantsAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureEquity2024CommonWarrantsAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureEquity2025EquityOfferingsAndCommonWarrantsAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureEquity2026NiowaveCommonWarrantsAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureEquityAtTheMarketOfferingAgreementAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureEquityStandbyEquityPurchaseAgreementAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureEquitySummaryOfCommonWarrantActivityDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureEquityTables" ], "lang": { "en-us": { "role": { "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r355", "r357", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r386" ] }, "apvo_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfReturningSharesFromOldPlanToBeAddedToSharesReserve": { "xbrltype": "sharesItemType", "nsuri": "http://aptevotherapeutics.com/20260630", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfReturningSharesFromOldPlanToBeAddedToSharesReserve", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum number of returning shares from old plan to be add to shares reserve", "label": "Share Based Compensation Arrangement By Share Based Payment Award Maximum Number Of Returning Shares From Old Plan To Be Added To Shares Reserve", "documentation": "Share based compensation arrangement by share based payment award maximum number of returning shares from old plan to be added to shares reserve." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock authorized for issuance under Stock Plan", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized", "verboseLabel": "Stock authorized for issuance under the plan", "documentation": "Number of shares authorized for issuance under share-based payment arrangement." } } }, "auth_ref": [ "r752" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of shares available for grant", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant", "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable." } } }, "auth_ref": [ "r8" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Number of Shares, Outstanding, Beginning balance", "periodEndLabel": "Number of Shares, Outstanding, Ending balance", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "terseLabel": "Number of shares outstanding under share-based payment arrangement", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": [ "r361", "r362" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period", "terseLabel": "Number of shares issued under share-based payment arrangement", "documentation": "Number of shares issued under share-based payment arrangement." } } }, "auth_ref": [ "r8" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "All Award Types", "terseLabel": "All Award Types", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": [ "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r380", "r381", "r382", "r383", "r384" ] }, "apvo_SharePortionEntitledToPurchaseByRights1": { "xbrltype": "stringItemType", "nsuri": "http://aptevotherapeutics.com/20260630", "localname": "SharePortionEntitledToPurchaseByRights1", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share portion entitled to purchase by rights", "label": "Share Portion Entitled To Purchase By Rights1", "documentation": "Share portion entitled to purchase by rights." } } }, "auth_ref": [] }, "us-gaap_SharePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "SharePrice", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureEquityAtTheMarketOfferingAgreementAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Share Price", "terseLabel": "Share price", "documentation": "Price of a single share of a number of saleable stocks of a company." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock plan termination period", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period", "documentation": "Period from grant to expiration date of share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r751" ] }, "apvo_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpectedToVestWeightedAveragePeriod": { "xbrltype": "durationItemType", "nsuri": "http://aptevotherapeutics.com/20260630", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExpectedToVestWeightedAveragePeriod", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Options expected to vest, weighted average period", "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Expected To Vest Weighted Average Period", "documentation": "Sharebased compensation arrangement by sharebased payment award options expected to vest weighted average period." } } }, "auth_ref": [] }, "us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "ShareholdersEquityAndShareBasedPaymentsTextBlock", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Equity", "label": "Shareholders' Equity and Share-Based Payments [Text Block]", "documentation": "The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP)." } } }, "auth_ref": [ "r963", "r977" ] }, "us-gaap_SharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "SharesIssued", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureEquity2026NiowaveCommonWarrantsAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureEquityAtTheMarketOfferingAgreementAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Shares issued", "label": "Shares, Issued", "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury." } } }, "auth_ref": [] }, "us-gaap_SharesIssuedPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "SharesIssuedPricePerShare", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureEquity2025EquityOfferingsAndCommonWarrantsAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock price per share", "label": "Shares Issued, Price Per Share", "verboseLabel": "Offering price", "documentation": "Per share or per unit amount of equity securities issued." } } }, "auth_ref": [] }, "us-gaap_SharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "SharesOutstanding", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "periodStartLabel": "Balance (in shares)", "periodEndLabel": "Balance (in shares)", "label": "Shares, Outstanding", "documentation": "Number of shares issued which are neither cancelled nor held in the treasury." } } }, "auth_ref": [ "r965", "r970", "r972" ] }, "apvo_SignificantAccountingPoliciesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://aptevotherapeutics.com/20260630", "localname": "SignificantAccountingPoliciesPolicyTextBlock", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureNatureOfBusinessAndSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Significant Accounting Policies [Policy Text Block]", "documentation": "Significant accounting policies.", "terseLabel": "Significant Accounting Policies" } } }, "auth_ref": [] }, "apvo_StandbyEquityPurchaseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://aptevotherapeutics.com/20260630", "localname": "StandbyEquityPurchaseAgreementMember", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureEquityStandbyEquityPurchaseAgreementAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Standby Equity Purchase Agreement [Member]", "documentation": "Standby equity purchase agreement.", "terseLabel": "Standby Equity Purchase Agreement" } } }, "auth_ref": [] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "StatementClassOfStockAxis", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Stock", "label": "Class of Stock [Axis]", "documentation": "Information by the different classes of stock of the entity." } } }, "auth_ref": [ "r33", "r72", "r73", "r90", "r91", "r92", "r93", "r94", "r95", "r119", "r123", "r154", "r155", "r158", "r160", "r168", "r169", "r209", "r252", "r254", "r255", "r256", "r259", "r260", "r293", "r294", "r296", "r297", "r299", "r302", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r320", "r321", "r324", "r325", "r326", "r483", "r549", "r550", "r556", "r557", "r558", "r571", "r602", "r603", "r604", "r605", "r611", "r613", "r614", "r615", "r616", "r617", "r618", "r619", "r620", "r621", "r622", "r624", "r634", "r655", "r677", "r687", "r688", "r689", "r690", "r691", "r871", "r920", "r922", "r930", "r971", "r976" ] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureEquity2023And2024CommonWarrantsAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureEquity2024CommonWarrantsAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureEquity2025EquityOfferingsAndCommonWarrantsAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersDeficitEquityUnauditedParenthetical", "http://aptevotherapeutics.com/20260630/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Components", "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r38", "r39", "r72", "r94", "r95", "r104", "r105", "r106", "r130", "r131", "r132", "r135", "r143", "r145", "r147", "r167", "r210", "r213", "r227", "r228", "r230", "r291", "r314", "r319", "r320", "r321", "r324", "r326", "r329", "r336", "r337", "r341", "r342", "r389", "r395", "r396", "r403", "r404", "r405", "r408", "r415", "r416", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r439", "r443", "r444", "r445", "r446", "r455", "r484", "r485", "r486", "r487", "r488", "r489", "r499", "r519", "r545", "r549", "r550", "r557", "r558", "r571", "r584", "r590", "r591", "r592", "r611", "r677", "r976" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "StatementLineItems", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersDeficitEquityUnauditedParenthetical", "http://aptevotherapeutics.com/20260630/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Line Items]", "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r72", "r73", "r74", "r75", "r78", "r87", "r89", "r90", "r93", "r94", "r95", "r97", "r130", "r131", "r132", "r167", "r293", "r294", "r296", "r299", "r304", "r314", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r326", "r328", "r329", "r333", "r499", "r547", "r549", "r550", "r556", "r557", "r558", "r601", "r612", "r624", "r627", "r628", "r629", "r630", "r631", "r632", "r634", "r637", "r638", "r639", "r640", "r641", "r643", "r644", "r645", "r646", "r648", "r649", "r650", "r651", "r652", "r656", "r657", "r663", "r664", "r665", "r666", "r667", "r668", "r669", "r670", "r671", "r672", "r673", "r674", "r677", "r704", "r713", "r714", "r776", "r1043" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": [] }, "srt_StatementScenarioAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2026", "localname": "StatementScenarioAxis", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureLiabilityRelatedToSaleOfRoyaltiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Scenario", "label": "Scenario [Axis]" } } }, "auth_ref": [ "r40", "r41", "r148", "r354", "r872", "r873" ] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "StatementTable", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersDeficitEquityUnauditedParenthetical", "http://aptevotherapeutics.com/20260630/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Table]", "label": "Statement [Table]", "documentation": "Presentation of information about comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity." } } }, "auth_ref": [ "r43", "r72", "r73", "r74", "r75", "r78", "r87", "r89", "r90", "r93", "r94", "r95", "r97", "r130", "r131", "r132", "r167", "r208", "r293", "r294", "r296", "r299", "r304", "r314", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r326", "r328", "r329", "r333", "r499", "r547", "r549", "r550", "r556", "r557", "r558", "r571", "r601", "r612", "r624", "r627", "r628", "r629", "r630", "r631", "r632", "r634", "r637", "r638", "r639", "r640", "r641", "r643", "r644", "r645", "r646", "r648", "r649", "r650", "r651", "r652", "r656", "r657", "r663", "r664", "r665", "r666", "r667", "r668", "r669", "r670", "r671", "r672", "r673", "r674", "r677", "r704", "r713", "r714", "r776", "r1043" ] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Stock Price or TSR Estimation Method [Text Block]", "terseLabel": "Stock Price or TSR Estimation Method" } } }, "auth_ref": [ "r793", "r803", "r813", "r845" ] }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "StockAppreciationRightsSARSMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Stock Appreciation Rights (SARs) [Member]", "terseLabel": "Stock Appreciation Rights (SARs)", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } }, "auth_ref": [ "r978", "r979", "r980", "r981", "r982", "r983", "r984", "r985", "r986", "r987", "r988", "r989", "r990", "r991", "r992", "r993", "r994", "r995", "r996", "r997", "r998", "r1000", "r1001", "r1002", "r1003", "r1004" ] }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureEquity2025EquityOfferingsAndCommonWarrantsAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureEquityAtTheMarketOfferingAgreementAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "netLabel": "Issuance of common stock shares", "verboseLabel": "Issuance of common stock ,shares", "terseLabel": "Issuance of common stock, shares", "label": "Private placement share agreed to sell", "documentation": "Number of new stock issued during the period." } } }, "auth_ref": [ "r602", "r677", "r688", "r889", "r898", "r899", "r965", "r967", "r968", "r970", "r972", "r1033", "r1034", "r1036", "r1037" ] }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "totalLabel": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures, Total", "terseLabel": "Common stock issued upon vesting of restricted stock units (in shares)", "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures", "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited." } } }, "auth_ref": [ "r889", "r898", "r899", "r965", "r967", "r968", "r970", "r972", "r1033", "r1034", "r1036", "r1037" ] }, "us-gaap_StockIssuedDuringPeriodSharesReverseStockSplits": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "StockIssuedDuringPeriodSharesReverseStockSplits", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Shares, Reverse Stock Splits", "terseLabel": "Payment in lieu of fractional shares in connection with the 1-for-44 reverse stock split effected on March 5, 2024 (in shares)", "verboseLabel": "Payment in lieu of fractional shares, shares", "negatedLabel": "Payment in lieu of fractional shares, shares", "documentation": "Reduction in the number of shares during the period as a result of a reverse stock split." } } }, "auth_ref": [ "r889", "r898", "r899", "r965", "r967", "r968" ] }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "StockIssuedDuringPeriodValueNewIssues", "crdr": "credit", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "proceeds from issuance of common stock", "verboseLabel": "Issuance of common stock", "terseLabel": "Issuance of common stock", "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering." } } }, "auth_ref": [ "r611", "r677", "r688", "r782", "r889", "r898", "r899", "r965", "r967", "r968", "r970", "r972", "r1033", "r1034", "r1036", "r1037" ] }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures", "crdr": "credit", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "totalLabel": "Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures, Total", "terseLabel": "Common stock issued upon vesting of restricted stock units", "label": "Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures", "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited." } } }, "auth_ref": [ "r889", "r898", "r899", "r965", "r967", "r968", "r970", "r972" ] }, "apvo_StockOfferingAggregatePrice": { "xbrltype": "monetaryItemType", "nsuri": "http://aptevotherapeutics.com/20260630", "localname": "StockOfferingAggregatePrice", "crdr": "credit", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureEquityAtTheMarketOfferingAgreementAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Stock Offering Aggregate Price", "documentation": "Stock offering aggregate price.", "terseLabel": "Stock offering aggregate price" } } }, "auth_ref": [] }, "apvo_StockPurchaseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://aptevotherapeutics.com/20260630", "localname": "StockPurchaseAgreementMember", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Stock Purchase Agreement [Member]", "documentation": "Stock Purchase Agreement [Member]" } } }, "auth_ref": [] }, "us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1", "crdr": "credit", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureEquityAtTheMarketOfferingAgreementAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureEquityStandbyEquityPurchaseAgreementAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Share Repurchase Program, Remaining Authorized, Amount", "terseLabel": "Remaining availability under SEPA", "verboseLabel": "Remaining availability", "documentation": "Amount remaining authorized for purchase of share under share repurchase plan. Includes, but is not limited to, repurchase of stock and unit of ownership." } } }, "auth_ref": [ "r976" ] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited", "http://aptevotherapeutics.com/20260630/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "periodStartLabel": "Balance", "periodEndLabel": "Balance", "label": "Equity, Attributable to Parent", "totalLabel": "Total stockholders' equity", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r19", "r636", "r653", "r678", "r679", "r769", "r783", "r902", "r918", "r922", "r923", "r940", "r1016", "r1044" ] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "StockholdersEquityAbstract", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDBALANCESHEETSUnaudited" ], "lang": { "en-us": { "role": { "label": "Equity, Attributable to Parent [Abstract]", "terseLabel": "Stockholders' equity:" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": { "xbrltype": "pureItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "StockholdersEquityNoteStockSplitConversionRatio1", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureReverseStockSplitAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersDeficitEquityUnauditedParenthetical" ], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio", "terseLabel": "Reverse stock split", "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one." } } }, "auth_ref": [ "r973", "r974", "r975" ] }, "us-gaap_StockholdersEquityReverseStockSplit": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "StockholdersEquityReverseStockSplit", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureReverseStockSplitAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Stockholders' Equity, Reverse Stock Split", "terseLabel": "Reverse Stock Split, outstanding common stock", "documentation": "Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements." } } }, "auth_ref": [ "r327", "r331", "r332" ] }, "apvo_StructuringFee": { "xbrltype": "monetaryItemType", "nsuri": "http://aptevotherapeutics.com/20260630", "localname": "StructuringFee", "crdr": "credit", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureEquityStandbyEquityPurchaseAgreementAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Structuring Fee", "documentation": "Structuring fee.", "terseLabel": "Structuring fee" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "SubsequentEventLineItems", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Subsequent Event [Line Items]", "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event." } } }, "auth_ref": [ "r490", "r528" ] }, "us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "SubsequentEventMember", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureEquity2023And2024CommonWarrantsAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureEquity2024CommonWarrantsAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureXomaTransactionAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureNatureOfBusinessAndSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Subsequent Event [Member]", "terseLabel": "Subsequent Events", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r490", "r528" ] }, "us-gaap_SubsequentEventTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "SubsequentEventTable", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Subsequent Event [Table]", "documentation": "Disclosure of information about significant event or transaction occurring between statement of financial position date and date when financial statements were issued." } } }, "auth_ref": [ "r490", "r528" ] }, "us-gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "SubsequentEventTypeAxis", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureEquity2023And2024CommonWarrantsAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureEquity2024CommonWarrantsAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureXomaTransactionAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureNatureOfBusinessAndSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Axis]", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r490", "r528" ] }, "us-gaap_SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "SubsequentEventTypeDomain", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureEquity2023And2024CommonWarrantsAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureEquity2024CommonWarrantsAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureXomaTransactionAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureNatureOfBusinessAndSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Domain]", "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r490", "r528" ] }, "us-gaap_SubsequentEventsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "SubsequentEventsAbstract", "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "SubsequentEventsTextBlock", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureSubsequentEvents" ], "lang": { "en-us": { "role": { "label": "Subsequent Events [Text Block]", "terseLabel": "Subsequent Events", "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business." } } }, "auth_ref": [ "r527", "r529" ] }, "us-gaap_SubsidiarySaleOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "SubsidiarySaleOfStockAxis", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureEquity2023And2024CommonWarrantsAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureEquity2024CommonWarrantsAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureEquity2025EquityOfferingsAndCommonWarrantsAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureEquity2026NiowaveCommonWarrantsAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureEquityAtTheMarketOfferingAgreementAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureNatureOfBusinessAndSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Sale of Stock [Axis]", "documentation": "Information by type of sale of the entity's stock." } } }, "auth_ref": [] }, "apvo_SummaryOfRightOfUseAssetsAcquiredUnderOperatingLeasesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://aptevotherapeutics.com/20260630", "localname": "SummaryOfRightOfUseAssetsAcquiredUnderOperatingLeasesTableTextBlock", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureLeasesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Right of Use Assets Acquired Under Operating Leases", "label": "Summary Of Right Of Use Assets Acquired Under Operating Leases Table [Text Block]", "documentation": "Summary of right of use assets acquired under operating leases." } } }, "auth_ref": [] }, "apvo_SummaryOfSignificantAssetCategoriesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://aptevotherapeutics.com/20260630", "localname": "SummaryOfSignificantAssetCategoriesTableTextBlock", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureSegmentInformationTables" ], "lang": { "en-us": { "role": { "label": "Summary Of Significant Asset Categories [Table Text Block]", "documentation": "Summary of significant asset categories.", "terseLabel": "Summary of Significant Asset Categories" } } }, "auth_ref": [] }, "apvo_SummaryOfSignificantExpenseCategoriesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://aptevotherapeutics.com/20260630", "localname": "SummaryOfSignificantExpenseCategoriesTableTextBlock", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureSegmentInformationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Significant Expense Categories", "label": "Summary Of Significant Expense Categories [Table Text Block]", "documentation": "Summary of significant expense categories." } } }, "auth_ref": [] }, "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "SupplementalCashFlowInformationAbstract", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "Supplemental Cash Flow Information" } } }, "auth_ref": [] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "TabularListTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Tabular List [Table Text Block]", "terseLabel": "Tabular List, Table" } } }, "auth_ref": [ "r839" ] }, "srt_TitleOfIndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2026", "localname": "TitleOfIndividualAxis", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureNatureOfBusinessAndSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Title of Individual", "label": "Title and Position [Axis]" } } }, "auth_ref": [ "r939", "r1023" ] }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2026", "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureNatureOfBusinessAndSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Title of Individual", "label": "Title and Position [Domain]" } } }, "auth_ref": [] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "TotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Amount", "terseLabel": "Total Shareholder Return Amount" } } }, "auth_ref": [ "r831" ] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Vs Peer Group [Text Block]", "terseLabel": "Total Shareholder Return Vs Peer Group" } } }, "auth_ref": [ "r838" ] }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "TradingArrAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement [Axis]", "terseLabel": "Trading Arrangement:" } } }, "auth_ref": [ "r858" ] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "TradingArrByIndTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangements, by Individual [Table]", "terseLabel": "Trading Arrangements, by Individual" } } }, "auth_ref": [ "r860" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2026", "localname": "TradingSymbol", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "apvo_TransactionCostsForMilestonesRelatedToSaleOfRoyalties": { "xbrltype": "monetaryItemType", "nsuri": "http://aptevotherapeutics.com/20260630", "localname": "TransactionCostsForMilestonesRelatedToSaleOfRoyalties", "crdr": "credit", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureLiabilityRelatedToSaleOfRoyaltiesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Transaction costs for milestones related to sale of royalties", "terseLabel": "Transaction costs", "label": "Transaction Costs For Milestones Related To Sale Of Royalties", "documentation": "Transaction costs for milestones related to sale of royalties." } } }, "auth_ref": [] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "TrdArrAdoptionDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Adoption Date", "terseLabel": "Adoption Date" } } }, "auth_ref": [ "r861" ] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "TrdArrDuration", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Duration", "terseLabel": "Arrangement Duration" } } }, "auth_ref": [ "r862" ] }, "ecd_TrdArrExpirationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "TrdArrExpirationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Expiration Date", "terseLabel": "Expiration Date" } } }, "auth_ref": [ "r862" ] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "TrdArrIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r860" ] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "TrdArrIndTitle", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Title", "terseLabel": "Title" } } }, "auth_ref": [ "r860" ] }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Securities Aggregate Available Amount", "terseLabel": "Aggregate Available" } } }, "auth_ref": [ "r863" ] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "TrdArrTerminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Termination Date", "terseLabel": "Termination Date" } } }, "auth_ref": [ "r861" ] }, "apvo_TwoThousandEighteenStockIncentivePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://aptevotherapeutics.com/20260630", "localname": "TwoThousandEighteenStockIncentivePlanMember", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2018 Stock Incentive Plan", "label": "Two Thousand Eighteen Stock Incentive Plan [Member]", "documentation": "Two thousand eighteen stock incentive plan." } } }, "auth_ref": [] }, "apvo_TwoThousandTwentyFiveCommonWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://aptevotherapeutics.com/20260630", "localname": "TwoThousandTwentyFiveCommonWarrantsMember", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureEquity2025EquityOfferingsAndCommonWarrantsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Two Thousand Twenty Five Common Warrants [Member]", "documentation": "Two thousand twenty five common warrants.", "terseLabel": "2025 Common Warrants" } } }, "auth_ref": [] }, "apvo_TwoThousandTwentyFourCommonWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://aptevotherapeutics.com/20260630", "localname": "TwoThousandTwentyFourCommonWarrantsMember", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureEquity2024CommonWarrantsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Two Thousand Twenty Four Common Warrants [Member]", "documentation": "2024 Common Warrants.", "terseLabel": "2024 Common Warrants" } } }, "auth_ref": [] }, "apvo_TwoThousandTwentySixNiowaveCommonWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://aptevotherapeutics.com/20260630", "localname": "TwoThousandTwentySixNiowaveCommonWarrantsMember", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureEquity2026NiowaveCommonWarrantsAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureEquitySummaryOfAssumptionsUsedToEstimateTheFairValueOfTheWarrantsUsingTheBlackscholesOptionPricingModelDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureEquityTables" ], "lang": { "en-us": { "role": { "label": "Two Thousand Twenty Six Niowave Common Warrants [Member]", "documentation": "Two thousand twenty six niowave common warrants.", "terseLabel": "2026 Niowave Common Warrants" } } }, "auth_ref": [] }, "apvo_TwoThousandTwentyThreeAndTwoThousandTwentyFourCommonWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://aptevotherapeutics.com/20260630", "localname": "TwoThousandTwentyThreeAndTwoThousandTwentyFourCommonWarrantsMember", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureEquity2023And2024CommonWarrantsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Two Thousand Twenty Three and Two Thousand Twenty Four Common Warrants [Member]", "documentation": "Two thousand twenty three and two thousand twenty four common warrants.", "terseLabel": "2023 and 2024 Common Warrants" } } }, "auth_ref": [] }, "apvo_TwoThousandTwentyThreeCommonWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://aptevotherapeutics.com/20260630", "localname": "TwoThousandTwentyThreeCommonWarrantsMember", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureEquity2023And2024CommonWarrantsAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureEquity2024CommonWarrantsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Two Thousand Twenty Three Common Warrants [Member]", "documentation": "2023 Common Warrants.", "terseLabel": "2023 Common Warrants" } } }, "auth_ref": [] }, "us-gaap_TypeOfAdoptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "TypeOfAdoptionMember", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureXomaTransactionAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureNatureOfBusinessAndSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Accounting Standards Update [Domain]", "documentation": "Amendment to accounting standards." } } }, "auth_ref": [ "r34", "r35", "r36", "r37", "r38", "r39", "r110", "r111", "r112", "r133", "r134", "r135", "r136", "r137", "r138", "r148", "r210", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r289", "r290", "r291", "r292", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r387", "r388", "r389", "r390", "r395", "r396", "r397", "r398", "r399", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r481", "r514", "r515", "r516", "r517", "r518", "r519", "r588", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598", "r599" ] }, "us-gaap_TypeOfArrangementAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "TypeOfArrangementAxis", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureEquity2023And2024CommonWarrantsAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureEquity2024CommonWarrantsAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureEquityStandbyEquityPurchaseAgreementAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureXomaTransactionAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureCollaborationAgreementsAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureNatureOfBusinessAndSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r419" ] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Underlying Security Market Price Change, Percent", "terseLabel": "Underlying Security Market Price Change" } } }, "auth_ref": [ "r857" ] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "UseOfEstimates", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureNatureOfBusinessAndSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Use of Estimates", "label": "Use of Estimates, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": [ "r30", "r31", "r170", "r171", "r172", "r173", "r565", "r567", "r716" ] }, "us-gaap_VariableLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "VariableLeaseCost", "crdr": "debit", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureLeasesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Variable expense", "label": "Variable Lease, Cost", "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases." } } }, "auth_ref": [ "r508", "r768" ] }, "us-gaap_VariableRateAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "VariableRateAxis", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Variable Rate [Axis]", "terseLabel": "Variable Rate", "documentation": "Information by type of variable rate." } } }, "auth_ref": [ "r891", "r896", "r959", "r1010" ] }, "us-gaap_VariableRateDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "VariableRateDomain", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureDebtAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Variable Rate", "label": "Variable Rate [Domain]", "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index." } } }, "auth_ref": [ "r891", "r896", "r959", "r1010" ] }, "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]", "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year" } } }, "auth_ref": [ "r827" ] }, "apvo_WarrantActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://aptevotherapeutics.com/20260630", "localname": "WarrantActivityTableTextBlock", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureEquityTables" ], "lang": { "en-us": { "role": { "label": "Warrant Activity [Table Text Block]", "documentation": "Warrant activity.", "terseLabel": "Summary of Common Warrant Activity" } } }, "auth_ref": [] }, "us-gaap_WarrantDownRoundFeatureDecreaseInNetIncomeLossToCommonShareholderAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "WarrantDownRoundFeatureDecreaseInNetIncomeLossToCommonShareholderAmount", "crdr": "debit", "calculation": { "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited": { "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureEquity2025EquityOfferingsAndCommonWarrantsAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureNetLossPerShareComputationOfBasicAndDilutedNetLossPerShareDetails3", "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited", "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Dividend attributable to down round feature of warrants", "label": "Warrant, Down Round Feature, Decrease in Net Income to Common Shareholder, Amount", "verboseLabel": "Increase in net loss attributable to common equity due to deemed dividend", "negatedLabel": "Dividend attributable to down round feature of warrants", "documentation": "Amount of decrease in net income available to common shareholder for down round feature triggered for warrant classified as equity." } } }, "auth_ref": [ "r152", "r160" ] }, "apvo_WarrantInducementAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://aptevotherapeutics.com/20260630", "localname": "WarrantInducementAgreementMember", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureEquity2023And2024CommonWarrantsAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureEquity2024CommonWarrantsAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Warrant Inducement Agreement [Member]", "terseLabel": "Warrant Inducement Agreement", "documentation": "Warrant inducement agreement." } } }, "auth_ref": [] }, "apvo_WarrantInducementAndReloadLettersMember": { "xbrltype": "domainItemType", "nsuri": "http://aptevotherapeutics.com/20260630", "localname": "WarrantInducementAndReloadLettersMember", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Warrant Inducement and Reload Letters.", "label": "Warrant Inducement and Reload Letters" } } }, "auth_ref": [] }, "apvo_WarrantIssueDuringPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://aptevotherapeutics.com/20260630", "localname": "WarrantIssueDuringPeriod", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureEquity2025EquityOfferingsAndCommonWarrantsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "label": "Warrant Issue During Period", "documentation": "Warrant Issue During Period.", "terseLabel": "Warrant issued during period" } } }, "auth_ref": [] }, "us-gaap_WarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "WarrantMember", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureEquity2023And2024CommonWarrantsAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureEquity2024CommonWarrantsAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureEquity2025EquityOfferingsAndCommonWarrantsAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureNetLossPerShareSummaryOfPotentiallyDilutiveSharesExcludedFromCalculationOfNetLossPerShareDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureEquityAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersDeficitEquityUnauditedParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Warrants", "label": "Warrant [Member]", "verboseLabel": "Common Warrants", "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount." } } }, "auth_ref": [ "r773", "r774", "r777", "r778", "r779", "r780" ] }, "apvo_WarrantModificationIncrementalValue": { "xbrltype": "monetaryItemType", "nsuri": "http://aptevotherapeutics.com/20260630", "localname": "WarrantModificationIncrementalValue", "crdr": "debit", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Warrant modification - incremental value", "documentation": "Warrant modification incremental value.", "label": "Warrant modification incremental value" } } }, "auth_ref": [] }, "us-gaap_WarrantsAndRightsOutstandingMaturityDate": { "xbrltype": "dateItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "WarrantsAndRightsOutstandingMaturityDate", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureEquity2023And2024CommonWarrantsAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureEquity2025EquityOfferingsAndCommonWarrantsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warrants expiration date", "label": "Warrants and Rights Outstanding, Maturity Date", "documentation": "Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in YYYY-MM-DD format." } } }, "auth_ref": [ "r1013", "r1014", "r1015" ] }, "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": { "xbrltype": "decimalItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "WarrantsAndRightsOutstandingMeasurementInput", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureEquitySummaryOfAssumptionsUsedToEstimateTheFairValueOfTheWarrantsUsingTheBlackscholesOptionPricingModelDetails" ], "lang": { "en-us": { "role": { "label": "Warrants and Rights Outstanding, Measurement Input", "terseLabel": "Warrants measurement input", "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur." } } }, "auth_ref": [ "r1013", "r1014", "r1015" ] }, "apvo_WarrantsIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://aptevotherapeutics.com/20260630", "localname": "WarrantsIssuanceCosts", "crdr": "debit", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureEquity2025EquityOfferingsAndCommonWarrantsAdditionalInformationDetails", "http://aptevotherapeutics.com/20260630/taxonomy/role/StatementCondensedConsolidatedStatementsOfChangesInStockholdersDeficitEquityUnauditedParenthetical" ], "lang": { "en-us": { "role": { "documentation": "Warrants issuance costs.", "label": "Warrants Issuance Costs", "terseLabel": "Total issuance costs" } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureNetLossPerShareComputationOfBasicAndDilutedNetLossPerShareDetails3", "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Weighted Average Number of Shares Outstanding, Diluted, Total", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Diluted shares used in calculation", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r153", "r160" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureNetLossPerShareComputationOfBasicAndDilutedNetLossPerShareDetails3", "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Shares used in calculation:", "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]" } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2026", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/DisclosureNetLossPerShareComputationOfBasicAndDilutedNetLossPerShareDetails3", "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_StatementCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Weighted Average Number of Shares Outstanding, Basic, Total", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Basic shares used in calculation", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r150", "r160" ] }, "exch_XNCM": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/exch/2026", "localname": "XNCM", "presentation": [ "http://aptevotherapeutics.com/20260630/taxonomy/role/Role_DisclosureNatureOfBusinessAndSignificantAccountingPoliciesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Nasdaq Capital Market", "label": "NASDAQ CAPITAL MARKET [Member]" } } }, "auth_ref": [] }, "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2026", "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]", "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested" } } }, "auth_ref": [ "r825" ] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(g)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "20", "Section": "25", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481284/470-20-25-2" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/470/tableOfContent" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(f)(2)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/810/tableOfContent" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8" }, "r29": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "SubTopic": "210", "Topic": "946", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-20" }, "r30": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r31": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r32": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "808", "Publisher": "FASB", "URI": "https://asc.fasb.org/808/tableOfContent" }, "r33": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "a", "Publisher": "SEC" }, "r34": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-7" }, "r35": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9" }, "r36": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "9", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9" }, "r37": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "9", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9" }, "r38": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "9", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9" }, "r39": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "9", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9" }, "r40": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481003/205-10-S50-2" }, "r41": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SAB Topic 1.B.2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480922/205-10-S99-7" }, "r42": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/205-20/tableOfContent" }, "r43": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-10" }, "r44": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-11" }, "r45": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-3" }, "r46": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-3A" }, "r47": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1" }, "r48": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-3" }, "r49": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-3A" }, "r50": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-4A" }, "r51": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-4B" }, "r52": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-4B" }, "r53": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-4B" }, "r54": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-4B" }, "r55": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-4B" }, "r56": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-4B" }, "r57": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-4B" }, "r58": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(d)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-4B" }, "r59": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5A" }, "r60": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5B" }, "r61": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5B" }, "r62": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5C" }, "r63": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5C" }, "r64": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5C" }, "r65": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5C" }, "r66": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r67": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480868/205-20-S45-2" }, "r68": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480837/205-20-S50-1" }, "r69": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.Z.5.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480781/205-20-S99-2" }, "r70": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480781/205-20-S99-3" }, "r71": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5" }, "r72": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480657/210-10-S50-11" }, "r73": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480657/210-10-S50-13" }, "r74": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480657/210-10-S50-8" }, "r75": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480657/210-10-S50-9" }, "r76": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r77": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r78": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r79": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r80": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r81": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r82": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r83": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r84": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r85": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r86": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r87": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r88": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r89": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r90": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r91": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r92": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r93": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r94": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r95": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r96": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r97": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r98": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r99": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r100": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r101": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r102": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r103": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r104": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r105": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r106": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r107": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r108": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 6.B)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-5" }, "r109": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6" }, "r110": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476151/220-40-65-1" }, "r111": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476151/220-40-65-1" }, "r112": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476151/220-40-65-1" }, "r113": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "21D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-21D" }, "r114": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r115": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r116": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4" }, "r117": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-7" }, "r118": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r119": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1" }, "r120": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-4" }, "r121": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r122": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r123": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r124": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r125": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r126": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r127": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r128": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r129": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3" }, "r130": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 11.M.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/260/tableOfContent" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-11" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-12B" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-12" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-6" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/280/tableOfContent" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(j)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26A" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "34", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-6" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-6" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-7" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-7" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482705/350-40-65-4" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482705/350-40-65-4" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482705/350-40-65-4" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482705/350-40-65-4" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482705/350-40-65-4" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482705/350-40-65-4" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482705/350-40-65-4" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482705/350-40-65-4" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482705/350-40-65-4" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/360/tableOfContent" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-14" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(f)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-1" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-2" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-3" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-1" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-2" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-3" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(01)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(01)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3A", "Subparagraph": "(24)(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-3A" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-11" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S35", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480125/505-10-S35-1" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480100/505-10-S45-2" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480100/505-10-S45-3" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480100/505-10-S45-4" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480100/505-10-S45-8" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480070/505-10-S50-1" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480070/505-10-S50-6" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "4", "Subparagraph": "(SAB Topic 4.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-4" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 4.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-5" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SAB Topic 5.Q.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-7" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481468/505-20-05-5" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S25", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479982/505-20-S25-2" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479951/505-20-S50-2" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-4" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479719/606-10-65-2" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479719/606-10-65-2" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479719/606-10-65-2" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479719/606-10-65-2" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479719/606-10-65-2" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479719/606-10-65-3" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479719/606-10-65-3" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479719/606-10-65-3" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "3", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479719/606-10-65-3" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "17", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480336/718-10-65-17" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "17", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480336/718-10-65-17" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "17", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480336/718-10-65-17" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "17", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480336/718-10-65-17" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479983/718-10-S45-1" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "720", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "9", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "9", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477349/740-270-45-3" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479279/805-10-65-5" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479279/805-10-65-5" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479279/805-10-65-5" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "808", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "808", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "808", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8A" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480339/815-10-65-8" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480339/815-10-65-8" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480339/815-10-65-8" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480339/815-10-65-8" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480339/815-10-65-8" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-7" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-7" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "7", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-7" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "45", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480865/815-45-50-1" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482477/820-10-65-13" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "832", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483507/832-10-50-3" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "832", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483507/832-10-50-3" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "832", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483507/832-10-50-4" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "832", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483507/832-10-50-4" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "832", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483507/832-10-50-4" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "832", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483507/832-10-50-4" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/842-20/tableOfContent" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "12A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-2" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-1" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/850/tableOfContent" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-6" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/855/tableOfContent" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480088/860-10-S50-1" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(cc)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-9" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-5" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "940", "SubTopic": "820", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477657/942-210-S45-1" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478478/942-210-S50-1" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13)(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(15)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(15)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(7)(e)(1)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(7)(e)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478671/942-235-S50-1" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.9-06)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-2" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478443/942-360-45-1" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "405", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477787/942-405-45-2" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r586": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r589": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r590": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r591": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r593": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r594": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r595": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r596": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r597": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r598": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r599": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r600": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.W.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1" }, "r601": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r602": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r603": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r604": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r605": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r606": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11" }, "r607": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-2" }, "r608": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-5" }, "r609": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-6" }, "r610": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3" }, "r611": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r612": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-6" }, "r613": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2" }, "r614": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27" }, "r615": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r616": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r617": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r618": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r619": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r620": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r621": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r622": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r623": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-21" }, "r624": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4" }, "r625": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r626": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r627": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r628": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r629": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r630": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r631": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r632": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r633": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r634": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r635": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r636": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r637": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r638": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r639": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r640": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r641": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r642": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r643": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r644": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r645": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r646": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r647": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r648": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r649": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r650": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r651": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r652": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r653": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r654": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7" }, "r655": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3" }, "r656": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r657": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r658": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r659": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r660": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r661": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r662": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r663": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r664": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r665": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r666": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r667": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r668": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r669": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r670": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r671": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r672": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r673": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r674": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r675": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r676": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r677": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r678": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r679": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r680": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r681": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r682": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r683": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r684": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r685": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r686": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r687": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1" }, "r688": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r689": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r690": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r691": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r692": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478322/948-310-S50-2" }, "r693": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1" }, "r694": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1" }, "r695": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1" }, "r696": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1" }, "r697": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1" }, "r698": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" }, "r699": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-3A" }, "r700": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5C" }, "r701": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "102", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483474/205-20-55-102" }, "r702": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "103", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483474/205-20-55-103" }, "r703": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r704": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r705": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r706": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "8", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-8" }, "r707": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16" }, "r708": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21" }, "r709": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22" }, "r710": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-12" }, "r711": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-14" }, "r712": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-18" }, "r713": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-21" }, "r714": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "220", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-4" }, "r715": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52" }, "r716": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482836/275-10-55-6" }, "r717": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r718": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r719": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r720": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r721": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r722": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r723": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r724": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "48", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48" }, "r725": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "49", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49" }, "r726": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r727": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r728": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r729": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r730": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r731": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A" }, "r732": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482338/360-10-05-3" }, "r733": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482338/360-10-05-3" }, "r734": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482338/360-10-05-3" }, "r735": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482338/360-10-05-3" }, "r736": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r737": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B" }, "r738": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C" }, "r739": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E" }, "r740": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F" }, "r741": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "64", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481620/480-10-55-64" }, "r742": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r743": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r744": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5" }, "r745": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5" }, "r746": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17" }, "r747": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11" }, "r748": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-6" }, "r749": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8" }, "r750": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r751": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r752": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r753": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-8" }, "r754": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "43", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-43" }, "r755": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-47" }, "r756": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J" }, "r757": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K" }, "r758": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r759": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "6A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480682/815-20-25-6A" }, "r760": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r761": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "103", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103" }, "r762": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r763": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r764": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r765": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482881/825-10-55-10" }, "r766": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482881/825-10-55-12" }, "r767": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8" }, "r768": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53" }, "r769": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10" }, "r770": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F" }, "r771": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "605", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-11" }, "r772": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "605", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-14" }, "r773": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r774": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r775": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1" }, "r776": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r777": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r778": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r779": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r780": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r781": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10" }, "r782": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11" }, "r783": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12" }, "r784": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r785": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r786": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r787": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r788": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "J", "Paragraph": "a" }, "r789": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r790": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r791": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r792": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r793": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r794": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r795": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r796": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r797": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r798": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r799": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r800": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r801": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r802": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r803": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r804": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r805": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r806": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r807": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r808": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r809": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r810": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r811": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r812": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r813": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r814": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r815": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r816": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r817": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r818": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r819": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r820": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r821": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r822": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r823": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii" }, "r824": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "ii" }, "r825": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "i" }, "r826": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "ii" }, "r827": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iii" }, "r828": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iv" }, "r829": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "v" }, "r830": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "vi" }, "r831": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r832": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "vi" }, "r833": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "3" }, "r834": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "4" }, "r835": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r836": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r837": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r838": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r839": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r840": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r841": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r842": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r843": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r844": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r845": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r846": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r847": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r848": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r849": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r850": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r851": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r852": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r853": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r854": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r855": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r856": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r857": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r858": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r859": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r860": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r861": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r862": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r863": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "D" }, "r864": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r865": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Number": "229", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1" }, "r866": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "A", "Number": "229" }, "r867": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Number": "229" }, "r868": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "i", "Number": "229" }, "r869": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r870": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r871": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3" }, "r872": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-10" }, "r873": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-3" }, "r874": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "SubTopic": "20", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r875": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "205", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483504/205-10-50-1" }, "r876": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-11" }, "r877": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1" }, "r878": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1" }, "r879": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1" }, "r880": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1" }, "r881": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-3" }, "r882": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-4B" }, "r883": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5A" }, "r884": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5B" }, "r885": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5C" }, "r886": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r887": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480781/205-20-S99-3" }, "r888": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r889": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480657/210-10-S50-11" }, "r890": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480657/210-10-S50-8" }, "r891": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480657/210-10-S50-9" }, "r892": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r893": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r894": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r895": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r896": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r897": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r898": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r899": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r900": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r901": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r902": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r903": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3" }, "r904": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3" }, "r905": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3" }, "r906": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3" }, "r907": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3" }, "r908": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3" }, "r909": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3" }, "r910": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-10" }, "r911": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-12" }, "r912": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r913": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12" }, "r914": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r915": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r916": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r917": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1" }, "r918": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1" }, "r919": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-4" }, "r920": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r921": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r922": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r923": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r924": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3" }, "r925": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/250/tableOfContent" }, "r926": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r927": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r928": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r929": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r930": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "55", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55" }, "r931": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r932": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r933": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r934": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18" }, "r935": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r936": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r937": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r938": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r939": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r940": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r941": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r942": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482558/350-40-50-1" }, "r943": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "30", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482222/360-10-30-2" }, "r944": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-5" }, "r945": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r946": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r947": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r948": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r949": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3A" }, "r950": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3A" }, "r951": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3A" }, "r952": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3A" }, "r953": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3A" }, "r954": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r955": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r956": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r957": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10" }, "r958": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r959": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480190/470-10-S50-1" }, "r960": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r961": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r962": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r963": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/505/tableOfContent" }, "r964": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r965": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r966": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r967": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480100/505-10-S45-2" }, "r968": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480100/505-10-S45-3" }, "r969": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480100/505-10-S45-4" }, "r970": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480070/505-10-S50-1" }, "r971": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480070/505-10-S50-2" }, "r972": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r973": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "4", "Subparagraph": "(SAB Topic 4.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-4" }, "r974": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "505", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S25", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479982/505-20-S25-2" }, "r975": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "505", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479951/505-20-S50-2" }, "r976": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "505", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-4" }, "r977": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/718/tableOfContent" }, "r978": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r979": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r980": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r981": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r982": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r983": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r984": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r985": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r986": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r987": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r988": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r989": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r990": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r991": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r992": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r993": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r994": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r995": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r996": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r997": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r998": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r999": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1000": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1001": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1002": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1003": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1004": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1005": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1006": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-7A" }, "r1007": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8" }, "r1008": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8" }, "r1009": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8" }, "r1010": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "6A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480682/815-20-25-6A" }, "r1011": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r1012": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/820/tableOfContent" }, "r1013": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1014": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1015": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1016": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r1017": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "832", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483507/832-10-50-3" }, "r1018": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r1019": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1" }, "r1020": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-2" }, "r1021": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r1022": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r1023": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2" }, "r1024": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r1025": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r1026": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r1027": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(b)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-1A" }, "r1028": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-8" }, "r1029": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-8" }, "r1030": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-2" }, "r1031": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "905", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478704/905-360-25-4" }, "r1032": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1" }, "r1033": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477657/942-210-S45-1" }, "r1034": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478478/942-210-S50-1" }, "r1035": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r1036": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r1037": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r1038": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.9-06)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-2" }, "r1039": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "825", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1" }, "r1040": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r1041": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r1042": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r1043": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3" }, "r1044": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r1045": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r1046": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "970", "SubTopic": "810", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477383/970-810-45-1" } } }